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Cholestatic liver diseases comprises a wide range of conditions characterized by defective 
bile formation and, therefore, impaired bile salt transport from the liver to the intestinal 
lumen. Physiological consequences include retention of bile salts in the hepatocytes, limited 
availability of bile salts in the intestinal lumen, hyperbilirubinemia and elevated plasma bile 
salt levels. These consequences eventually lead to liver injury, lipid malabsorption, jaundice, 
pruritus and potentially peripheral tissue injury. As a result of malabsorption, cholestatic 
patients, especially children, can develop serious nutritional defects. For instance, 
cholestatic disorders are frequently associated with essential fatty acid (EFA) deficiency. 
The resultant malnutritional state strongly affects prognosis and treatment outcome of 
cholestatic patients 1. Identifying specific nutritional defects associated with cholestasis and 
EFA deficiency and the mechanism(s) underlying these defects will open possibilities 
towards successful therapies. 
In this general introduction, an overview of bile salt metabolism in health and disease 
(cholestasis) as well as bile salt functions in lipid metabolism will be provided. Processes 
involved in lipid and carbohydrate absorption from the intestine will be discussed and, finally, 
the aim of the work described in this thesis will be defined.  
 
 
BILE SALT SYNTHESIS 
Bile acids are present in the form of sodium salts under physiological conditions prevailing in 
the body (pH 5-7.5) and therefore will be referred to as bile salts. Bile salts are synthesized 
from cholesterol via the classical (neutral) pathway or the alternative (acidic) pathway. A 
schematic image of bile salt synthesis is depicted in Figure 1. The classical pathway 
involves modification of the sterol nucleus including saturation of the double bond, 
epimerization of the 3β-hydroxyl group and hydroxylation at the 7α and 12α-positions, 
preceding oxidative cleavage of the side chain. Microsomal cholesterol 7α-hydroxylase 
(CYP7A1) catalyzes the first and rate-controlling step, yielding 7α-hydroxycholesterol which 
is subsequently converted into 7α-hydroxy-4-cholesten-3-one by micosomal HSD3B7 (3β-
hydroxy-∆5-C27-steroid dehydrogenase/isomerase). 7α-Hydroxy-4-cholesten-3-one can 
either enter the pathway towards synthesis of cholic acid (CA) or the pathway towards 
synthesis of chenodeoxycholic acid (CDCA). Microsomal sterol 12-hydroxylase (CYP8B1) 
catalyzes the hydroxylation of 7α-hydroxy-4-cholesten-3-one into 7α,12α-dihydroxy-4-
cholesten-3-one, the precursor of CA. The cytosolic enzymes AKR1D1 (∆4-3-oxosteroid-5β-
reductase) and AKR1C4 (3α-hydroxysteroid dehydrogenase) catalyze reduction of 7α-
hydroxy-4-cholesten-3-one and 7α,12α-dihydroxy-4-cholesten-3-one, yielding 5β-cholestan-
3α,7α,12α-triol (CA precursor) and 5β-cholestan-3α,7α-diol (CDCA precursor), respectively. 
Mitochondrial sterol 27-hydroxylase (CYP27A1) oxidizes the side chains of both precursors, 
yielding 3α,7α,12α-trihydroxy-5β-cholestanoic acid and 3α,7α-dihydroxy-5β-cholestanoic 
acid. These precursors are ligated to coenzyme A by bile acid CoA synthetase (BACS) 
activity and are subsequently transported into the peroxisomes for side chain cleavage. Side 
chain cleavage eventually leads to the formation of CA (3α.7α,12α) and CDCA (3α,7α). In 
the alternative pathway, cholesterol is hydroxylated into oxidized intermediates (oxysterols) 
through the actions of CYP27A1 and oxysterol 7α-hydroxylase (CYP7B1). While the 
classical pathway is exclusive to the liver, the alternative pathway also occurs in peripheral 




muricholic acid (α-MA) and subsequently to β-muricholic acid (β-MA) in the liver. In rodents, 
CA and β-MA are the main bile salts present in bile 5,6. 
Nearly all bile salts undergo conjugation with glycine or taurine in liver peroxisomes, 
catalyzed by bile acid-CoA:amino acid N-acetyltransferase (BAAT) In humans, the majority 
of bile salts are conjugated with glycine, while rodent bile salts mainly consist of taurine-
conjugates 2-4,7.  
A small fraction of the (conjugated) primary bile salts enter the colon, where they can be 
deconjugated and converted to hydrophobic secondary bile salts by colonic bacteria, or are 
excreted into the feces. After deconjugation, the primary bile salt CA can be 7α-
dehydroxylated into deoxycholic acid (DCA) and CDCA can be 7α-dehydroxylated into 
lithocholic acid (LCA) 8. In addition, CDCA can be converted to the more hydrophilic bile salt 
ursodeoxycholic acid (UDCA) by colonic bacterial oxidation of the 7α-hydroxyl group and 
stereospecific reduction of the 7-keto group, generating the corresponding 7β-hydroxyl 
group 9. In mice and rats, β-MA is converted to hyodeoxycholic acid (HDCA) through 7β-
hydroxylation and 6β-hydroxy epimerization and or to ω-muricholic acid (ω-MA) through 




















Under non-cholestatic conditions, conjugated primary and secondary bile salts are secreted 
into the bile. Bile functions as a route for the excretion of endogenous and exogenous 
compounds such as bile salts, bilirubin, phospholipids, cholesterol, drugs and toxins. In 
humans and mice, bile salts are stored and concentrated in the gallbladder during the 
interdigestive period and are excreted postprandially to aid in the absorption of lipids, 
cholesterol and fat-soluble vitamins. The turnover of the bile salt pool is ~5%, that is ~5% is 
lost in the feces per cycle, and ~95% is (passively and actively) reabsorbed by the intestine. 
The majority of bile salts is absorbed via active transport in the terminal ileum and 
transported back to the liver via the portal circulation 11-13.  
Hepatic bile formation is driven by the osmotic gradient generated by secretion of relatively 
non-permeant solutes into the canalicular lumen. Thus, accumulation of osmotically active 






























































Figure 1 Classical and alternative pathway of bile salt 




membrane. Bile salts account at least for 40-50% of bile flow, while the remainder depends 
on electrolytes 14,15, bicarbonate and mostly gluthathione and its conjugates 16-18. Most of the 
gluthathione (70-80%) in bile is in the reduced form (GSH) 15. Figure 2 represents a 



















Bile salt transport across the canalicular membrane into the bile canaliculi occurs against a 
100-1000 fold concentration gradient 19. Canalicular secretion of bile salts involves the 
actions of transporters whose function depends on ATP hydrolysis. The major transporters 
involved are Bile Salt Export Pump (BSEP/ABCB11), responsible for transport of 
monovalent bile salts, and the Multidrug Resistance-associated Protein 2 (MRP2/ABCC2), 
the main transporter of divalent bile salts 12,13,19-23. BSEP is essential for canalicular bile 
secretion, evidenced by knockout mice exhibiting impaired bile secretion and intrahepatic 
cholestasis. Wang et al. demonstrated that secretion of CA (monovalent) was greatly 
reduced (6% of wild-type), while total bile salt output was about 30% of wildtype mice in 
mice lacking BSEP 24. BSEP is exclusively expressed in the liver 25. BSEP has high affinity 
for TCDCA > TCA > TUDCA > GCA 26,27. MRP2 is localized to the canalicular membrane of 
hepatocytes, the apical membrane of renal proximal tubule epithelial cells, and the apical 
membrane of duodenal en jejunal enterocytes 28. Besides divalent bile salts like sulphated 
TLCA and GLCA, MRP2 mediates the export of bilirubin conjugates, gluthathione, 
glucuronide and sulphate conjugates, and some unconjugated drugs 12,28-30. MRP2 does not 
have the capacity to transport monovalent bile salts 12,31. MRP2-deficient rats (GY/TR-- and 
EHBR rats) are characterized by permanent hyperbilirubinemia and strong induction of 
MRP3 12,32-34. 
Bile salts are actively absorbed by cholangiocytes lining the bile ducts to recycle back to the 
hepatocytes for their re-secretion (cholehepatic shunt pathway) 12,13,35. Apical Sodium-
dependent Bile Salt Transporter (ASBT) mediates active transport of bile salts from the bile 
ducts across the apical membrane 36,37. Ileal Bile Acid Binding Protein (IBABP) is also 
expressed in cholangiocytes, though its exact function is still unclear 36. It is suggested that 
IBABP modulates transcellular transport and prevents intracellular bile salt toxicity by 


























































Figure 2 Schematic image of the enterohepatic 
circulation of bile salts with the bile salt 




membrane is mediated by t-ASBT, an alternatively spliced form of ASBT 38, Multidrug 
resistance protein 3 (MDR3/ABCB4) is also expressed at the basolateral membrane of 
cholangiocytes 39. However, there is no direct evidence that MDR3 is involved in 
cholangiocyte bile salt efflux. Recently, the heterodimeric Organic Solute Transporter α/β 
(OSTα/β) has been indentified in cholangiocytes. OSTα/β can transport bile salts via 
facilitated diffusion 40,41.  
Bile salts that have not been transported back to the liver via the cholehepatic shunt 
pathway enter the intestinal lumen and are passively and actively absorbed by the 
enterocytes. Apical uptake of bile salts in the enterocytes occurs via passive diffusion of 
unconjugated bile salts in the small intestine and the colon (after deconjugation by intestinal 
microflora), which accounts for a small fraction of intestinal bile salt conservation 42,43. ASBT 
is also expressed in the terminal ileum and is responsible for absorption of the majority of 
luminal bile salts 44-46. Human ASBT efficiently transports conjugated and unconjugated bile 
salts with a preference for the taurine and glycine conjugates 47,48. ASBT mediated transport 
is electrogenic with 2:1 Na+/bile salt coupling stoichiometry 49. ASBT exhibits a higher affinity 
for dihydroxy bile salts (CDCA and DCA) compared to trihydroxy bile salts such as CA, TCA 
and GCA 47. The phenotype of ASBT knockout mice involves intestinal bile salt 
malabsorption and interruption of the enterohepatic circulation, emphasizing the importance 
of ASBT 50.  A Na+-independent bile salt transporter (Organic anion transporting polypeptide; 
Oatp1a5) was found to be expressed in rat jejunal enterocytes 12. OATP1A2 has been 
suggested as the human Oatp1a5 ortholog 51,52. OATPs transport anions via a Na+-
independent mechanism. Jejunal uptake of bile salts occurs via in-to-out HCO3- gradient; 
however the role of OATPs herein remains unclear 53. Intracellular transport of bile salts in 
enterocytes is thought to occur via IBABP. Intestinal IBABP expression is restricted to the 
terminal ileum 12,54. No data is yet available about IBABP knockout models, but the 
observation that downregulation of IBABP expression resulted in increased fecal bile salt 
loss is suggestive of a function in ileal bile salt absorption 55. However, Kok et al. 
demonstrated that intestinal bile salt reabsorption was markedly increased in Fxr-/- mice 
despite complete absence of Ibabp, suggestive of a function as a negative regulator of bile 
salt reabsorption rather than a positive 56. Concluding, IBABP function in bile salt 
reabsorption remains unclear. t-ASBT MRP3 and OSTα/β have been proposed as 
candidates for basolateral bile salt efflux transporters in enterocytes; their specific roles, 
however, have remained undefined so far 12.  
To complete their enterohepatic circulation, absorbed bile salts are transported back to the 
liver via the portal blood. The basolateral membrane of the hepatocytes is in direct contact 
with the space of Disse that receives its content from the portal blood through large pores of 
the sinusoidal endothelium. The majority of bile salts reaches the space of Disse bound to 
albumin and needs to be dissociated for translocation across the membrane 57. Na+-
dependent Taurocholate Co-transporting Polypeptide (NTCP) is the main transporter 
mediating bile salt uptake. NTCP has been shown to mediate the transport of both 
conjugated and unconjugated bile salts in a Na+-dependent manner with a stoichiometry of 
2:1 58. Several studies have also suggested a role for microsomal epoxide hydrolase (mEH) 
in Na+-dependent bile salt uptake 12. However, since mice lacking mEH expression have no 
apparent abnormalities in bile salt homeostasis, the contribution of mEH to hepatocyte bile 
salt uptake has become debated 59. Though, hypercholanemia was associated with a 85% 
decrease of mEH protein due to a point mutation in a patient with no alteration in NTCP 
expression 60. Zhu et al. proposed that mEH is more efficient for transporting bile salts 
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conjugated with glycine compared to NTCP in humans 60. Since the majority of bile salts in 
humans are conjugated with glycine, in contrast to rats and mice, it is possible that mEH is 
responsible for hepatic uptake of a higher percentage of bile salts compared to NTCP 60. 
Most unconjugated bile salts are transported in a Na+-independent manner via passive 
diffusion or carrier-mediated transport 57,61. Several members of the OATP family have been 
implicated in basolateral bile salt influx; OATP1A2, OATP1B1 and OATP1B3 12,57,62. OATPs 
mediate the exchange of extracellular HCO3- or gluthathione, indicating that they are also 
involved in GSH efflux 63.  
Under physiological conditions, bile salt transport from the hepatocyte across the basolateral 
membrane into the portal blood is negligible 51. Transport is mediated by members of the 
MRP family. MRP1 (ABCC1), 3 (ABCC3) and 4 (ABCC4) are localized to the basolateral 
membrane and can transport bile salts and other compounds in a ATP-dependent fashion 
12,64,65
. Zelcer et al. demonstrated that bile salt homeostasis was unaltered in mice lacking 
Mrp3, indicating that Mrp3 is not solely responsible for bile salt efflux or may not be involved 
66
.  
Hepatic transcellular transport of bile salts can occur via intracellular traficking and vesicle-
mediated transport. Under physiological conditions, the majority of bile salts is transported 
based on the basolateral to canalicular concentration gradient, possibly be mediated by 
intracellular bile salt-binding proteins. The involvement of vesicle-mediated transport was 
concluded from several observations that indicated the partitioning of hydrophobic bile salts 





PHYSIOLOGICAL FUNCTIONS OF BILE SALTS 
Physiological functions of bile salts include cholesterol elimination, stimulation of bile flow, 
stimulation of biliary phospholipid secretion, regulation of bile salt and cholesterol 
biosynthesis and enhancement of lipid absorption 67. Apart from their role in dietary lipid 
absorption and cholesterol homeostasis, bile salts also function as signaling molecules. 
Through activation of diverse signaling pathways, bile salts can regulate their own 
enterohepatic circulation, and metabolism of triglycerides, cholesterol, energy and glucose 
68
. Bile salts can activate nuclear hormone receptors such as the farnesoid X receptor (FXR) 
69-71
, involved in the regulation of bile salt metabolism, lipid metabolism and glucose 
metabolism. The role of FXR in bile salt homeostasis and enterohepatic circulation will be 
discussed below in combination with cholestasis.  
Bile salts have also been shown to affect the microflora and the integrity of the small 
intestine. Obstruction of bile flow in humans and rodents causes proliferation of intestinal 
bacteria and mucosal injury, which can lead to bacterial translocation across the mucosal 
barrier and systemic infection 72. Bacterial overgrowth and translocation caused by biliary 
obstruction in rats was inhibited by oral administration of bile salts 73,74. In addition, oral 
administration of bile salts blocked endotoxemia in patients with obstructive jaundice 75-77. 
Recently, Inagaki et al. demonstrated that FXR induces genes involved in enteroprotection, 
such as iNOS, IL18 and angiogenin, and thereby inhibits bacterial growth and ileal mucosal 
injury in cholestatic mice. Moreover, mice lacking FXR had increased ileal levels of bacteria 
and a compromised epithelial barrier 78. 
In addition to FXR, bile salts have also been shown to activate other nuclear receptors, the 




leading to a reduction of bile salt toxicity 79-82. Bile salts can also activate MAPK pathways, 
usually by activating cellular membrane receptors, and thereby affect proliferation and 
apoptosis 83-88. Recently, bile salts were also found to be ligands for a G protein-coupled  
membrane receptor (TGR5/GPBAR1) 89,90. Watanabe et al. provided data to suggest that 




Cholestatic liver disease has been associated with numerous nutritional deficiencies, 
including EFA deficiency, and subsequent failure to thrive (reviewed in chapter 2) 1. Despite 
numerous treatment options to alleviate the clinical manifestations of cholestasis, cholestatic 
liver disease can necessitate a liver transplantation 93,94. In children, cholestasis-induced 
malnutrition or failure-to-thrive is associated with a worse outcome of their disease 95-99. 
Cholestatic disorders can be divided in hereditary (genetic) disorders and acquired 
disorders. The majority of hereditary cholestatic disorders are characterized by defects in 
transporters involved in bile formation 100-102.  
 
Etiology of cholestatic disorders 
Progressive Familial Intrahepatic Cholestasis (PFIC) comprises a group of autosomal 
recessively inherited disorders associated with transporter defects. Mutations in the FIC-1 
(ATP8B1) gene, encoding FIC-1, can cause PFIC type 1 (PFIC-1) or Benign Recurrent 
Intrahepatic Cholestasis (BRIC) 100,102,103. PFIC-1 is most commonly diagnosed in newborns 
and often begins with cholestatic episodes progressing to permanent cholestasis with 
fibrosis, cirrhosis and liver failure in the first two decades of life. PFIC-1 is also associated 
with jaundice, pruritus, diarrhea and a failure to thrive. Plasma levels of bile salts and 
cholesterol are elevated 104. BRIC is characterized by recurrent spells of cholestasis 
associated with pruritus, jaundice, fatigue, loss of appetite, anorexia and elevated plasma 
bile salt levels 103,104. The age of onset, severity and number of these episodes vary greatly 
105
. FIC-1 profoundly acts as an aminophospholipid translocase, ‘flipping’ specific 
phospholipids (phosphatidylserine and phosphatidylethanolamine) from the outer leaflet to 
the inner leaflet of the membrane 106,107. FIC-1 and other homologues have been detected 
all over the body, including the bile canalicular membrane of hepatocytes and, with higher 
abundance, in the intestine and cholangiocytes 106,108,109. Studies with FIC-1 knockout mice 
revealed disturbed bile salt homeostasis, but only mildly impaired bile secretion, despite 
elevated plasma bile salt levels 110,111. The former findings are suggestive of an important 
role for the intestine in PFIC-1. This was confirmed by the observation that biliary diversion 
is a successful treatment for PFIC-1 patients, alleviating intrahepatic and extrahepatic 
symptoms 112,113. Chen et al. demonstrated that FIC-1 mRNA was absent in the ileum of 
PFIC-1 patients, coinciding with strongly reduced FXR expression and fourfold higher ASBT 
expression. They also showed that BSEP promoter activity was diminished while ASBT 
promoter activity was greatly enhanced in FIC-1 antisense treated Caco-2 cells, presumably 
via the loss of FXR 114. Therefore, it is likely that bile salt uptake from the ileum is enhanced 
and bile salt secretion from the liver is diminished in PFIC-1 patients, explaining the 
manifestation of cholestasis. Studies with Fic1 (Atp8b1) knockout mice, however, did not 
reveal enhanced bile salt absorption or increased Asbt expression, suggesting that the 
accumulation of bile salts in the plasma is not caused by increased intestinal bile salt 
absorption 110. Moreover, Paulusma et al. showed that Atp8b1 deficiency resulted in a loss 
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of canalicular phospholipid asymmetry that in turn renders the canalicular membrane less 
resistant toward hydrophobic bile salts, which may impair bile salt transport and cause 
cholestasis 115.  
PFIC-2 is caused by mutations in the BSEP (ABCB11), encoding BSEP, the canalicular bile 
salt efflux pump 116. Jansen et al. demonstrated that BSEP was absent from the canalicular 
membrane in PFIC-2 patients 117. The clinical symptoms of PFIC-2 overlap with PFIC-1, but 
with fewer extrahepatic abnormalities and generally with a less episodic character, though 
often with more severe symptoms 102-104. Bsep knockout mice show a clear decrease in bile 
salt secretion 24,103, explaining the manifestation of cholestasis. 
PFIC-3 is associated with mutations in the MDR3 (ABCB4) gene, encoding MDR3 102-104. 
MDR3 is a phospholipid floppase at the canalicular membrane, facilitating the secretion of 
phosphatidylcholine in bile 118. The clinical symptoms of PFIC-3 are different from PFIC-1 
and PFIC-2 as in that symptoms usually present somewhat later in life and also liver failure 
occurs at a later age. The histological picture shows strong bile duct proliferation and 
cirrhosis. PFIC-3 is also associated with jaundice, pruritus and elevated plasma bile salt 
levels 102-104. A mouse model in which the mouse homolog of the human MDR3 gene, Mdr2, 
was disrupted revealed absence of biliary phospholipids despite normal bile salt secretion, 
progressive liver disease and histology similar to that in PFIC-3 patients 119. Biliary 
phospholipids form mixed micelles with bile salts and prevent crystallization of cholesterol. In 
the absence of phospholipid secretion, the detergent bile salts tend to solubilize lipids from 
the biliary epithelium and cholangiocytes, leading to bile duct damage and secondary biliary 
fibrosis and cirrhosis 104.  
Inborn errors of bile salt biosynthesis can also lead to cholestasis. Seven defects have been 
characterized so far, including mutations in the genes encoding for HSD3B7 120-122, AKR1D1 
123,124
, CYP7A1 125, CYP27A1 126, CYP7B1 127, BAAT 128 and 2-Methylacyl-CoA racemase 
129
. The phenotype of these defects is highly variable and they do not all lead to cholestasis. 
Liver disease tends to be more severe in defects that involve modifications of the cholesterol 
side chain than defects responsible for catalyzing reactions in the steroid nucleus (except for 
CYP7A1 deficiency) 130. 
Finally, the autosomal dominant hereditary Alagille syndrome is the most common form of 
hereditary cholestatic liver disease in children. Alagille syndrome is associated with 
mutations in the human JAGGED gene, leading to hypoplasia of the intrahepatic bile ducts 
among various other defects 131,132.  Clinical manifestations include chronic cholestasis, 
characteristic facial features, pulmonary artery hypoplasia and congenital heart disease. 
Severely affected children account for about 20% of the patients and may require liver 
transplantation 133. Jagged 1 encodes a ligand for Notch 1, which seems essential for 
remodeling of embryonic vasculature 134,135. 
Acquired forms of cholestasis can be caused by changes in transporter expression or 
function and, more commonly, by obstructions or destruction of the bile ducts. Changes in 
transporter or function are usually due to cholestatic agents such as drugs, hormones or 
pro-inflammatory cytokines. Gallstones and tumors can cause obstruction of extrahepatic 
bile ducts, while vanishing bile duct syndromes such as biliary atresia, primary biliary 
cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are associated with the destruction 
of bile ducts.  
Biliary atresia is characterized by the immune-mediated destruction of the extrahepatic and 
intrahepatic bile ducts and development of biliary cirrhosis. Biliary atresia is the leading 




births and is slightly more common in females (1.2:1). Biliary atresia can be distinguished in 
perinatal (acquired) and the embryonic (fetal) types. The majority (80%) of biliary atresia 
cases are of the perinatal type. These otherwise normal infants are presumably born with a 
patent biliary system which undergoes progressive inflammation initiated by a perinatal 
insult. The embryonic form of biliary atresia is associated with other congenital anomalies, 
most commonly involving abdominal situs inversus (major visceral organs are inversed or 
mirrored from their normal positions) 136.  The clinical symptoms of both types are similar, 
though the etiologies may differ 131,137. Several potential mechanisms involved in the 
pathogenesis of both forms have been suggested, including defects in morphogenesis, 
defects in prenatal circulation (embryonic), immunologic dysregulation, viral infection and 
toxin exposure (perinatal) 137-140.  
PBC is an autoimmune disease marked by slow but progressive disappearance of the 
intrahepatic bile ducts. Both autoreactive T cells and natural killer cells have been 
associated with the pathogenesis of PBC 141,142. Also PSC is an inflammatory autoimmune 
disease leading to the progressive destruction of the biliary tree. Though several 
mechanisms contributing to PSC have been postulated, including portal bacteremia, viral 
infections, toxins and ischemic injury, the etiology of PSC remains unknown 131.  
 
Treatment of cholestatic disorders 
Current surgical treatment options include biliary drainage for obstructive cholestasis and  
Kasai-portoenterostomy for biliary atresia. Despite good results, however, the need for liver 
transplantation remains for many cases.   
A convential treatment for cholestasis-induced pruritis is the anion-exchange resin 
cholestyramine. Cholestyramine is a hydrophilic, water-insoluble, non-absorbable agent that 
binds bile salts, preventing their absorption from the terminal ileum. Recently, a new bile 
salt-binding polymer, colesevalem hydrochloride has been reported to be more effective 
than cholestyramine 143. Alternative anti-pruritus treatments include rifampicine and 
naltrexon. 
UDCA, at present, is the only approved drug for cholestatic disorders 94, and has been 
proven beneficial for PBC 144-149, PSC 150-152, PFIC 153 and some forms of drug-induced 
cholestasis 154. The beneficial effects of UDCA have been attributed to three major actions: 
protection of cholangiocytes against cytotoxicity of hydrophobic bile salts, stimulation of 
hepatobiliary and renal secretory routes, and protection of hepatocytes against bile salt-
induced apoptosis.  
Hydrophobic bile salts are known to damage cell membranes at high micromolar to 
millimolar concentrations in vitro. UDCA conjugates counteract these effects, by modulating 
the structure and composition of phospholipid-rich micelles in bile 155,156. Moreover, 
enrichment with UDCA renders bile more hydrophilic and less cytotoxic in humans, 
decreasing the degree of cholangiocellular injury 157. Ca2+ and PKC-dependent mechanisms 
have been shown to contribute to anticholestatic actions of UDCA conjugates in hepatocytes 
158-160
. In cholangiocytes, UDCA might work in a similar fashion.  
The disturbance common to all forms of cholestasis is impaired bile production. This results 
in a retention of bile salts and other potentially toxic biliary constituents in the liver, which 
can leads to or aggravate liver cell injury with further implication for bile formation and 
hepatocellular apoptosis 161. UDCA has been shown to stimulate biliary secretion of bile 
salts and other organic anions and prevent cholestasis induced by hydrophobic bile salts in 
the rat liver 160,162.  
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Apoptosis is the major form of hepatocyte cell death in cholestatic liver diseases such as 
PBC, and has been attributed to the actions of accumulating hydrophobic bile salts in liver 
cells 160,162,163. In vitro and in vivo studies in rats revealed that UDCA inhibits apoptosis via 
reduction of mitochondrial membrane permeability transition and of mtochondrial 
cytochrome c release 164,165. In addition, UDCA induced survival signaling in hepatocytes via 
activation of the epidermal growth factor receptor (EGFR) and mitogen activated protein 
kinase (MAPK) 166. 
 
 
LIPID ABSORPTION AND METABOLISM 
Cholestasis is frequently accompanied by lipid malabsorption and essential fatty acid (EFA) 
deficiency. Lipids are a large and diverse group of naturally occuring organic compounds 
that are related by their solubility in nonpolar organic solvents and general insolubility in 
water. Lipids serve many physiological functions, including energy storage, structural 
components of cell membranes and signaling molecules. Fahy et al. developed a well-
defined classification system for lipids. Lipids were divided into eight categories; fatty acyls, 
glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids 
and polyketides. The lipids that are discussed here are triglycerides (glycerolipids), 
phospholipids (glycerophospholipids), fatty acids (fatty acyls) and cholesterol (sterol lipids). 
Bile salts are also included in the sterol lipid category 167. Lipid absorption and metabolism 
can divided in several steps; lipolysis, solubilization, mucosal uptake, re-esterification and 
chylomicron formation, and lipoprotein metabolism. Figure 3 shows the chemical structures 
of triglycerides, phospholipids, cholesterol and bile salts and a schematic overview of lipid 



















Triglycerides (triacylglycerols) are the major lipid contents in the human diet and constitute 
about 40% of the energy intake in Western diets. Other dietary lipids include phospholipids, 
glycolipids, sterols and vitamins A, D, E and K. Prior to lipolysis, the chewing process 
disperses the lipids, whereby the surface area is increased and a food bolus is formed. The 












































Figure 3 Chemical structures of cholesterol, a bile 





into diacylglycerol and free fatty acids takes place 168,169. Hydrolysis is performed by gastric 
lipase or lingual lipase. Lingual lipase is released from von Ebner’s glands, the lingual 
serous glands on the tongue, and is transferred with the food bolus from the mouth into the 
stomach where its activity is exerted 170,171. Gastric lipase is released from the gastric 
mucosa 172. The relative contribution of these lipases to hydrolysis depend on the species 
considered. Rodents have high activity of lingual lipase and low activity of gastric lipase, 
while primates and humans have high activity of gastric lipase 173. About 10-30% of dietary 
triglycerides are hydrolyzed in the stomach in humans and rats 174,175. The predominant 
fraction of dietary triglycerides is hydrolyzed by pancreatic lipase. The entry of triglyceride 
degradation products in the duodenum causes gallbladder emptying and cholecystokinin 
release with subsequent pancreatic lipase secretion 176-178. Pancreatic lipase binds to the 
surface of the food bolus with co-lipase as a mediator to overcome the expulsion of the 
lipase into the water-phase caused by bile salts and digests the triglycerides. This lipolytic 
process results in the formation of monoacylglycerol and free fatty acids 179. Phospholipids 
in the duodenum are derived from diet, bile and intestinal epithelial sloughing. Pancreatic 
phospholipase A2 catalyzes the hydrolysis of a variety of phospholipids in the duodenum, 
yielding lysophospholipids and free fatty acids 168.  Cholesterol in the intestinal lumen can be 
derived from diet, from bile and from epithelial sloughing. In response to a meal, carboxyl 
ester lipase is secreted from the pancreas and catalyzes de-esterification of cholesteryl 
esters. The pool of unesterfied cholesterol (mainly derived from bile) in the intestinal lumen 
is relatively much larger than the esterified dietary pool of cholesterol 180. Accordingly, 
targeted disruption of the gene encoding for carboxyl ester lipase only has a slight inhibitory 
effect on intestinal cholesterol absorption in mice 181,182.  
 
Solubilization 
The products of pancreatic lipolysis of dietary lipids (fatty acids, monoacylglycerol, 
lysophospholipids, unesterified cholesterol) are more polar than their parent lipids, but still 
have limited solubility in the aquous environment of the intestinal lumen. Bile provides the 
ideal detergent for the solubilization of these lipolytic products. The amphipathic nature of 
bile salts allows them to form micelles. Micelles are water-soluble poly-molecular 
aggregrates with a discoid configuration in which the polar groups of the lipid molecules are 
at the surface projecting into the aqueous medium, while the apolar hydrocarbon parts are at 
the core. Bile salt micelles desorb polar lipids from the surface of emulsified droplets, thus 
allowing hydrolysis to proceed 183-185. A substantial proportion of dietary triglycerides can be 
absorbed even in the absence of bile salts (even up to 75%), as in biliary obstruction and 
diversion 186, suggesting that a mechanism of lipid solubilization can compensate for bile salt 
deficiency. Phospholipids for instance, are relatively independent from bile components for 
their efficient intestinal absorption. Phospholipids have a higher tendency than triglycerides 
to interact with water and can associate into liquid crystals, which have been suggested to 
play a role in luminal lipid solubilization under bile-deficient conditions 187.  
  
Mucosal uptake 
Lipolytic products are mainly absorbed taken up by proximal jejunal enterocytes 188. During 
the process intestinal absorption, lipids solubilized in micelles must dissociate from them, 
and this occurs at a thin water layer adjacent to the lumenal surface of the enterocytes, the 
unstirred water layer 189,190. The existence of an acidic microclimate in this water layer (pH 
5.3-6.0), promotes both micellar dissociation and fatty acid protonation, facilitating diffusion 
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of fatty acids across the cellular lipid membrane 191. Schoeller et al. identified a 
sodium/hydrogen exchanger in the brush border membrane of rat jejunal enterocytes, which 
is probably responsible for the acidification of the unstirred water layer 192. Passive diffusion 
of fatty acid monomers across the microvillous membrane is very rapid 188,193.  
In addition to rapid diffusion some fatty acid transport proteins have been identified. Fatty 
acid transport protein 4 (FATP4) and fatty acid translocase (FAT/CD36) are present on 
intestinal brush border membrane transporters and have been suggested to facilitate 
transport of fatty acids across the cellular membrane 194,195. Recently, Nassir et al. 
postulated that Fat is important for fatty acid and cholesterol uptake by the proximal intestine 
but not the distal intestine, based on reduced uptake of fatty acids (50%) and cholesterol 
(60%) in Fat-deficient primary proximal enterocytes 196. However, Goudriaan et al. 
demonstrated that lipid absorption was not affected in Fat knockout mice 197. Targeted 
disruption of Fatp4 in mice was shown to be lethal. Heterozygous Fatp4 deletion mice 
showed decreased fatty acid uptake by enterocytes ex vivo, but not in vivo, possibly due to 
the large excess capacity of the small intestine for lipid absorption 198. The subcellular 
localization of  FATP4 has been a subject of debate. Stahl et al. showed significant amounts 
of FATP4 on the apical membrane of enterocytes 195, while Milger et al. found that FATP4 
was localized exclusively intracellularly in enterocytes 199. Milger et al. showed increased 
fatty acid uptake rate in case of FATP4 overexpression. However, they proposed that 
FATP4 may not be involved in fatty acid translocation at the plasma membrane, but may 
rather drive fatty acid uptake indirectly by stimulating its intracellular esterification 199.  
Cholesterol uptake by the enterocyte can occur via diffusion or active transport systems 
180,200-202
. Two groups identified two adjacent genes ABCG5 and ABCG8 encoding 
membrane transporters in the intestine and the liver 203,204. Studies with transgenic and 
knockout mice showed that heterodimerization of ABCG5 and ABCG8 results in a functional 
sterol transporter, transporting cholesterol and plant sterols out of the cell across the apical 
membrane of enterocytes or hepatocytes. ABCG5 and ABCG8 are localized at the apical 
brush border membrane of enterocytes and at the canalicular membrane of hepatocytes 205-
209
. Altmann et al. identified Niemann Pick C1 Like1 (NPC1L1) as a cholesterol uptake 
transporter. NPC1L1 is predominantly expressed in the intestine, with peak expression in 
the jejunum, corresponding with the efficiency of intestinal cholesterol absorption 210,211. 
Davies et al. showed that NPC1L1 is localized at the apical membrane of enterocytes 212. 
NPC1L1 is essential for intestinal cholesterol absorption, evidenced by the observation that 
Npc1l1 knockout mice are defective in intestinal cholesterol uptake 210,213.  
 
Re-esterification and chylomicron formation 
Once taken up by via the apical membrane of the enterocyte, fatty acids bind to IFABP and 
diffuse to the endoplasmic reticulum. Induction of cytosolic intestinal fatty acid binding 
protein (IFABP) expression in differentiated intestinal cells correlated with increased re-
esterification, but not with enhanced fatty acid uptake 214. In the endoplasmic reticulum fatty 
acids are activated to acyl-CoA and are subsequently re-esterificated into triglycerides 188. 
Two major pathways exist for synthesizing diacylglycerol: the glycerol phosphate pathway 
and the monoacylglycerol pathway. In the glycerol pathway, which functions in most cells, 
diacylglycerol is derived by the dephosphorylation of phosphatidic acid produced by 
sequential acylations of glycerol phosphate. In the monoacylglycerol pathway, reported 
predominantly in the intestine, diacylglycerol is formed directly from monoacylglycerol and 




(MGATs) 215,216. MGAT1 is expressed in most tissues but not the intestine. MGATs 2 and 3 
are primarily expressed in the intestine and may be the key contributors to triglyceride 
packaging within the enterocytes 217-219. Esterification of diacylglycerol into triglycerides is 
catalyzed by acyl-CoA:diacylglycerol acyltransferase (DGAT) 1 and 2. In humans, DGAT1 is 
highly expressed in the small intestine and the colon 220,221. Mice lacking Dgat1 were found 
to have normal plasma triglyceride levels, suggesting alternative mechanisms by which 
triglycerides can be synthesized 222. DGAT2 possesses widespread expression in humans, 
with particularly high levels in liver and adipose tissue 223. The expression patterns of 
DGAT1 and DGAT 2 indicate that they might have different functions within different tissues. 
DGAT1 likely plays a role in intestinal triglyceride resynthesis, whereas DGAT2 may function 
primarily in triglyceride synthesis and export from the liver 224. Esterification of cholesterol 
into cholesteryl esters is catalyzed by acyl-CoA cholesterol acyltransferase 2 (ACAT2). 
ACAT2 expression is limited to the liver and small intestine 225. The importance of ACAT2 in 
cholesteryl ester synthesis was evidenced by the observation that Acat2 knockout mice 
have impaired dietary cholesterol absorption and are resistant to diet-induced 
hypercholesterolemia and gallstone formation 226,227. Microsomal triglyceride transfer protein 
(MTTP) is responsible for the assembly of cholesterol, triglycerides and phospholipids 
together with one apolipoprotein ApoB48 molecule (among other lipoproteins) to form a 
chylomicron particle, and with one ApoB100 molecule (among other lipoproteins) to form a 
very low density lipoprotein (VLDL) particle 228,229. Humans only have ApoB48 in the 
intestine, thus VLDL particles of intestinal origin contain ApoB48. Phospholipids of luminal 
origin are predominantly used by enterocytes for the assembly of the surface coat of 
chylomicrons 230,231. Mice with a conditional intestine-specific Mttp deletion had impaired 
cholesterol absorption, large cytoplasmic triglyceride droplets and no chylomicron-sized 
particles 232, stressing the significance of MTTP in chylomicron formation. Moreover, 
Wetterau et al. demonstrated that a defect absence of MTTP is responsible for the disorder 
abetalipoproteinemia, characterized by a defect in assembly or secretion of VLDLs and 
chylomicrons 233. 
VLDLs (diameter 30-80 nm, 0.93<ρ<1.006 g/ml) are the predominant lipoproteins secreted 
during the fasting state 234,235. In the postprandial state, chylomicrons (diameter 75-450 nm, 
ρ<0.93 g/ml) secretion is induced after fat digestion 236,237. Chylomicrons and VLDLs are 
secreted through the basolateral membrane of enterocytes into the interstitium, enter the 
lymphatic capillaries of intestinal microvilli that drain into omental lymphatic channels, 
eventually reaching the systemic circulation through the thoracic duct 188. 
 
Lipoprotein metabolism 
Once entered the circulation, chylomicrons and VLDLs interact with other lipoproteins such 
as LDL and HDL. Lipid transfer between these plasma lipoproteins is mediated by plasma 
lipid transfer proteins, cholesteryl ester transfer protein (CETP) and phospholipid transfer 




























ESSENTIAL FATTY ACIDS 
The essential fatty acids (EFAs), linoleic acid (LA) and α-linolenic acid (ALA), are not 
synthesized de novo and thus must be derived from the diet. Since EFAs are abundantly 
available in the normal diet, EFA deficiency is relatively rare in humans. LA can be 
elongated and desaturated to dihomo-γ-linolenic acid (DGLA) and arachidonic acid (AA), 
and ALA to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EFAs are 
polyunsaturated fatty acids (PUFAs), which are characterized by a long carboxyl chain and 
the presence of double bond. There are four independent families of PUFAs, depending on 
the parent fatty acid from which they are synthesized. The ω-3 series is derived from ALA 
(18:3ω-3), the ω-6 series from cis-LA (18:2ω-6), the ω-9 series from oleic acid (OA; 18:1ω-9) 
and the ω-7 series is derived from palmitoleic acid (PA; 16:1ω-7). The first number 
designates the amount of carbon atoms, the second number designates the amount of 
double bonds, and the (ω-X) or (n-X) indicates position of the double bond carbon closest to 
the methyl end. The latter two series are not EFAs, since they can be synthesized in 
mammals. 
EFAs and their metabolites have been shown to affect cell membrane fluidity, induce second 
messenger action and exhibit antibiotic actions. Cell membrane fluidity is determined by its 
lipid composition among other factors. Increased incorporation of saturated fatty acids and 
cholesterol into the cell membrane phospholipids renders the cell membrane more rigid, 
while increased incorporation of unsaturated fatty acids will make it more fluid 239-241. 
Moreover, EFA metabolites are precursors to prostaglandins, thromboxanes, leukotrienes, 
lipoxins and resolvins. EFAs and EFA-derived compounds have been shown to play 
significant roles in the pathobiology of many disorders, including collagen vascular diseases, 
hypertension, diabetes mellitus, metabolic syndrome, psoriasis, eczema, atopic dermatitis, 
coronary heart disease, atherosclerosis and cancer 239. Figure 5 shows an overview of 














































































































































































Figure 4 Schematic image of the specific phases of lipid absorption. CE = cholesteryl ester, 
FC = free cholesterol, TG = triglyceride, DG = diacylglycerol, MG = monoacylglycerol, FA = 






















FAT MALABSORPTION IN CHOLESTASIS AND EFA DEFICIENCY 
High incidence of fat malabsorption and EFA deficiency has been reported in cholestatic 
patients 1,97,242-244. Fat malabsorption is defined by an intestinal absorption efficiency lower 
than 95% of the amount ingested via the diet 188. Interestingly, EFA deficiency can not only 
be caused by fat malabsorption, it can also itself induce fat malabsorption 243,245,246. For 
reasons of clarity, fatty acid absorption will be referred to as fat absorption. 
Previous studies in our laboratory revealed that both cholestasis and bile-deficiency are 
associated with impaired plasma LA status in relevant rat models (bile duct ligation and 
permanent bile diversion, respectively) 247,248. Interestingly, impaired plasma LA status in 
cholestatic rats was due to decreased net absorption 247, while in bile-deficient rats 
posabsorptive metabolism of LA (increased plasma AA) was increased 248.  
The mechanism underlying EFA deficiency-induced fat malabsorption has been extensively 
studied, but has not been entirely elucidated yet. Fat digestion and fat uptake were not 
affected in EFA deficient rats 249,250. Levy et al. demonstrated that bile flow and biliary 
secretion of bile salts, phospholipids and cholesterol were significantly decreased in EFA 
deficient rats 250,251. In addition, intracellular events such as re-esterification and chylomicron 
production were impaired during EFA deficiency in rats 249,250. Thus, EFA deficiency-induced 
fat malabsorption in rats can be ascribed to both intraluminal (bile formation) and 
intracellular events (fat processing). In contrast to rats, however, EFA deficiency in mice was 
associated with increased bile flow and biliary secretion of bile salts, phospholipids and 
cholesterol 252.  
Biliary phospholipids can stimulate dietary fat absorption by facilitating intraluminal lipid 
solubilization and by providing surface components for chylomicron assembly. Biliary 
secretion of phospholipids with a different composition could theoretically be involved in EFA 
deficiency-induced malabsorption in mice 253. Voshol et al. showed that postprandial 
appearance of chylomicrons was impaired in mice deficient for phospholipid floppase Mdr2. 
Net absorption of dietary lipids, however, was unchanged in Mdr-/- mice 254. Werner et al. 
demonstrated that absence of biliary phospholipid secretion (Mdr2-/-) did not change fat 




































. Werner et al. also demonstrated that absence of biliary phopsholipid secretion (Mdr2-/-) 
increased chylomicron size, while enhanced biliary phospholipid secretion (EFA deficient) 
yielded smaller chylomicrons in mice lymph 253, further emphasizing the importance of biliary 
phospholipid secretion in fat absorption.  
Some pathological changes have been noted in the intestine of EFA deficient rats, i.e. a 
restricted surface area due to villi shortening and a lack of cellular differentiation 255. This 
effect has been ascribed to decreased EFA content of biliary phosphatidylcholine found in 
EFA deficient rats. Acyl chain analysis of biliary phosphatidycholine revealed strongly 
decreased LA and AA content, compensated by increased oleic acid and palmitoleic acid 
content 249,250. The concentration and composition of fatty acids in biliary 
phosphatidylcholine was also found to affect chylomicron assembly, secretion and clearance 
256,257
.  
In normal diets, 90% of EFAs are present as acyl esters in triglycerides (90%), and only 10% 
as acyl esters in phospholipids and cholesteryl esters. Biliary phospholipids can facilitate 
dietary lipid absorption under bile-deficient conditions (e.g. cholestasis) 258. Indeed, oral EFA 
supplementation in the form of phospholipids was found more effective than in the form of 
triglycerides in increasing LCPUFA concentrations in liver and brain of cholestatic EFA 
deficient mice 259. 
 
 
INTESTINAL CARBOHYDRATE DIGESTION AND ABSORPTION 
Besides lipids, dietary carbohydrates serve as an important source of energy. Figure 6 
shows a schematic overview of disaccharidase digestion and absorption. Dietary 
carbohydrates include polysaccharides (starches) and sugars (di- and monosaccharides). 
Starches from plants make up 75% of dietary carbohydrates and are composed of amylase 
(linear α-1-4-linked D-glucose polymer) and amylopectin (linear α-1-4-linked D-glucose 
polymer, with additional α-1-6 linkages). Intestinal digestion commences with salivary and 
pancreatic amylases. Alpha-amylase produces linear maltose (glucose-α-1-4-glucose) and 
isomaltose (glucose-α-1-6-glucose) oligosaccharides as well as some large oligomers. Final 
hydrolysis occurs in the small intestine where brush-border membrane maltase-
glycoamylase and sucrase-isomaltase hydrolyze oligosaccharides to glucose, which is 
subsequently taken up by the sodium-dependent glucose transporter SGLT1. Sucrase-
isomaltose digests all of the sucrose and 80% of the dietary maltose, while maltase-
glycoamylase digests the remaining maltose and glucose oligomers. Dietary sugars 
(disaccharides) include lactose (milk), sucrose (sugar beet and sugar cane) and minor 
amounts of trehalose (mushrooms). These sugars are hydrolyzed by intestinal brush border 
membrane disaccharidases; lactase, sucrase and trehalase. Lactose is hydrolyzed into 
glucose and galactose, while hydrolysis of sucrose yields glucose and fructose. Dietary 
monosaccharides (mostly derived from fruits) are transported into the enterocytes directly by 
brush-border membrane transporters. Fructose is transported by the uniporter glucose 
transporter GLUT5 and glucose and galactose by SGLT1. Transport into the circulation of all 
monosaccharides occurs via GLUT2 202,260. Regulation of sucrase and lactase gene 
transcription has been shown to be exerted by cooperative action of transcription factors 
HNF1α, GATA4 and CDX2 261-264.  
It is rather unexplored whether cholestasis affects intestinal carbohydrate digestion and 
absorption. Borges et al. reported that obstructive jaundice did not affect jejunal absorption 




be unaffected in cholestyramine-fed and bile-diverted rats, based on determinations in 


















FARNESOID X RECEPTOR 
As stated before, FXR is involved in the regulation of the enterohepatic circulation of bile 
salts and the feedback regulation of bile salt synthesis. FXR activation has been suggested 
to serve as a protective mechanism, because potential toxicity of bile salt accumulation, 
evident in cholestatic disorders, is counteracted by bile salt-activated FXR 267. Three groups 
simultaneously identified bile salts as ligands for FXR 69-71. There are two known FXR 
genes, commonly referred to as FXRα and FXRβ. In humans and mice, FXRα encodes four 
isoforms, FXRα1-4, result from different promoters and transcription intitation sites as well 
as alternative splicing of the RNA 268,269. FXRβ encodes a functional member of the nuclear 
receptor family in rodents, rabbit and dogs, but is a pseudogene in humans and primates 270. 
FXRα is mainly expressed in the liver, gut, kidney and adrenal glands, with much lower 
levels in adipose tissue 268,269,271,272. Many FXR target genes are regulated in an isoform-
independent manner, however, IBABP and fibroblast growth factor 19 (FGF19) are more 
responsive to the FXRα2 and FXRα4 269,273,274. FXR isoforms modulate expression of genes 
by binding either as a monomer or as a heterodimer with retinoid X receptor (RXR) to DNA 
sequence motifs 267. FXR isoforms can be activated by structurally different ligands, 
including several primary and secondary bile salt species conjugated to either taurine or 
glycine, CDCA being the most potent ligand 69,71. The ligand binding domain is not 
conserved between species. For instance, mouse FXR is more responsive to CA than its 
human counterpart 275. In the next sections, the role of FXR (referred to as FXR) in bile salt 
metabolism, lipid metabolism and glucose metabolism will be discussed. 
 
FXR in control of bile salt metabolism 
During the last decade, it has become clear that FXR has a crucial role in regulating bile salt 
metabolism. FXR regulates expression of genes involved in (1) bile salt synthesis, (2) 
hepatic secretion of bile salts and (3) phospholipid into the bile, (4) remaining (apart from 



















































Figure 6 Schematic image of enterocytes digesting lactose and sucrose and 
subsequently absorbing the hydrolysis products; monosaccharides glucose 
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detoxification 276. Figure 7 is a schematic image of the effect of bile salt-induced FXR 
activation on its target genes involved in bile salt metabolism. 
(1) Expression and induction of Cyp7a1 in rodents are dependent on oxysterol-activated 
liver X receptor α (LXRα) and liver receptor homolog 1 (LRH1) 277. The human CYP7A1 
gene, in contrast, lacks a LXRα response element 278. FXR activation induces 
expression of small heterodimer partner (SHP) 279,280, a member of the nuclear receptor 
family that lacks a DNA-binding domain 281. SHP, in turn, can dimerize with and 
inactivate both LXRα and LRH1, resulting in a decrease in Cyp7a1 expression 279,280,282. 
Support for this regulatory cascade comes from studies showing that treatment of Shp 
knockout mice with a potent, synthetic FXR agonist (GW4064) fails to repress Cyp7a1 
283,284
. Another pathway that regulates bile salt synthesis is initiated after activation of 
FXR in enterocytes. This activation results in enhanced transcription and secretion of 
fibroblast growth factor 15 (Fgf15; FGF19 in humans) 285. Subsequent binding of Fgf15 
to fibroblast growth factor receptor 4 (FGFR4) on the hepatocyte cell membrane results 
in the activation of the JNK pathway and repression of Cyp7a1 and Cyp8b1 285. 
Moreover, FXR was found to induce expression of intestinal fibroblast growth factor 19 
(FGF19; Fgf15 in rodents), a secreted growth factor that signals through the FGFR4 
cell-surface receptor tyrosine kinase. FGF19/Fgf15 strongly suppresses expression of 
CYP7A1 in primary cultures of human hepatocytes and mouse liver through a JNK-
dependent pathway 286. Mice lacking Fgf15 have increased hepatic CYP7A1 mRNA, 
protein levels and enzyme activity 285. 
(2) Bile salt-activated FXR activates transcription of the canalicular bile salt export pump 
BSEP, and thus facilitates bile salt excretion into the bile 287. Also MRP2 expression 
was induced upon FXR activation 288.  
(3) Huang et al. demonstrated that FXR activation by CDCA and GW4064 induces 
expression of the human MDR3 gene 289. The mouse MDR3 homolog Mdr2 was also 
shown to be induced upon FXR activation 290. Induction of MDR3/Mdr2 expression by 
bile salt-activated FXR increases phospholipid excretion into bile. 
(4) Negative feedback regulation rat Ntcp by bile salt-activated Fxr has been shown to 
occur via Shp induction, leading to decreased transport of bile salt into the hepatocytes 
291
. Ileal expression of ASBT in the rat is unaffected by bile salts, while in humans and 
mice it is under negative feedback regulation via a FXR mediated, SHP dependent 
effect 292. Thus, bile salt-activated FXR reduces the amount of bile salts reabsorbed in 
cholangiocytes and terminal ileal enterocytes in humans and mice. In contrast to ABST, 
human IBABP was shown to be induced upon FXR activation in vitro and in vivo 293. 
Ballatori et al. demonstrated that bile salt transporter OSTα/β is localized to the 
basolateral membrane in humans and rodents 40. Apical to basolateral transport of TCA 
was shown to be increased by expression of Ostα/β in polarized canine kidney cells, 
while basolateral to apical transport was unaffected 294. This indicates that OSTα/β 
transports bile salts out of the cell. Human and mice OSTα/β was shown to be positively 
regulated by bile salts via FXR 274,295. Strikingly, Frankenberg et al. found both Fxr 
response elements and a Lrh1 response element in the mouse Ostα and Ostβ 
promoters. Mouse Ostα/β is thus positively and negatively regulated by bile salts. 
Although the positive regulatory pathway appears to be dominant, this arrangement 
provides a mechanism to finely titrate Ostα/β expression to the bile salt flux 295. 
(5) FXR is also involved in the regulation of bile salt conjugation with glycine or taurine, 




CoA:amino acid N-acetyltransferase) are induced by Fxr in the rat liver. Furthermore, 
Bacs and Baat mRNA levels were upregulated by treatment with the Fxr agonist 
GW4064 in rats 296, facilitating bile salt conjugation. SULT2A1 
(dehydroepiandrosterone-sulfotransferase) is a cytosolic enzyme that mediates 
sulphate conjugation of bile salts. SULT2A1 is expressed in the liver and the intestine, 
and its expression has been shown to be increased upon FXR activation by CDCA. 
Song et al. speculated that increased solubility of sulphated bile salts facilitates their 
intracellular transport and clearance 297. Finally, expression of human UGT2B4 (uridine 
5’-disphosphate-glucuronosyltransferase 2B4), which catalyzes the conversion of 
hydrophobic bile salts into more hydrophilic glucuronide derivatives, was increased 


















FXR in control of lipid metabolism 
The involvement of bile salts in the regulation of lipid metabolism became apparent when 
treatment of patients suffering from gallstones or hypertriglyceridemia with CDCA reduced 
plasma triglycerides 299,300. Some important FXR actions related to lipid metabolism are 
listed below. Sinal et al. demonstrated that FXR is involved in the control of plasma lipid 
levels, evidenced by increased plasma levels of triglycerides and cholesterol in Fxr-/- mice 
301
. Fxr-/- mice were also shown to have higher levels of HDL cholesterol, consistent with 
reduced expression of SR-B1, the scavenger receptor that facilitates clearance of HDL 
cholesterol from blood 302,303. Moreover, administration of FXR agonists to healthy rats and 
mice reduced plasma triglyceride levels 304,305. FXR activation also alters transcription of 
genes involved in fatty acid and triglyceride synthesis and lipoprotein metabolism 306. Bile 
salt activated Fxr led to lower plasma triglyceride levels via induction of Shp and subsequent 
repression of mouse Srebp-1c, a transcription factor that controls genes involved in fatty 
acid and triglyceride synthesis 307. These decreased levels of plasma lipids were associated 
with decreased VLDL secretion, caused by reduced expression of MTTP in hamsters fed 
































Figure 7 Schematic image of stimulatory and inhibitory actions of FXR with respect to bile salt homeostasis 
[adapted from 68]. 
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SCOPE OF THIS THESIS 
As stated before, cholestatic liver disease is frequently associated with nutritional defects, 
including EFA deficiency. The resultant malnutritional state strongly affects prognosis and 
treatment outcome in cholestatic children. Our ultimate goal is to improve the prognosis of 
cholestatic children by optimization of their nutritional status. As one of the strategies to 
achieve this, we herewith aimed to elucidate the effects of cholestasis and EFA deficiency 
on intestinal function, with emphasis on nutrient absorption.  
This thesis focusses on the intestinal digestion and absorption of fat and carbohydrates in 
cholestasis and EFA deficiency. In chapter 2, the nutritional status of children with 
cholestatic liver disease and potential treatment options are discussed. The majority of 
cholestatic disorders are associated with elevated plasma bile salt levels. Bile salts have 
been shown to induce proliferation and apoptosis in intestinal cells in vitro. Theoretically, 
high plasma bile salt levels could affect intestinal epithelial cells and their capacity to absorb 
nutrients. In chapter 3, intestinal function in cholestatic rats is compared to intestinal 
function in control rats to elucidate the intestinal effects of cholestasis. With stable isotope 
methodology intestinal digestion and absorption of sucrose and glucose were assessed. To 
be able to pinpoint possible effects to high plasma bile salt levels, cholestatic and control 
rats were compared to bile-deficient rats. In chapter 4 the effects of cholestatic conditions 
on enterocytes in different developmental stages are investigated, by exposing human 
intestinal epithelial cells to bile salts in cholestatic concentrations in vitro.  
Cholestasis-induced fat malaborption is often associated with EFA deficiency. EFA 
deficiency itself can also induce fat malabsorption. The underlying mechanism, however, 
has not been elucidated. Since EFA deficiency has been associated with pathological 
changes in small intestine, i.e., a restricted surface area due to villi shortening and a lack of 
cellular differentiation, intestinal absorption of other nutrients could theoretically also be 
affected. To test this theory, intestinal function and its capacity to digest and absorb 
carbohydrates will be investigated during EFA deficiency. In chapter 5 intestinal function 
and digestion and absorption of lactose and glucose was assessed in EFA deficient mice.  
Finally, like EFAs, the nuclear receptor FXR has been shown to be involved in bile salt 
homeostasis and lipid homeostasis. We speculate that FXR is involved in EFA deficiency-
induced fat malabsorption. In chapter 6 the involvement of FXR in bile formation and fat 
malabsorption was assessed by comparing these parameters in EFA deficient Fxr knockout 
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Nutrition for children with 





























Cholestatic liver disease (CLD) in children negatively affects nutritional status, growth and 
development, which all lead to an increased risk of morbidity and mortality. This is illustrated 
by the fact that the clinical outcome of children with CLD awaiting a liver transplantation is in 
part predicted by their nutritional status, which is integrated in the Pediatric End-Stage Liver 
Disease model. Preservation of the nutritional status becomes more relevant as the number 
of patients waiting for liver transplantation increases and the waiting time for a donor organ 
becomes prolonged. Nutritional strategies are available to optimize feeding of children with 
CLD. Patients with CLD, however, form a heterogeneous group and the clinical 
manifestations of their disease vary. This makes a tailor-made approach for these children 
crucial. Not all aspects of nutrient metabolism and absorption in children with CLD are well 
understood and studied. Experiments with stable isotope-labeled triglycerides and fatty 
acids have provided essential information about fat absorption under physiological and 
cholestatic conditions in animal models and humans. We expect that in the future, tests 
using other isotope-labeled macronutrients, i.e. carbohydrates and proteins, can be used to 


































CHOLESTASIS AND NUTRITIONAL STATUS 
Cholestatic liver disease (CLD) negatively affects nutritional status, growth and 
development, particularly in infancy, i.e. when growth rates are highest. The presence of 
malnutrition and growth retardation (failure to thrive) compromises the clinical outcome for 
children with end-stage liver disease. Cholestatic children with a poor nutritional status, who 
require liver transplantation have an increased risk of morbidity and mortality 1,2. To illustrate 
this, the nutritional status is an important contributor to Pediatric End-stage Liver Disease 
(PELD) score for children under 2 years of age. The PELD score is a reliable predictor of 
mortality in children with CLD on the waiting list for liver transplantation. The PELD model 
was implemented by the United Network of Organ Sharing (UNOS) in the United States in 
February 2002 as an improved algorithm for allocating livers among pediatric orthotopic liver 
transplant candidates, and will be adopted by the Eurotransplant society in January 2007. It 
has recently been shown that the PELD score also correlates with posttransplant survival 3. 
Preservation of the nutritional status becomes more relevant as the number of patients 




NUTRITION FOR CHOLESTATIC CHILDREN 
Poor dietary intake is an important factor in the pathophysiological basis of malnutrition in 
children with CLD. Furthermore, their nutritional status may be further compromised by 
decreased absorption of macronutrients, including fat, carbohydrates and proteins 4. At an 
early age, fat accounts for the most important dietary energy source (up to 50% of total 
ingested energy). Essential fatty acids (EFA) and long-chain polyunsaturated fatty acids 
(LCPUFA) are indispensable for proper development and function of different organs, for 
example the central nervous system. Micronutrient absorption may also be affected in CLD, 
including absorption of fat-soluble vitamins A, D, E and K.  
The dietary prevention or treatment of failure to thrive during CLD involves some general 
principles applicable to virtually all patients and some more individual tailor-made 
approaches. Nutrition in infancy consists predominantly of breast milk or formula. For 
children with CLD, the dietary energy intake is usually increased to levels of 120-150% of 
recommended daily energy intake (corrected for age and gender). The adaptation of the 
formula diet usually involves increasing the concentration and amount ingested. In addition, 
up to 60% of the fat components, particularly long-chain triglycerides are substituted by 
medium-chain triglycerides (MCTs), whose absorption can occur relatively independently 
from the presence of bile components in the intestinal lumen. The carbohydrate content can 
be increased by supplementation of formula with maltodextrin. Breastfed children receive 
additional formula and MCT-rich oil, while for older children feeding with formula is often 
prolonged and energy-rich liquids are provided. Adequate absorption of fat-soluble vitamins 
during CLD can usually be obtained by considerably increasing the dosages administered 
daily, well above regular recommendations for the age groups. Serum levels of fat-soluble 
vitamins are regularly monitored, in order that dosages can be adapted. Adequate intake of 
EFA and LCPUFA is not frequently monitored in CLD patients, but should be reached when 
these fatty acids are provided in ample amounts in the diet. Nevertheless, we reported that 
~70% of children with CLD requiring liver transplantation have biochemical indications of 
EFA and LCPUFA deficiency 5.    
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Reduced gastric volume, vomiting, ascites and hypoglycemia lead to limited absorption of 
the required dietary nutrients when administered in regular (bolus) feedings. Under these 
circumstances, continuous nasogastric drip feeding may be needed to guarantee maximal 
uptake of nutrients.  
For some time now, a special formula for infants with CLD has been available. The 
composition of this formula aimed to accommodate the general aspects of nutritional support 
needed for infants with CLD. So far, however, no data have become available to 
substantiate its benefit, nor its advantage over conventional dietary treatment: 
supplementation of MCT-rich formulas with carbohydrates, fat-soluble vitamins and EFA. 
Clinical data are needed to determine the role that this formula can play in the dietary 
treatment of infants with CLD. 
 
 
BIOLOGICAL ASPECTS OF NUTRITION FOR CHOLESTATIC CHILDREN 
 
Cholestatic diseases in children 
CLD is characterized by decreased or absent hepatic secretion of bile into the intestine. The 
most common cause of CLD in children requiring liver transplantation is biliary atresia. 
Biliary atresia is a progressive disorder characterized by an inflammatory reaction towards 
the extrahepatic and intrahepatic bile ducts, leading to their destruction and subsequent 
replacement by fibrotic scar tissue. The etiology of biliary atresia remains unknown, although 
an inflammatory reaction to a detrimental stimulus seems to play an initiating role. 
Suggested initiating stimuli include specific perinatal viral infections, genetic factors, defects 
in immune response, as well as defects in morphogenesis. Another disease that can lead to 
end-stage liver disease in infancy is Alagille’s syndrome, an autosomal dominantly inherited 
syndrome including bile duct hypoplasia, and congenital anatomical defects in other organs. 
Progressive Familial Intrahepatic Cholestasis (PFIC) is also a genetically transmitted 
disorder, but is inherited in an autosomal recessive fashion. Three phenotypic forms of PFIC 
have been characterized and attributed to gene defects in three different genes (PFIC1-3). 
Another cause of CLD is nonsyndromic paucity of the intrahepatic bile ducts, which is 
suggested to be the result of various infections, chromosomal disorders or metabolic 
disorders. Finally, inborn errors in bile acid synthesis account for part of the children with 
CLD. Defects have been identified in enzymes catalyzing cholesterol catabolism and bile 
acid synthesis 6.  
CLD in adolescents and young adults is often due to autoimmune hepatitis, primary biliary 
cirrhosis or primary sclerosing cholangitis 6,7. 
 
Although the causes and clinical manifestations of CLD may vary, it is often accompanied by 
liver damage. The obstruction or absence of bile ducts leads to accumulation of bile acids in 
hepatocytes, which results in liver damage. Because the enterohepatic circulation of bile 
acids is interrupted, the resulting absence of bile acids in the intestinal lumen leads to 
impaired micellization and therefore to strongly reduced absorption of fats and fat-soluble 
nutrients. Another feature of CLD is the high serum bile acid level, which can cause 
secondary tissue injury.  
In biliary atresia, it is often attempted to correct the enterohepatic circulation of bile acids by 
performing a Kasai portoenterostomy. During this procedure the liver is directly connected to 
the proximal small intestine to optimize bile flow into the intestine as much as possible. 
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However, Kasai portoenterostomy is frequently only a transient solution, due to the presence 
of intrahepatic bile duct damage and ongoing liver damage. Most patients with biliary atresia 
eventually need liver transplantation. As is pointed out above, the nutritional status of 
children with CLD is important for the clinical outcome of liver transplantation and for long-
term survival after liver transplantation. Besides the obviously reduced absorption of fats and 
fat-soluble vitamins, chronic cholestasis also affects dietary intake, energy metabolism and 
metabolism of macronutrients as well as micronutrients. 
 
 
DIETARY INTAKE AND ENERGY EXPENDITURE 
 
Dietary intake 
Reduced dietary intake is an important contributor to malnutrition in children with CLD. 
Fatigue, anorexia, nausea, vomiting, diarrhea, altered or reduced ability to taste, and early 
satiety may all contribute to decreased ingestion of food. Organomegaly and ascites can 
further compromise dietary intake by reducing gastric capacity. Additionally, many diet 
modifications, for example sodium, fluid or protein restrictions, make food even more 
inpalatable. These dietary restrictions are imposed on patients with relatively high risks of 
fluid overload and encephalopathy, which, when left untreated, can lead to serious 
irreversible defects 8.  
 
Energy metabolism 
Energy expenditure is composed of the basal metabolic rate (BMR), the amount needed for 
growth and metabolism. Although clinical data are conflicting, some children with CLD have 
been shown to have an increased BMR. Shanbhogue et al. 9 reported a higher BMR, when 
related to lean tissue in patients with end-stage liver disease. In children with biliary atresia 
energy expenditure was 29% higher than healthy controls 10. Also Shepherd 11 reported 
higher energy expenditure per unit body cell mass in children with biliary atresia In contrast, 
Muller et al. 12 found that patients with cirrhosis showed a variable BMR, in the range from 
hypometabolic to hypermetabolic Another study showed an unchanged BMR in children with 
Alagille syndrome 13. A hypermetabolic state could be an important factor in the clinical 
outcome for CLD, because it further aggravates nutritional status. 
Recently, Watanabe et al. 14 found that bile acids induce energy expenditure by promoting 
intracellular thyroid hormone activation. In this study, mice were fed a bile acid (cholic acid)-
containing high fat diet. These mice showed subsequent reduction in weight gain, white 
adipose tissue weight and brown adipose tissue weight compared to mice on a high fat diet. 
In addition, animals fed a high fat diet containing cholic acid had higher CO2 production and 
O2 consumption, indicating a higher level of energy expenditure. Human skeletal muscle 
myocytes showed an increase in O2 consumption after treatment with bile acids It is 
presently unknown, however, whether bile acid accumulation in patients with CLD is partly 




Apart from reduced intraluminal bile acid concentrations, other consequences of CLD, such 
as gastrointestinal bleeding, impaired digestive enzyme production and secretion, mucosal 
congestion, villous atrophy, bacterial overgrowth or pancreatic insufficiency, can lead to 
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maldigestion and malaborption of nutrients. In addition, even certain medications can 
aggravate malabsorption. For example, cholestyramine binds to bile acids in the intestinal 
lumen and thereby further reduces absorption of fat-soluble nutrients. Also, reduced 
availability of specific nutrients involved in digestion and/or absorption of other nutrients, 
specifically vitamins and minerals, affects intestinal absorption 8. In the remaining part of this 
article we will focus on metabolism of fat, carbohydrates, protein and micronutrients in CLD.  
 
Fat metabolism 
CLD is characterized by malabsorption of fat. Especially long-chain triglycerides, which are 
digested to fatty acids and monoacylglycerols in the intestinal lumen, are poorly absorbed 
during cholestasis, due to their impaired micellization during bile deficiency.  
The route that fat undertakes from the diet to the blood can be divided in four steps: 
emulsification, lipolysis (lipases), solubilization (bile) and translocation (mucosa). During 
lipolysis lipases catalyze the conversion of triglycerides to glycerol and fatty acids. The latter 
need to be solubilized by bile acids to be transported towards the vicinity of the mucosa. 
Here, at the unstirred water layer, the micelles disintegrate, after which fatty acids and 
monoacylglycerols are taken up across the apical membrane of the mucosal cells. Inside the 
enterocytes, the absorbed lipids are reacylated to triacylglycerols, assembled into 
chylomicrons, which are then secreted into lymph and subsequently appear in the 
circulation.  
In our laboratory, Kalivianakis et al. 15 developed a stable isotope test to quantify lipolysis 
and absorption of long-chain fatty acids in rats. We determined absorption and appearance 
in plasma of 13C-labeled palmitic acid in rats with malabsorption either due to chronic bile 
deficiency (permanent bile diversion as developed in our laboratory by Kuipers et al. 16) or 
due to oral administration of the lipase inhibitor Orlistat. These models were used to 
discriminate between potential causes of fat malabsorption such as impaired intestinal 
lipolysis or reduced uptake of fatty acids. Rats were given a high fat diet (35% of total 
energy) compared to a low fat diet (14% of total energy) to potentiate the effect of fat 
malabsorption. Results were compared with the percentage absorption of ingested fat 
determined by fat balance. As expected, dietary fat absorption was significantly impaired in 
bile-deficient animals as compared to controls (Fig 1D). However, the net fat uptake (Fig 
1C), defined as the difference between the amount of fat ingested (Fig 1A) and the amount 
of fat excreted (‘lost’) via the feces (Fig 1B) through fat malabsorption, was not significantly 
affected by the presence or absence of intestinal bile (control vs. chronic bile diversion), or 
the amount of fat in the diet (high fat vs. low fat). The percentage of total ingested fat 
absorbed in bile-deficient rats was only 87% with the low fat diet and 54% with the high fat 
diet (Fig 1D). Apparently, bile deficieny (without cholestasis) increases the nutrient ingestion 
in rats, compensating sufficiently for the increased energy and fat loss via the feces. Bile 
deficiency due to bile diversion in rats led to a decreased concentration of plasma 13C-
palmitic acid, indicating impaired absorption of long-chain fatty acids. Control experiments 
showed that lipolysis was not affected in bile-deficient rats. Impairment of fat absorption due 
to Orlistat had no effect on plasma 13C-palmitic acid, indicating the specificity of the test 15. 
This test can also be utilized to generate clinical data as was demonstrated by Rings et al. 
17
. Rings et al. showed that the absorption of free fatty acids, but not fat digestion was rate-
limited in neonates, and developed to adult competence within 2 months after term age. 
Neonates are known to have a mild ‘physiological’ cholestasis during the first months of life, 






















EFA and LCPUFA are crucial for normal development and function. They cannot be 
synthesized endogenously and therefore must be provided by the diet. As is reviewed by 
Sealy et al. 5, the percentage of n-3 and n-6 fatty acids is reduced in pediatric cholestasis. 
This observation reflects the inability of CLD patients to absorb sufficient amounts of EFA 
and LCPUFA, due to absence of bile in the intestinal lumen in combination with frequently 
compromised dietary intake. An important consequence of this inability to acquire sufficient 
amounts of LCPUFA is EFA deficiency. The quantitatively most important EFAs are linoleic 
acid (LA) and α-LA, members of the n-6 and n-3 family of fatty acids. Linoleic and linolenic 
acid are precursors for LCPUFAs, including arachidonic acid (C20:4n-6), eicosapentaenoic 
acid (C22:5n-3), and docosahexaenoic acid (C22:6n-3), respectively.  
Minich et al. 18 investigated fat malabsorption as a possible cause of EFA deficiency in rats 
that were intestinally bile deficient due to either permenant bile diversion or to bile duct 
ligation (cholestasis). Absorption of the EFA LA was quantified by fat balance and by 
measuring plasma concentrations of [13C]-LA after its intraduodenal administration. Plasma 
concentration of [13C]-LA was decreased in bile-diverted rats, while net absorption of LA 
from the intestine was unaffected. The fact that net absorption of fat and LA was not affected 
in bile-deficient rats corresponded with increased food intake (see above) in addition to 
relative preservation of EFA absorption under bile-deficient conditions, in comparison with 
nonessential saturated fatty acids, such as palmitic acid (C16:0) and stearic acid (C18:0). In 
cholestatic rats, however, both plasma concentration and net absorption of unlabeled or 
[13C]-labeled LA were decreased. Metabolism of LA into arachidonic acid was not affected, 
indicating that LA deficiency in these rats is due to decreased net absorption. The 
compensatory increase in nutrient ingestion during intestinal bile deficiency on the basis of 
permanent bile diversion (see above) did apparently not occur in rats with intestinal bile 
deficiency on the basis of bile duct ligation. It is tempting to speculate that the accumulation 
of bile products during the latter cholestatic condition abolishes the compensatory 
mechanism of increased nutrient ingestion. This observation is in accordance with clinical 













































































































































































































Figure 1 Fat absorption in bile-deficient and cholestatic rats on low fat and high fat diet, with (A) fat intake, 
(B) fecal fat excretion, (C) net fat uptake, and (D) dietary fat absorption as % of amount ingested. [adapted 
from 15 and 18]. 
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Children with CLD are sometimes given a fat-restricted diet, since effects such as 
steatorrhea/diarrhea are expected. According to the study of Kalivianakis et al. 15 the amount 
and fraction of dietary fat lost via the feces is indeed significantly less on a low fat than on a 
high fat diet (Fig 1B). However, net fat uptake from a high fat diet was almost 2-fold higher 
than that from a low fat diet (Fig 1C). The net absorption reflects the amount of nutrients (fat) 
that actually becomes available for energy and growth needs of CLD patients. This 
observation underlines a clinical strategy to increase, rather than to restrict the amount of fat 
intake in patients with CLD, even at the expense of steatorrhea, in order to maximize their 
nutritional condition.   
 
Carbohydrate metabolism 
In children with CLD, carbohydrate homeostasis can be affected by hepatic failure itself, for 
example by a decreased capacity of gluconeogenesis. Frequently also peripheral utilization 
of glucose is reduced, which may decrease the risks of hypoglycemia. In CLD, hepatic 
degradation of insulin may also be decreased, which may be one of the causes for the 2-fold 
higher insulin response in CLD compared to control patients. Elevated plasma levels of 
insulin in combination with glucose tolerance imply insulin resistance, which could be further 
aggravated by increased circulating free fatty acids as seen in CLD 8.  
Apart from the hepatic effects on glucose homeostasis, the intestinal carbohydrate 
absorption could also be affected by CLD. However, no data are yet available about 
carbohydrate absorption under cholestatic conditions. Recently our group has started to 
investigate intestinal carbohydrate absorption under cholestatic conditions in vitro and in 
vivo. The underlying hypothesis for this research is that cholestasis, i.e. high serum bile acid 
concentrations could alter intestinal function by affecting proliferation, differentiation and/or 
apoptotic cell death of the absorptive intestinal epithelium 19. These effects of cholestatic bile 
acid concentrations on other cell types have been well delineated. For example, relatively 
low concentrations of bile acids induce apoptosis in hepatocytes 20.  
 
Protein metabolism 
The catabolic reduction in total body protein as seen in CLD is mainly due to extensive liver 
damage. Tavill 21 and McCullough and Glamour 22 found no significantly changed protein 
turnover in CLD patients. Amino acid oxidation is normal or reduced in these patients, 
consistent with appropriate adaptation to reduced nutrient supplies. Due to hepatic 
insufficiency occurring in later stages of CLD, oxidation of aromatic amino acids is reduced 
as is the metabolism of branched-chain amino acids. Mager et al. 23 reported an increased 
dietary need for branched-chain amino acids in children with mild-to-moderate chronic CLD, 
due to increased postabsorptive leucine oxidation. In general, amino acids seem to be 
conserved in CLD, probably due to the body’s ability to increase protein synthesis and 
reduce amino acid oxidation. This increased protein synthesis is, however, at the cost of 
muscle proteolysis 21,22. Increased protein oxidation resulted in a virtually zero nitrogen 
balance in children with biliary atresia and even in oxidation of endogenous proteins 10. 
Stable experimental conditions do not necessarily reflect the spectrum of clinical conditions 
frequently encountered, such as episodes of metabolic stress or infections that can increase 
protein turnover and catabolism 8. Interestingly, Sokal et al. 24 found that branched chain 




Overall, addition of proteins, and especially specific amino acids such as branched chain 
amino acids, could improve nutritional status of children with CLD. However, care must be 
taken, because an excess of protein can negatively influence encephalopathy. 
 
Micronutrient metabolism 
The absence of bile acids in the intestinal lumen as observed in cholestasis reduces  
absorption of fat-soluble vitamins A, D, E and K, as briefly described above. Calcium uptake 
is at risk as a result of formation of nonsoluble calcium fatty acid soaps during fat 
malabsorption. Hypovitaminosis D may increase renal loss of phosphate and 
hypovitaminosis A may induce zinc deficiency. Zinc deficiency has a negative impact on 
cognitive function, appetite and taste, immune function, wound healing and protein 
metabolism. In addition, zinc deficiency has frequently been associated with EFA deficiency 
25
. Finally, uptake of selenium can be disturbed due to EFA deficiency and iron depletion is 
seen as a result of gastrointestinal bleeding, insufficient uptake, transport and handling of 
iron. In addition, liver dysfunction strongly reduces storage capacity of vitamins such as 
folate, riboflavin, nicotinamide, pantothenic acid, pyroxidine, vitamin B12, thiamine and 
vitamin A. Hepatocellular injury in CLD also results in defects in vitamin activation, 
conversion, release and transport 8. 
As described above, children with CLD receive higher dosages of fat-soluble vitamins. 




Influencing nutritional intake and metabolism is a critical aspect of the management of 
children with CLD. Patients with CLD form a heterogeneous group and the clinical 
manifestations of their disease vary. This makes a tailor-made approach for these children 
crucial. Not all aspects of nutrient metabolism and absorption in children with CLD are well 
understood and studied. Experiments with stable isotope-labeled triglycerides and fatty 
acids have provided essential information about fat absorption under physiological and 
cholestatic conditions in animal models and humans. We expect that in the future, tests 
using other isotope-labeled macronutrients, i.e. carbohydrates and proteins, can be used to 
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Cholestasis is associated with systemic accumulation of bile salts and by deficiency of bile in 
the intestinal lumen. During the past years bile salts have been identified as signaling 
molecules that regulate lipid, glucose and energy metabolism. Bile salts have also been 
shown to activate signaling routes leading to proliferation, apoptosis or differentiation. It is 
unclear, however, whether cholestasis affects the constitution and absorptive capacity of the 
intestinal epithelium in vivo. We studied small intestinal morphology, proliferation, apoptosis, 
expression of intestine-specific genes and carbohydrate absorption in cholestatic (1 wk bile 
duct ligation), bile-deficient (1 wk bile diversion) and control (sham) rats. Absorptive capacity 
was assessed by determination of plasma 2H- and 13C-glucose concentrations after 
intraduodenal administration of 2H-glucose and naturally-enriched 13C-sucrose, respectively. 
Small intestinal morphology, proliferation, apoptosis and gene expression of intestinal 
transcription factors (mRNA levels of Cdx-2, Gata-4 and Hnf-1α, and Cdx-2 protein levels) 
were similar in cholestatic, bile-deficient and control rats. The (unlabeled) blood glucose 
response after intraduodenal administration was delayed in cholestatic animals, but the 
absorption over 180 minutes, was quantitatively similar between the groups. Plasma 
concentrations of 2H-glucose and 13C-glucose peaked to similar extents in all groups within 
7.5 min and 30 min, respectively. Absorption of 2H-glucose and 13C-glucose in plasma was 
similar in all groups. The present data indicate that neither accumulation of bile salts in the 
body, nor their intestinal deficiency, two characteristic features of cholestasis, affect rat small 






Cholestasis is associated with accumulation of bile salts in the body and by deficiency of bile 
salts in the intestinal lumen 1. Bile salts facilitate dietary lipid absorption in the intestinal 
lumen and contribute to cholesterol homeostasis 2. More recently, bile salts have been 
identified as signaling molecules. Through activation of the farnesoid X receptor (FXR), bile 
salts regulate various aspects of glucose and lipid metabolism as well as intestinal barrier 
function 2,3. Watanabe et al. described a role for bile salts in the regulation of energy 
metabolism via the G protein-coupled bile acid receptor (GPBAR1) 4. Finally, bile salts can 
activate MAPK pathways, leading to proliferation or apoptosis 2. 
In children, cholestatic liver disease negatively affects nutritional status, growth and 
development, which cannot be explained by solely the inability to absorb lipids and lipid-
soluble vitamins 5-7. Sofar, it has remained unclear to what extent cholestasis, i.e. systemic 
accumulation and intestinal deficiency of bile salts, affects small intestinal epithelial 
proliferation, differentiation or apoptosis and, consequently, absorptive capacity in vivo.  
In the small intestinal lumen sucrose is hydrolyzed into glucose and fructose by the brush 
border membrane enzyme sucrase. Glucose is actively transported across the apical 
membranes of enterocytes by the sodium-dependent glucose co-transporter SGLT-1. The 
majority of glucose is passively transported from the enterocyte into the circulation by the 
facilitated glucose transporter GLUT-2 8. Intestinal sucrase-isomaltase (SI) gene 
transcription is regulated by the intestine-specific transcription factors Gata binding protein 4 
(GATA-4), hepatic nuclear factor 1α (HNF-1α) and caudal type homeobox transcription 
factor 2 (CDX-2) 9. 
In the present study, we investigated whether cholestasis affects small intestinal constitution 
and the absorptive capacity for carbohydrates in rats.  
 
 
MATERIALS AND METHODS 
 
Rats and housing 
Male Wistar rats, weighing 270-300 g at the beginning of the study, were obtained from 
Harlan (Horst, The Netherlands). They were individually housed in Plexiglas cages (25 x 25 
x 30 cm) on a layer of wooden shavings under controlled temperature, humidity and on a 
12:12-h light-dark cycle. Water and chow diet (Hope Farms, Woerden, The Netherlands) 
were available ad libitum. All experiments were approved by the Animal Experiments Ethical 
Committee of the University of Groningen. 
 
Materials  
6,6–2H-glucose, 98% 2H was obtained from Isotec Inc (Miamisburg, OH). Isotopic purity was 
confirmed by GC-MS. Cane sugar (Caribbean Gold, Amstelveen, The Netherlands) was 
used as naturally-enriched 13C-sucrose.  
 
Surgery 
All rats were equipped with permanent catheters in the jugular vein and duodenum, as 
described by Kuipers et al. 10. Bile duct ligated (cholestatic; n = 5) and bile-diverted (bile-
deficient; n=7) rats were compared to sham-operated rats (control; n = 6). The experimental 
model allows for physiological studies in unanaesthetized rats with bile duct ligation and 
diversion without the interference of stress or restraint. These models have been proven 
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useful to analyze intestinal absorption capacity 11-13. After surgery, the rats were allowed to 
recover for 1 wk. 
 
Experimental procedures 
Feces were collected for 24 h, between day 5 and 6 after surgery. Cholestatic, bile-deficient 
and control rats were subjected to a combined 2H-glucose /13C-sucrose absorption test at 1 
week after surgery. On the day of the experiment, the rats received an intraduodenal bolus 
of 1 mg 2H-glucose and 0.25 g 13C-sucrose in 1 ml water, after an overnight fast. At t = 0, 
7.5, 15, 30, 45, 60, 90, 120 and 180 minutes, blood samples were taken for determination of 
blood glucose concentrations and plasma 2H- and 13C-glucose enrichments. At the end of 
the experiment, the rats were sacrificed and the small intestine was collected for analysis. 
The small intestine was flushed with ice-cold PBS and was divided into the duodenum, the 
jejunum and the ileum. Material was harvested for histology and gene expression. Small 
intestinal mucosa was scraped for the determination of enzyme activity. 
 
Analytical methods 
Plasma bile salts were determined as described previously 14. Fat ingestion, fecal fat 
excretion and net fat absorption were measured and calculated as described previously 11. 
 
Stable isotope test 
Blood glucose concentrations were measured with a Lifescan EuroFlash glucose meter 
(Lifescan Benelux, Beerse, Belgium). The sample preparation procedure of plasma 2H-
glucose enrichment and plasma 13C-glucose enrichment was as described by Vonk et al. 15. 
The 2H enrichment was measured by GC-MS (Trace MS, Interscience, Breda, The 
Netherlands) 16. The 13C/12C isotope ratio measurement of the glucose penta-acetate 
derivative was determined by Gas Chromatography/Combustion/Isotope Ratio Mass 
Spectrometry (GC-C-IRMS) using a Delta Plus instrument (Thermofinnigan, Bremen, 
Germany) 15. Concentrations were calculated as described by Vonk et al. 16. 
 
Disaccharidase activity 
Enzyme activity levels of sucrase were measured in freshly scraped intestinal mucosa as 
described by Dahlqvist 17. Activity levels were normalized to protein levels, measured by the 
BCA method as described by the manufacturer (Pierce, Rockford, IL). 
 
RNA isolation and measurement of mRNA levels by real-time PCR (Taqman) 
mRNA expression levels in duodenum, jejunum and ileum were measured by real-time PCR, 
as described previously 18. PCR results were normalized to β-actin mRNA levels. The 
sequences of the primers and probes are listed in Table 1. 
 
Histology 
Morphology of jejunal sections of the small intestine was assessed by haematoxylin and 
eosin staining of formaline-fixated material. Proliferating cells were detected by staining of 
nuclear Ki-67 antigen. Apoptosis was assessed by staining DNA strand breaks with TUNEL 
staining according to the manufacturer’s instructions (In Situ Cell Death Detection Kit, 




















Values represent means ± SE for the indicated number of rats per group. Using SPSS 
version 12.0.2 statistical software (Chicago, IL, USA), we calculated significance of 
differences. Significance of differences was calculated with regard to the treatments as well 
as the different intestinal segments. Body weight and food intake were normally distributed 
and tested with the One-Way ANOVA. When the One-Way ANOVA resulted in a significant 
difference among the groups (P < 0.05) the two-tailed T-Test was used to calculate 
differences among the treatments or intestinal segments separately. All other parameters 
were not normally distributed and therefore tested with Kruskal-Wallis H and subsequently 
with the Mann-Whitney U for differences among the treatment groups or intestinal segments 





Characterization of the model 
Plasma bile salt concentration was significantly higher in cholestatic rats compared to 
control and bile-deficient rats (187 ± 20 vs. 10 ± 4 and 1.0 ± 0.5 µmol/L, respectively), and 
significantly lower in bile-deficient rats compared to control rats (all, P < 0.01).  
In accordance with the localization of intestinal bile salt reabsorption, expression of the 
apical sodium-dependent bile acid transporter (Asbt) and the ileal bile acid binding protein 
(Ibabp) was restricted to the ileum 19,20. Asbt expression was not quantitatively changed in 
cholestatic or bile-deficient rats, while Ibabp expression was reduced in cholestatic rats (by 
~35%) and significantly reduced in bile-deficient rats compared to control rats (by ~60%; P < 
0.05, Fig 1). Expression of the short heterodimer partner (Shp) was similar in all three 
segments and significantly reduced in cholestatic and bile-deficient rats in the duodenum by 
~60% and ~45% (both P < 0.05), in the jejunum by ~75% and ~70% (both P < 0.01) and in 
the ileum both by ~95% (both P < 0.01, Fig 1). Expression of Gpbar1 was similar in 
duodenum, jejunum and ileum and was not affected by cholestasis or bile diversion (Fig 1). 
After surgery the body weight decreased in all groups, but to a greater extent in cholestatic 
and bile-deficient rats compared to the sham-operated controls (93.7 ± 0.6 and 92.7 ± 0.7 
vs. 97.5 ± 0.6% of initial weight at day 2 after surgery; both P < 0.01). Body weight of control 
rats remained stable over the experimental period, while body weight of bile-deficient rats 
Gene GenBank Forward Primer Reversed Primer TaqMan® probe 
β-actin NM_031144 AGC CAT GTA CGT 
AGC CAT CCA 
TCT CCG GAG TCC ATC 
ACA ATG 
TGT CCC TGT ATG CCT 
CTG GTC GTA CCA C 
Asbt NM_017222 ACC ACT TGC TCC 
ACA CTG CTT 
CGT TCC TGA GTC AAC 
CCA CAT 
CTT GGA ATG ATG CCC 
CTT TGC CTC T 
Ibabp NM_017098.1 CCC CAA CTA TCA 
CCA GAC TTC G 
ACA TCC CCG ATG GTG 
GAG AT 
TCC ACC AAC TTG TCA 
CCC ACG ACC T 
Shp NM_057133 ACC TGC AAC AGG 
AGG CTC ACT 
TGG AAG CCA TGA 
GGA GGA TTC 
TCC TGG AGC CCT GGT 
ACC CAG CTA GC 
Gpbar1 NM_177936.1 ACT GGT CCT GCC 
TCC TTC TC 
GCT GCA ACA CTG CCA 
TGT AG 
TCC CTG CTT GCC AAT 
CTG CTG CT 
Hnf-1α NM_012669 CTC CAG CAG CCT 
GGT GTT GT 
GAG GCC ATC TGG 
GTG GAG AT 
CAC AGC CAC CTG CTG 
CCA TCC AAC 
Gata-4 NM_144730.1 GAG ATG CGC CCC 
ATC AAG 
GAC ACA GTA CTG AAT 
GTC TGG GAC AT 
CTG TCA TCT CAC TAT 
GGG CAC AGC AGC TC 
Cdx-2 NM_023963 GTC CCT AGG AAG 
CCA AGT GAA A 
CTC CTG ATG GTG ATG 
TAT CGA CTA 
CCT TCT CCA GCT CCA 
GCC GCT G 
Sglt-1 NM_013033 GCT GGA GTC TAC 
GTA ACA GCA CA 
GGG CTT CTG CAT CTA 
TTT CAA TG 
TCC TCC TCT CCT GCA 
TCC AGG TCG 
Glut-2 NM_012879 GCA TCA GCC AGC 
CTG TGT ATG 
GCA GCA CAG AGA 
CAG CTG TGA 
CCA TCG GCG TTG GTG 
CCA TCA AC 
Si NM_013061 TGT TTG GGT GAA 
TGA GTC AGA TG 
CCC ACC ACT CGA 
TGG TTT G 
ACT GTT AAT CCT GGC 
CAT ACC TCT CCA ATA A 
 
Table 1. Primer and probe sequences. 
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increased over time to the level of control rats at day 7. Body weight of the cholestatic rats 
remained stable over the experimental period and was significantly lower than body weight 
of control rats over the entire experimental period (approximately -4%, P < 0.05). Average 
food intake during the experimental period was similar in control and cholestatic rats (4.5 ± 
0.2 and 4.1 ± 0.1 % of body weight). Average food intake of bile-deficient rats was 
significantly higher than that of cholestatic rats (4.9 ± 0.1 vs. 4.1 ± 0.1 % of body weight, P < 
0.01) 10. 
Fat balance was measured from day 5 to 6 after surgery (Fig 1). Fat ingestion was slightly, 
but not significantly higher in bile-deficient rats compared to control rats, as previously found 
11
. Fecal fat excretion was significantly higher in cholestatic and bile-deficient rats compared 
to control rats (1.2 ± 0.1 and 1.2 ± 0.1 vs. 0.2 ± 0.0 mmol fatty acids/day, respectively, each 
P < 0.01). The resulting net fat absorption was significantly lower in cholestatic rats 
compared to control rats (2.9 ± 0.1 vs. 3.7 ± 0.2 mmol/day, respectively, P < 0.05), while net 
fat absorption in bile-deficient rats was not significantly different from the control rats. 
Cholestatic and bile-deficient rats had significantly lower coefficients of fat absorption than 
control rats (71.8 ± 0.5** and 73.1 ± 0.9** vs. 93.9 ± 0.2 % of ingested amount, respectively, 



















Jejunal morphology, proliferation and apoptosis are not affected in cholestatic rats 
Jejunal sections of control, cholestatic and bile-deficient rat intestines were stained with HE, 
Ki-67 and TUNEL to assess morphology, proliferation and apoptosis, respectively (Fig 2). 
Villous and crypt morphology, proliferation and apoptosis did not differ between the groups. 
Villous length was similar in control, cholestatic and bile-deficient rats (394 ± 36, 445 ± 26 
and 510 ± 27 µm, respectively, Table 2), however, villous length in bile-deficient rats showed 
a trend towards being higher than villous length in control rats (Kruskal-Wallis H: P = 0.064 
and Mann-Whitney U of bile-deficient rats vs. control rats: P = 0.032) 12. Crypt/villous ratios 
were similar in control, cholestatic and bile-deficient rats (0.29 ± 0.02, 0.30 ± 0.02 and 0.28 ± 


























































































































































































































































































































































































Figure 1. Gene expression of intestinal bile salt transporters/receptors and fat balance in control (white bars), 
cholestatic (black bars) and bile-deficient (grey bars) rats. (A) Duodenal, jejunal and ileal Asbt expression, (B) 
Ibabp expression, (C) Shp expression, and (D) Gpbar1 expression, all normalized to β-actin levels. (E) Fat 
balance, measured from day 5 to 6 after surgery. Data represent means ± SE of 5-7 rats per group. *P < 0.05 




















Expression of intestinal transcription factors is maintained in cholestatic rats  
The expression of intestine-specific transcription factors was determined to assess effects of 
the experimental manipulations on enterocyte differentiation. CDX-2, HNF-1α and GATA-4 
are known to cooperatively regulate sucrase-isomaltase gene transcription 9. Hnf-1α 
expression was similar in duodenum, jejunum and ileum, while Gata-4 expression was 
significantly lower in the ileum compared to the duodenum and jejunum (both P < 0.01; Fig 
3) 21 No significant differences in Hnf-1α or Gata-4 expression were found among the 
groups. Cdx-2 expression increased slightly from the proximal to the distal part of the 
intestine of control rats (NS; Fig 3). No significant differences were found in duodenum, 





















Table 2. Villus length and crypt-to-villus ratios of control, 

















Control 394 ± 36 0.29 ± 0.02 
Cholestatic 445 ± 26 0.30 ± 0.02 
Bile-deficient 510 ± 27 0.28 ± 0.00 
 
Figure 2. Jejunal morphology, proliferation and apoptosis in 
control, cholestatic and bile-deficient rats. Intestinal 
morphology was assessed by HE staining, proliferation by Ki-
67 staining and apoptosis by TUNEL staining. Crypts and villi 
are indicated in the pictures. Cells positively stained with Ki-










































































































































































































































Figure 3. Expression of intestine-specific transcription factors in control (white bars), 
cholestatic (black bars) and bile-deficient (grey bars) rats. (A) Duodenal, jejunal and ileal 
expression of Hnf-1α, (B) Gata-4, and (C) Cdx-2, all normalized to β-actin levels. (D) Jejunal 
Cdx-2 protein expression. Cells positively stained with α-Cdx-2 are indicated by the arrow. 
Data represent means ± SE of 5-7 rats per group. Gata-4 expression was higher in the 
duodenum and jejunum compared to the ileum (P < 0.01). 
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Blood glucose response is delayed in cholestatic rats 
The blood glucose concentration in response to the intraduodenal bolus of labeled glucose 
and sucrose was delayed in cholestatic rats compared to bile-deficient and control rats and 
peaked at 15 min rather than at 7.5 min, respectively. Figure 4 shows significantly higher 
glucose concentrations in cholestatic rats compared to control and bile-deficient rats at 30 
and 45 min after bolus administration. The area under the curve was not significantly 
changed in cholestatic rats compared to control and bile-deficient rats (1108 ± 51 vs. 1050 ± 












Monomeric glucose absorption is maintained in cholestatic rats 
Monomeric glucose absorption was assessed by determination of plasma appearance of 2H-
glucose after its intraduodenal administration. Plasma 2H-glucose concentrations peaked at 
7.5 min in control, cholestatic and bile-deficient rats (38 ± 4, 39 ± 6 and 41 ± 3 µmol/L, 
respectively; Fig 5). Areas under the curve were similar in cholestatic, control and bile-
deficient rats (2220 ± 363, 1956 ± 315, and 1763 ± 222 µmol/L*min, respectively, NS).  
In all groups, expression of the apical glucose transporter Sglt-1 and that of the basolateral 
glucose transporter Glut-2 were slightly lower in the ileum compared to the duodenum and 
jejunum (all P < 0.05; Fig 5). Jejunal Sglt-1 expression was significantly increased in bile-
deficient rats compared to control rats (P < 0.01). Glut-2 expression was not significantly 


















Figure 5. Glucose absorption in response to a 1 ml 
intraduodenal bolus containing 13C-sucrose (0.25 g) and 
2H-glucose (1 mg) in control (white circles/bars), 
cholestatic (black circles/bars) and bile-deficient (grey 
circles/bars) rats. (A) Plasma 2H-glucose concentration. 
(B) Duodenal, jejunal and ileal expression of the apical 
glucose transporter Sglt-1, and (C) the basolateral 
glucose transporter Glut-2, both normalized to β-actin 
levels. Data represent means ± SE of 5-7 rats per group. 
**P < 0.01 vs. control group. Sglt-1 expression and Glut-
2 expression were higher in the duodenum and the 























































































































































































































































































Figure 4. Blood glucose concentration in 
response to a 1 ml intraduodenal bolus 
containing 13C-sucrose (0.25 g) and 2H-glucose 
(1 mg) in control (white circles), cholestatic 
(black circles) and bile-deficient (grey circles) 
rats. Data represent means ± SE of 5-7 rats per 
group. *P < 0.05 vs. control group. *P < 0.05 




Sucrose digestion is maintained in cholestatic rats 
Sucrose digestion was assessed by appearance of plasma 13C-glucose derived from 13C-
sucrose. Plasma 13C-glucose concentrations peaked at 30 min in control, cholestatic and 
bile-deficient rats (3.4 ± 0.2, 4.1 ± 0.5 and 3.2 ± 0.3 mmol/L, respectively; Fig 6). Area under 
the curve was not significantly changed in cholestatic rats, when compared to control and 
bile-deficient rats (346 ± 42 vs. 312 ± 17 and 266 ± 21 mmol/L*min, respectively, NS). 
Sucrase enzyme activity was highest in the jejunum and lowest in the ileum in control rats 
(all P < 0.01; Fig 6). Duodenal sucrase enzyme activity was significantly lower in bile-
deficient rats compared to control rats (6.9 ± 1.0 vs. 8.3 ± 0.8 µmol/mg protein.h, 
respectively, P < 0.05). The expression pattern of sucrase-isomaltase (Si) was less 
pronounced than that of sucrase enzyme activity, but jejunal expression was also 





















In this study, we investigated whether cholestasis; i.e. the combination of systemic 
accumulation of bile salts and the deficiency of bile salts in the intestinal lumen, affects the 
constitution and absorptive capacity of the rat small intestinal epithelium. We compared 
cholestatic rats with bile-deficient rats, without systemic accumulation, and with control rats. 
We found that short-term extrahepatic cholestasis in rats does not affect intestinal 
morphology, proliferation or apoptosis, nor the functional capacity of the intestine to digest 
sucrose and to absorb glucose. 
Several studies describe the effect of the absence of bile components in the intestinal lumen 
on intestinal bile salt transporter expression in rats. They report that rat Asbt expression is 
not regulated by bile salts, while rat Ibabp expression is positively regulated by bile salts via 
Fxr activation 19,22-27. In accordance with the literature, our data indicate that Asbt expression 
is not affected in cholestatic and bile-deficient rats. Ibabp expression was decreased in 
cholestatic rats and significantly decreased in bile-deficient rats. The increased expression 
of Ibabp in cholestatic rats compared to bile-deficient rats may be explained by the 
occurrence of retrograde transport of bile salts from the blood compartment into the 
Figure 6. Sucrose digestion and subsequent glucose absorption in 
response to a 1 ml intraduodenal bolus containing 13C-sucrose 
(0.25 g) and 2H-glucose (1 mg) in control (white circles/bars), 
cholestatic (black circles/bars) and bile-deficient (grey circles/bars) 
rats. (A) Plasma 13C-glucose concentration. (B) Duodenal, jejunal 
and ileal activity of the brush border enzyme sucrase. (C) 
Duodenal, jejunal and ileal gene expression of the brush border 
enzyme sucrase-isomaltase (Si), normalized to β-actin levels. Data 
represent means ± SE of 5-7 rats per group. *P < 0.05 vs. the 
control group. Sucrase activity was higher in the jejunum compared 
to the duodenum and the ileum (P < 0.01) and higher in the 
duodenum compared to the ileum (P < 0.01). Si expression was 



























































































































































































































epithelial layer of the small intestinal lumen. However, expression of bile salt-sensitive Shp 
was markedly decreased in both cholestatic and bile-deficient rats. The strongest reduction 
was observed in the ileum, coinciding with the highest Fxr expression 28. The bile duct-
ligated rats had strongly elevated plasma bile salt levels and significantly reduced net fat 
absorption, in accordance with cholestasis. As previously described 10, cholestatic rats lost 
slightly more weight than bile-deficient and control rats, despite similar food intakes. The 
weight loss may be related to the decreased net fat absorption in cholestatic rats 13, 
compared with unchanged net fat absorption in bile-deficient rats fed a chow diet 11. It is 
well-known that the composition of chow is variable between batches. Therefore we used 
only one batch to feed all rats before and during our experiments. Usage of a purified diet, 
such as AIN-93M, is not possible in this experimental setting, because the cornstarch in the 
diet is naturally enriched in 13C as is the sucrose (cane sugar) we used to assess sucrose 
digestion. Pilot experiments showed that the enrichment of 13C-glucose in the plasma is 
immeasurable, due to the high baseline enrichment in rats fed a diet containing cornstarch 
(unpublished observations). 
In light of numerous in vitro data in the literature, we anticipated cholestasis to induce either 
proliferation or apoptosis in the small intestinal epithelium. Conjugated bile salts in 
concentrations found during cholestasis induce proliferation in the rat small intestinal cell line 
IEC-6, and in the human colon carcinoma cell line Caco-2, which gains small intestinal 
epithelial features upon differentiation 29-31. In contrast to enterocytes, relatively low 
concentrations (50 µM) of conjugated bile salts induce apoptosis in human hepatoma cell 
lines and primary rat hepatocytes 32-34. Bile salts in cholestatic concentrations can also be 
indirectly implicated in inhibition of differentiation and function of small intestinal epithelial 
cells. Suh and Traber demonstrated that the intestine-specific transcription factor Cdx-2 is 
an important regulator of differentiation in the small intestine 35. Differentiation is regulated 
by phosphorylation and subsequent activation of Cdx-2 via the MAPK/ERK route. 
Phosphorylated Cdx2 inhibits transcription of the sucrase-isomaltase gene 36. MAPK/ERK, in 
turn, appears to be activated by various bile salts 37. However, our present results indicate 
that cholestatic concentrations of bile salts do not affect proliferation, apoptosis or 
differentiation in rat small intestinal epithelium in vivo. The discrepancy between the in vitro 
and in vivo data can possibly be explained by the fact that enterocytes might be more 
resistant in an in vivo setting, related to protective environmental factors. Besides, the 
absorption of nutrients and of bile salts takes place in different intestinal segments. In 
cholestatic rat models, enterocytes are exposed to bile salt concentrations only at their 
basolateral membrane, while intestinal cell lines are exposed to both sides or are not 
(completely) polarized. Bile salts do not need to enter the cells to activate cellular signaling 
routes. Kawamata et al. reported that membrane-type G protein coupled receptor Gpbar1 is 
expressed in the intestine 38. In our rats, Gpbar1 was expressed at similar amounts in 
duodenum, jejunum and ileum. It is unknown whether Gpbar1 is expressed at apical or 
basolateral membrane domains. Finally, several in vitro studies have addressed intestinal 
cell exposure to high concentrations of unconjugated bile salts in the context of colon 
cancer. Small intestinal cells in vivo are, however, normally not exposed to free bile salts in 
those concentrations and compositions. 
Data addressing to what extent cholestasis or intestinal bile deficiency affect small intestinal 
function in vivo is scarce. In accordance with our current results several rat models of 
cholestasis or intestinal bile deficiency have been reported to have unchanged small 
intestinal function. Borges et al. reported that obstructive jaundice did not affect jejunal 
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absorption of glucose in rats 39. Sucrase enzyme activity was shown to be unaffected in 
cholestyramine-fed and bile-diverted rats 40. Corresponding with unaffected or minimally 
affected epithelial integrity, we have previously shown that fat absorption in 1 wk bile-
diverted rats could be quantitatively reconstituted within hours using the infusion of model 
bile 41.  
Vonk et al. developed a stable isotope test for the quantification of lactose digestion and 
glucose absorption in humans 15,16. We adapted this test to quantify intestinal digestion and 
absorption of sucrose and glucose in rats. In the future, this test might be utilized or adapted 
to quantify the effect of other clinical conditions on intestinal absorption of carbohydrates or 
other macronutrients. 
Malnutrition in children with cholestasis has a profound effect on mortality rate of children 
with end-stage cholestatic liver disease 5,7,42. The association between cholestatic liver 
disease and fat malabsorption is well-known. Previous studies in our group have 
demonstrated that cholestatic rats and bile-deficient rats have severe fat malabsorption 11-13, 
as confirmed in the present study. Rings et al. showed that the absorption of free fatty acids 
but not fat digestion was rate-limiting for overall fat absorption in neonates that are known to 
have a mild ‘physiological’ cholestasis during the first months of life 43. Our data indicate that 
intestinal deficiency of bile salts, with or without systemic accumulation of bile salts, does not 
impair intestinal carbohydrate digestion or absorption in rats. These observations suggest 
that increasing the dietary carbohydrate intake above conventional levels could be used in 
preventive or therapeutic fashion for a poor nutritional status induced by fat malabsorption in 
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Cholestatic conditions and 

























Cholestasis in children impairs their nutritional status and growth. Recently we demonstrated 
in a rat model of cholestasis that increased plasma bile salt concentrations did not affect 
intestinal carbohydrate digestion or absorption. We addressed to what extent cholestatic 
conditions affect proliferation or differentiation of enterocytes in vitro, and what underlies 
their apparent resistance to bile salts. We studied proliferation and differentiation of an 
intestinal cell line, Caco-2, exposed to bile salts in cholestatic concentrations. Exposure of 
proliferating or short-term differentiated cells to cholestatic conditions did not affect DNA 
content, cell number or sucrase activity. In contrast, exposure of long-term differentiated 
cells to cholestatic conditions reduced sucrase activity, coinciding with increased expression 
of bile salt transporter ASBT. Unconjugated CDCA reduced sucrase activity earlier in the 
differentiative phase. Present data suggest that enterocytes are protected from bile salt-






Cholestatic liver disease negatively affects nutritional status and growth in children. For 
cholestatic children requiring liver transplantation, a poor nutritional status imposes an 
increased risk of morbidity and mortality. Malnutrition and growth retardation in cholestatic 
disorders are usually ascribed to insufficient fat solubilization and absorption due to reduced 
presence of bile components in the intestinal lumen 1-3.  
Cholestasis is also characterized by elevated bile salt plasma concentrations, which 
theoretically could affect intestinal function. Lower concentrations of bile salts have been 
shown to induce proliferation, differentiation or apoptosis in intestinal epithelial cell lines, 
depending on hydrophobicity and cell line 4-6. In contrast to in vitro data, we recently 
demonstrated that carbohydrate digestion and absorption was maintained in a rat model of 
cholestasis, but we could only speculate about the mechanism underlying the functional 
protection against cholestatic conditions 7.  
To address this issue, we exposed the human colon carcinoma cell line Caco-2 to 
cholestatic concentrations of conjugated bile salts and assessed bile salt transport 
parameters, proliferation, differentiation and apoptosis. Caco-2 cells develop small intestinal 
features upon reaching confluency 8. We separately studied proliferating Caco-2 cells, which 
can be regarded as a model for proliferating crypt cells, and differentiated Caco-2 cells, 
which can be regarded as a model for differentiated villous cells of the small intestine. 
Results were compared to those of unconjugated chenodeoxycholic acid (CDCA) since it 
can enter the cells independent of transporters as opposed to conjugated bile salts. 
Finally, we studied at the interaction between nutrient absorption and bile salt absorption in 
vivo by looking at the correlation between expression of proteins involved in carbohydrate 
digestion and absorption in the ileal part of the small intestine and plasma bile salt 
concentrations in cholestatic, bile-deficient and control rats. 
Present data indicate that exposure of proliferating and short-term differentiated cells to 
conjugated bile salts in cholestatic concentrations did not affect Caco-2 cell proliferation or 
differentiation. Exposure of long-term differentiated cells to cholestatic conditions reduced 
differentiation, coinciding with increased expression of bile salt transporter ASBT. 
 
 
MATERIALS AND METHODS 
 
Materials 
The bile salts glycocholic acid (GCA) and CDCA, (sodium salts), were from Calbiochem 
(San Diego, CA, USA). Taurocholic acid (TCA), glycochenodeoxycholic acid (GCDCA) and 
taurochenodeoxycholic acid (TCDCA), (sodium salts), were from Sigma (St. Louis, MI, 
USA). All bile salts were dissolved in demineralized H2O in 50 mM stock solutions and mixed 
with the medium before addition to the cells. 
 
Cell culture 
The human colon carcinoma cell line Caco-2 was obtained from the American Type Tissue 
Culture Collection (Manassas, VA, USA) and maintained in DMEM (Gibco BRL, USA) 
supplemented with 10% (vol/vol) FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 1% non-
essential amino acids and 0.25% human transferrin in a humidified atmosphere of 95% air–





Caco-2 cells were seeded at 5x104 cells per well in 6-well plates (Corning Costar, 
Cambridge, MA, USA). Caco-2 cells were exposed to 0, 150, 300 and 450 µmol/L of a bile 
salt mixture containing GCA, TCA, GCDCA and TCDCA in a 2:2:1:1 molar ratio or to 250 
µmol/L CDCA. The effects of bile salts on proliferating and differentiated Caco-2 cells were 
assessed by exposing the cells to bile salts 24h after seeding and after confluency was 
reached (~8 days), respectively. Proliferating cells were harvested at day 0, 2, 4, 6 and 14 
(P0, P2, P4, P6 and P14) and differentiated cells were harvested at day 0, 7, 14 and 21 (D0, 
D7, D14 and D21). The effect of exposure to CDCA was assessed at P4, P14, D7, D14 and 
D21. Caco-2 cells in Transwell plates were harvested at day 7, 14 and 21 (D7, D14 and 
D21). Medium with or without bile salts was changed every 2-3 days.  
 
Analyses 
Cell numbers were counted manually with the Burker Cell System. DNA was quantified with 
a DNA quantification kit (Sigma, St. Louis, MI, USA) according to the manufacturer’s 
instructions. Caspase-3 activity was measured with the CaspACETM Assay System 
(Promega, Madison, USA) according to the manufacturer’s instructions. mRNA expression 
levels were measured by real-time PCR, as described previously 9. PCR results were 
normalized to GAPDH mRNA levels. The sequences of the primers and probes are listed in 
Table 1. Enzyme activity levels of sucrase were measured as described by Dahlqvist 10. 
Activity levels were normalized to protein levels, measured by the BCA method as described 
by the manufacturer (Pierce, Rockford, IL, USA). Lactate dehydrogenase (LDH) in the 
















Gene expression and plasma bile salt concentrations in cholestatic, bile-deficient and 
control rats 
mRNA levels of  SI, Sglt-1 and Glut-2 and plasma bile salt concentrations in cholestatic, 





Values represent means ± SEM of 3-6 experiments. Using SPSS version 12.0.2 statistical 
software (Chicago, IL, USA), we calculated significance of differences with the Mann-
Gene GenBank Forward Primer Reversed Primer TaqMan® probe 
GAPDH NM_002046 GGT GGT CTC CTC TGA 
CTT CAA CA 
GTG GTC GTT GAG 
GGC AAT G 
ACA CCC ACT CCT CCA 
CCT TTG ACG C 
FXR AF384555 (α1) 
NM_005123 (α2) 
TTC TGA AAA TTT ATT 
TGG TGT TTT AAC AGA 
TGG AAT AAT AGG ATG 
ACG AGG AAA TC 
CAT TGC TGT ATT GCG 
AGT ATG GTT CCA CTT CC 
ASBT NM_000452 CAC GCA GCT ATG TTC 
CAC CAT 
GAG CGG AAG GTG 
AAT ACG A 
CAG CTC TCC TTC ACT 
CCT GAG GAG CTC A 
IBABP NM_001445 AAG GCC CGC AAC TTC 
AAG AT 
GGA GTA GTG CTG 
GGA CCA AGT G 
CCA TCC TGC TGC ACC 
TCC GTG A 
GPBAR1 NM_001077191.1 CGT CTA CTT GGC TCC 
CAA CTT C 
GGC CTC AGG ACT 
GCC ATG TA 
CTC TCC CTG CTT GCC 
AAC CTC TTG C 
SI NM_001041 TGT GGA TAA ATG AGT 
CAG ATG GAA G 
GCC CAC CAA TCA ATG 
CAG TT 
ACT GTT AAT CCT GGC 
CAT ACC TCT CCA ATA A 
CDX-2 NM_001265 CTC GGC AGC CAA 
GTG AAA AC 
TGG TGA TGT AGC GAC 
TGT AGT GAA 
CCT TCT CCA GCT CCA 
GCC GCT G 
GATA-4 NM_002052.2 GGA GAT GCG TCC 
CAT CAA GA 
CTG ACT GAG AAC GTC 
TGG GAC A 
CAT CTC ACT ACG GGC 
ACA GCA GCT CC 
 
Table 1. Primer and probe sequences 
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Whitney U-test. Statistical information is provided regarding differentiative (D0) vs. 
proliferative cells (P0), alterations during the differentiative phase (D0 vs. D21) and control 
cells vs. conjugated bile salts in cholestatic concentrations (450 µmol/L) or CDCA (250 





Cholestatic conditions increase IBABP expression in proliferating and differentiated 
cells. 
First, we assessed key parameters regarding to bile salt transport and signaling; bile salt-
activated farnesoid X receptor (FXR), apical sodium-dependent bile salt transporter (ASBT), 
ileal bile acid-binding protein (IBABP) and G protein-coupled membrane bile acid receptor 
(GPBAR). 
In Figure 1 is shown that the expression of FXR was increased (~5-fold; P<0.05) in 
differentiated cells (D0) compared to proliferating cells (P0). FXR expression was further 
increased during the differentiative phase (D0 vs. D21) of Caco-2 cells (~11-fold; P<0.01). 
Similarly, ASBT expression was increased in differentiative cells (~3-fold; P<0.05) and 
during the differentiative phase (~7-fold; P<0.01). In contrast, IBABP expression and 
GPBAR1 expression (data not shown) were not induced during the differentiative phase, but 
were increased in differentiative cells compared to proliferative cells (~4-fold; P<0.01 and 
~1.5-fold; P<0.05, respectively; Fig 1).  
Exposure to conjugated bile salts in cholestatic concentrations significantly increased IBABP 
expression at day 6 (~2-fold; P<0.01) and 14 (~20-fold; P<0.05) in proliferating cells and at 
day 7-21 (~20-35 fold; P<0.01) in differentiated cells, while exposure to conjugated bile salts 
in cholestatic concentrations did not affect FXR, ASBT or GPBAR1 expression. 
In contrast to conjugated bile salts in cholestatic concentrations, CDCA significantly reduced 
ASBT expression in differentiated cells (by ~40% at day 14 and by ~75% at day 21; both 
P<0.05, Fig 1). IBABP expression was strongly induced upon exposure to CDCA in 
differentiated cells (Fig 1).  
Conjugated bile salts in concentrations of 150 and 300 µmol/L generated similar results as 
450 µmol/L. For sake of clarity, we only present results of cells exposed to 450 µmol/L 
conjugated bile salts or 250 µmol/L CDCA compared to control cells. 
 
Cholestatic conditions do not affect DNA content or cell number in proliferating or 
differentiated cells. 
DNA content and cell number were quantified to assess cell proliferation under cholestatic 
conditions. DNA content in differentiative cells was ~9-fold (P<0.01) higher compared to 
proliferative cells, independent of the presence or absence of conjugated bile salts. During 
the differentiative phase, however, DNA content remained similar. CDCA decreased DNA 
content in proliferating cells, but not in differentiated cells (Fig 2).  
Cell number showed a similar pattern during differentiation. Cholestatic bile salt 
concentrations did not affect cell number at any time point, but CDCA reduced cell number 












































Cholestatic conditions do not affect caspase-3 activity in proliferating or 
differentiated cells. 
Caspase-3 activity was quantified to assess the occurrence of apoptosis. Caspase-3 activity 
was very low and similar in control cells and in cells exposed to conjugated bile salts in 
cholestatic concentrations. Unconjugated CDCA increased caspase-3 activity by ~50% in 
proliferating cells (P<0.05, data not shown).  
LDH leakage in the medium was quantified to assess potential bile salt-induced cytotoxicity. 
Neither in proliferating nor differentiated cells, LDH leakage was induced by exposure to 







































































































































































































































































































































































































































































Figure 1. Bile salt transporter/receptor gene expression in Caco-2 cells exposed to conjugated bile 
salts in cholestatic concentrations (450 µmol/L) or CDCA (250 µmol/L) compared to control cells. (A) 
FXR, (B) ASBT, (C) IBABP expression, normalized to GAPDH, in cells exposed to conjugated bile 
salts in cholestatic concentrations compared to control cells. (D) ASBT, (E) IBABP expression, 
normalized to GAPDH, in cells exposed to CDCA compared to control cells. P0, P2, P4, P6 and P14 
represent proliferating cells at day 0, 2, 4, 6 and 14 after exposure to bile salts and D0, D7, D14 and 





















































Figure 2. DNA content of Caco-2 cells exposed to conjugated bile salts in cholestatic concentrations 
(450 µmol/L) or CDCA (250 µmol/L) compared to control cells. (A) DNA content of cells exposed to 
conjugated bile salts in cholestatic concentrations compared to control cells. (B) DNA content of cells 
exposed to CDCA compared to control cells. P0, P2, P4, P6 and P14 represent proliferating cells at 
day 0, 2, 4, 6 and 14 after exposure to bile salts and D0, D7, D14 and D21 represent differentiated 




Cholestatic conditions reduce sucrase enzyme activity in long-term differentiated 
cells. 
Sucrase enzyme activity and sucrase-isomaltase (SI) mRNA levels were quantified as 
markers for Caco-2 cell differentiation. Sucrase enzyme activity was markedly induced  
(~27-fold; P<0.05) in differentiative cells compared to proliferative cells and further during 
the differentiative phase (~16-fold; P<0.01) as also described by Van Beers et al. 12. 
Exposure to conjugated bile salts in cholestatic concentrations did not affect sucrase 
enzyme activity in proliferating cells or in differentiated cells up to day 7. Conjugated bile 
salts significantly reduced sucrase enzyme activity in differentiated cells after day 14 ~20-
25%; P<0.05; Fig 3). Unconjugated CDCA abolished sucrase enzyme activity in proliferating 
cells at day 14, and in differentiated cells from day 14 on (by ~25-45%; P<0.01; Fig 3).  
The expression pattern of SI mRNA during differentiation was comparable to that of sucrase 
enzyme activity. SI expression was strongly increased in differentiative cells compared to 
proliferative cells (~81-fold; P<0.01) and further increased during the differentiative phase 
(~5-fold; P<0.01). Conjugated bile salts in cholestatic concentrations significantly reduced SI 
expression in proliferating cells at day 2 (by ~65%; P<0.05). In differentiative cells, SI 
expression was also reduced upon exposure to conjugated bile salts, but this did not reach 







































































































































































































































































































































































Figure 3. Sucrase enzyme activity and sucrase-isomaltase (SI) expression in Caco-2 cells exposed to 
conjugated bile salts in cholestatic concentrations (450 µmol/L) or CDCA (250 µmol/L) compared to 
control cells. (A) Sucrase enzyme activity in cells exposed to conjugated bile salts in cholestatic 
concentrations compared to control cells. (B) Sucrase enzyme activity in cells exposed to CDCA 
compared to control cells. (C) SI expression, normalized to GAPDH, in cells exposed to conjugated 
bile salts in cholestatic concentrations compared to control cells. P0, P2, P4, P6 and P14 represent 
proliferating cells at day 0, 2, 4, 6 and 14 after exposure to bile salts and D0, D7, D14 and D21 
represent differentiated cells at day 0, 7, 14 and 21 after exposure to bile salts. *P<0.05 and **P<0.01. 
(D) Ileal expression of SI, Sglt-1 and Glut-2 in cholestatic (black bars), control (grey bars) and bile-
deficient (white bars) rats, normalized to β-actin. Values of cholestatic rats are set on 1. Plasma bile 
salt concentrations cover a range from 187±20 µmol/L in cholestatic rats, 10±4** µmol/L in control rats 
to 1.0±0.5**## µmol/L in bile-deficient rats of which **P<0.01 vs. cholestatic group and ##P<0.01 vs. 
control group. #P=0.064 (Kruskal-Wallis H) and P=0.032 (Mann-Whitney U) vs. control group. 
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Plasma bile salt concentrations correlate inversely with ileal SI, Sglt-1 and Glut-2 
expression in rats. 
As stated before, we previously demonstrated that intestinal carbohydrate absorption was 
maintained in cholestatic rats 7. Figure 3D shows mRNA levels of SI, and intestinal glucose 
transporters Sglt-1 (apical) and Glut-2 (basolateral) in the ileal segment of the small intestine 
of cholestatic, control and bile-deficient rats. The average plasma bile salt concentrations in 
cholestatic, control and bile-deficient rats were 187±20, 10±4 (P<0.01 vs. cholestatic rats) 
and 1.0±0.5 (P<0.01 vs. cholestatic and control rats) µmol/L, respectively. Though not 
significantly different among the groups, a clear pattern can be observed. SI, Sglt-1 and 
Glut-2 expression showed a trend towards being higher in bile-deficient rats compared to 
control and cholestatic rats. SI expression was increased by ~45% in bile-deficient rats 
compared to cholestatic rats (Kruskal-Wallis H: P=0.064 and Mann-Whitney U: P=0.028; Fig 
3).  
 
Cholestatic conditions do not affect CDX-2 or GATA-expression in proliferating and 
long-term differentiated cells. 
CDX-2 and GATA-4 are intestine-specific transcription factors known to cooperatively 
regulate sucrase-isomaltase gene transcription 13. Expression of CDX-2 and GATA-4 was, 
respectively, ~3-fold (P<0.05) and ~5-fold (P<0.01) higher in differentiative cells compared 
to proliferative cells. During the differentiative phase, CDX-2 and GATA-4 expression 
showed similar patterns, specifically slight inductions of expression at day 7 and 14, 
returning to base level at day 21 (Fig 4). 
CDX-2 expression was not changed upon exposure to conjugated bile salts. Conjugated bile 
salts in cholestatic concentrations did not affect GATA-4 expression in proliferating or 


























































































































































Figure 4. Gene expression of intestine-specific transcription factors in Caco-2 cells exposed to 
conjugated bile salts in cholestatic concentrations (450 µmol/L) compared to control cells. (A) CDX-2, 
(B) GATA-4 expression, both normalized to GAPDH, in cells exposed to conjugated bile salts in 
cholestatic concentrations compared to control cells. P0, P2, P4, P6 and P14 represent proliferating 
cells at day 0, 2, 4, 6 and 14 after exposure to bile salts and D0, D7, D14 and D21 represent 




We recently demonstrated that carbohydrate digestion and absorption is maintained in a rat 
model of cholestasis 7. In this study we set out to find an explanation for enterocyte 
protection against cholestatic conditions. We found that exposure of proliferating and short-
term differentiated Caco-2 cells to conjugated bile salts in cholestatic concentrations did not 
affect proliferation or differentiation, whereas exposure of long-term differentiated cells to 
cholestatic conditions reduced differentiation, coinciding with increased expression of bile 
salt transporters. 
The lifespan of an enterocyte between crypt cells entering the villous-crypt junction, 
migrating upwards reaching the villous tip and eventually shedding off, ranges from 
approximately 2 to 3 days in mice and rats to 6 days in humans 14,15. Based on this 
physiological knowledge, one would consider short-term exposure as physiologically most 
relevant. We realized, however, that a cell model may not mimic physiological conditions in 
this respect. We first determined relevant features of Caco-2 cells at different developmental 
stages, including long-term differentiated cells, to find the condition most relevant to study 
our research question.  
Our results clearly showed a discrepancy with respect to proliferating–short-term 
differentiated cells and long-term differentiated cells, i.e. exposure to cholestatic conditions 
in long-term differentiated cells reduced differentiation in contrast to proliferating and short-
term differentiated cells. This discrepancy might be due to the higher quantity of the bile salt 
transporters in long-term differentiated cells compared to proliferating and short-term 
differentiated cells. Corresponding with this, our data indicate that ASBT mRNA levels are 
strongly increased in long-term differentiated cells compared with proliferative and short-
term differentiative cells, coinciding with increased FXR mRNA levels as previously 
described by De Gottardi et al. 16. Though bile salts seem to be able to enter cells with 
relatively low ASBT expression, indicated by reduced IBABP expression upon exposure to 
conjugated bile salts in proliferating and short-term differentiated cells, the quantity is most 
likely to low to exert effects on sucrase activity. Unconjugated CDCA can cross the cellular 
membrane independent of active transporters. The observation that exposure to CDCA 
already reduces sucrase activity earlier in the differentiative phase is compatible with the 
theory stated above. 
Bile salts, however, do not need to enter the cells to activate cellular signaling. Marayuma et 
al. identified a cell surface G protein-coupled receptor, GPBAR1, responsive to low 
concentrations of extracellular bile salts 17. Human GPBAR1 mRNA has been shown to be 
expressed in the small intestine and activation by bile salts leads to the activation of cellular 
signaling routes 18. The elevated plasma bile salt level during cholestasis could theoretically 
activate signaling routes via GPBAR1. Since GPBAR1 was present in proliferating and 
differentiated Caco-2 cells, cholestatic bile salt concentrations might be able to influence 
enterocyte proliferation or differentiation via GPBAR1. The observation that reduced activity 
and mRNA levels of sucrase did not coincide with changes in GPBAR1 expression, 
however, does not support this theory. 
Effects of bile salts on human intestinal cell proliferation range from inhibition to induction, 
usually related to the hydrophobicity of the bile salt. Unconjugated CDCA induces profound 
apoptosis in human intestinal cells, while similar concentrations of conjugated bile salts 
induce proliferation 5. Effects of bile salts on intestinal cell differentiation have not been 
studied extensively. Ursodeoxycholic acid (UDCA) has been found to induce differentiation 
in a HCT116 cell line, derived from human colon carcinoma cells 4. Interestingly, in culture, 
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hepatocytes seem to be much more sensitive to bile salt exposure than enterocytes. 
Glycochenodeoxycholic acid already induces apoptosis at 50 µmol/L in hepatocytes, while 
similar concentrations do not affect enterocytes in vitro 6. We cannot appoint a cause for the 
differences in behavior between hepatocytes and enterocytes exposed to bile salts, but we 
can speculate about the underlying basis. First, hepatocytes possibly possess more bile salt 
uptake transporters than enterocytes, with possible higher affinity. Second, cell signaling 
pathways might be differentially regulated. 
Nutrient absorption is most efficient in the jejunal part of the small intestine, while active bile 
salt absorption is restricted to the terminal ileum 19. This observation would suggest that 
enterocytes involved in nutrient absorption are protected from bile salts. The observation 
that reduced sucrase enzyme activity in long-term differentiated cells exposed to conjugated 
bile salts in cholestatic concentrations coincided with high expression of the bile salt 
transporter ASBT, supports this theory. Thus, bile salts could potentially be harmful for 
enterocyte function when nutrient absorption and bile salt absorption would have been 
localized in the same intestinal segment. The significance of different intestinal segments 
involved in nutrients absorption and bile salt reabsorption has been well defined by Bosse et 
al 20. They identified Gata-4 as an essential mediator of the maintainance of jejunal-ileal 
identities in mice. Synthesis of a transcriptionally inactive Gata-4 mutant in the mouse 
jejunum resulted in an attenuation of expression of genes involved in nutrient absorption and 
an induction of genes involved in bile salt absorption 20. Moreover, results from our in vivo 
study showed reduced sucrase activity in rats with higher plasma bile salt concencentrations 
(bile-deficient > control > cholestatic rats) in the ileal part of the small intestine, while this 
pattern was not observed in the duodenal and jejunal part of the intestine 7. The effect could 
possibly be more pronounced in the terminal ileum of rats exposed to even higher plasma 
bile salt concentrations, as seen in human cholestasis. 
Since Caco-2 cells are derived from colon carcinoma cells it is impossible to ascribe 
features gained upon differentiation to any part of the small intestine. However, since 
differentiated Caco-2 cells express proteins involved in nutrient absorption as well as 
proteins involved in bile salt absorption, it is the ideal model to study interactions between 
these processes. 
In conclusion, our data indicate that intestinal epithelial cells involved in nutrient absorption 
are resistant to exposure to conjugated bile salts in cholestatic concentration and 
composition. The maintenance of intestinal cell proliferation and differentiation under 
cholestatic conditions suggests that the absorptive function of the small intestine is 
preserved, which is most likely related to the fact that nutrient absorption and bile salt 
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Background: Essential fatty acid (EFA) deficiency in mice induces fat malabsorption. We 
previously reported indications that the underlying mechanism is located at the level of the 
intestinal mucosa. 
Aim: To characterize the effects of EFA deficiency on small intestinal morphology and 
function. 
Methods: Mice were fed an EFA-deficient or control diet for 8 weeks. A 72 h fat balance, the 
EFA status, and small intestinal histology were determined. Carbohydrate absorptive and 
digestive capacities were assessed by stable isotope methodology after administration of U-
13C-glucose and 1-13C-lactose. Concentrations of the EFA linoleic acid (LA), and the enzyme 
activity and mRNA expression of lactase, were measured in small intestinal mucosa.  
Results: Mice fed the EFA-deficient diet were markedly EFA-deficient with a profound fat 
malabsorption. EFA deficiency did not affect the histology or proliferative capacity of the 
small intestine. Blood 13C6-glucose appearance and disappearance were similar in both 
groups, indicating unaffected monosaccharide absorption. In contrast, blood appearance of 
13C-glucose, originating from 13C-lactose, was delayed in EFA-deficient mice. EFA 
deficiency profoundly reduced lactase activity (-58%, p<0.01) and mRNA expression (-55%, 
p<0.01) in mid small intestine. Both lactase activity and its mRNA expression strongly 
correlated with mucosal LA concentrations (r=0.89 and 0.79, resp., p< 0.01).  
Conclusions: EFA deficiency in mice inhibits the capacity to digest lactose, but does not 
affect small intestinal histology. These data underscore the observation that EFA deficiency 





Essential fatty acid (EFA) deficiency can occur in cholestatic liver diseases as a 
consequence of fat malabsorption 1,2. However, EFA deficiency itself also induces fat 
malabsorption 3,4. The underlying mechanism of EFA-deficient fat malabsorption remains 
unclear. Absorption of fat involves lipolysis, solubilization and intestinal translocation from 
the lumen into the mucosa, chylomicron assembly and transport into the lymph 5,6. Previous 
studies in EFA-deficient mice have indicated that impaired lipolysis or bile formation do not 
cause the fat malabsorption in EFA deficiency 4. Recently we reported data to suggest that 
EFA deficiency in mice affects fat absorption at the level of the small intestinal mucosa 4. 
However, it has not been proven that EFA deficiency impairs the mucosal phase of fat 
absorption.  
In contrast to fat absorption, the absorption of di- and monosaccharide carbohydrates 
exclusively depends on mucosal function 7. The monosaccharide glucose is actively 
transported across the brush border membrane in the small intestine by the brush-border 
transporter SGLT1 (Sodium-dependent glucose transporter) 7,8. The disaccharide lactose is 
first hydrolyzed by the mucosal membrane anchored lactase-phlorizin hydrolase (lactase, 
LPH) into glucose and galactose, prior to their active transport across the brush border by 
SGLT1 8,9. Besides being an important enzyme in lactose hydrolysis, lactase is a marker of 
enterocyte differentiation 10. Throughout development total intestinal lactase activity remains 
similar to that found in newborns 11. This characteristic makes lactase a good marker for 
functional assessment of the small intestine in adult animal.  
Essential fatty acids (EFAs) are structural components of membrane phospholipids. 
Enterocyte membrane phospholipids are particulary rich in linoleic acid (LA, C18:2n-6) 12 
which is necessary for modulations of a wide variety of biological functions and for 
physiochemical adaptations of the membrane lipid matrix to alterations in membrane fluidity 
13
. The lipid matrix influences the conformation and function of proteins embedded in the 
inner and/or outer leaflet of the membrane 14. Recently, an additional role of EFAs in 
alterations of bilayer elastic properties and lipid composition in lipid rafts have been reported 
15,16
. Through activation of peroxisome proliferator-activated receptors (PPARs), EFAs can 
regulate transcriptional activity of several genes, including of those involved in fatty acid 
transport and metabolism 17,18.  
In the present study we characterized the effects of EFA deficiency on small intestinal 
morphology and function in mice. Korotkova et al. have shown that EFA deficiency affects 
the fatty acid composition in the phospholipids of the rat small intestinal mucosa by 
decreasing the jejunal concentrations of linoleic acid 12. However, no studies have been 
performed on the effect of EFA deficiency on the small intestinal function. We assessed the 
absorption of glucose, a major source of metabolic energy for mammalian cells 19, and 
lactose, as appropriate functional markers of the small intestine, in a previously developed 
and characterized murine model of EFA deficiency 4. We applied stable isotope 
methodology 20, since this approach allows extension to similar studies in patients with EFA 
deficiency, cholestasis, or other forms of malabsorption 21-23. U-13C-labeled glucose and 1-
13C-labeled lactose were administered to EFA-deficient and control mice. Blood appearance 
of labels derived from administered glucose (13C6-glucose) and lactose (13C-glucose) into 
the blood glucose fraction was subsequently quantified. We also determined the activity and 
expression of lactase, as well as the concentration of LA, in the mucosa along the proximal-
to-distal axis of the small intestine.  
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Our data show that EFA deficiency is associated with impaired lactose digestion in mice. 
This functional observation corresponds with lower lactase mRNA expression and enzyme 




MATERIALS AND METHODS 
 
Mice and housing 
Wild type mice with a free virus breed (FVB) background were obtained from Harlan (Horst, 
The Netherlands). Male mice (25-35 g) were housed in a light-controlled (lights on 6 AM-6 
PM) and temperature-controlled facility and were allowed tap water and chow (AB diets, 
Woerden, Netherlands) ad libitum. The experimental protocol was approved by the Ethics 




U-13C-glucose and 1-13C-lactose were obtained from Isotec Inc. (Miamisburg, Ohio, USA) 
with isotopic enrichments of 99%. Unlabeled lactose was obtained from Fluka (Buchs, 
Switzerland). 
 
Experimental diets  
Similar to previous studies, we used high-fat EFA-deficient and EFA-sufficient (control) diets 
(16 wt% and 34 energy% fat), in order to mimic more closely the human diet composition 4. 
The diets were custom synthesized by Arie Bloks BV (Woerden, the Netherlands, diet codes 
EFA deficient #4141.08 and EFA-sufficient #4141.07). The EFA-deficient diet contained 64 
mol% palmitic acid (C16:0), 18 mol% stearic acid (C18:0), 13 mol% oleic acid (C18:1n-9) 
and 5 mol% linoleic acid (C18:2n-6). The isocaloric EFA-sufficient diet contained 36 mol% 
C16:0, 5 mol% C18:0, 31 mol% C18:1n-9 and 29 mol% C18:2n-6. Fatty acid contents of the 
diets were analyzed by extracting, hydrolyzing and methylating total dietary fatty acids as 
described by Muskiet et al. and subsequent separation and quantification of fatty acid methyl 
esters was performed by gas chromatograhy as described previously 4,24. 
 
Experimental procedures 
Induction of EFA deficiency. Mice were fed standard laboratory chow containing 6 weight% 
fat from weaning, and were switched to EFA-deficient or control diet at eight weeks of age. 
At the end of eight weeks-period on EFA-deficient or control diet, fat absorption was 
assessed by measuring food intake and collecting feces for 72 h. Following this eight weeks-
period the mice underwent a glucose/lactose absorption test with U-13C- glucose and 1-13C-
lactose (details see below) 24,25. After the test the mice were anesthetized and sacrificed by 
obtaining a large blood sample through cardiac puncture for determination of erythrocyte 
EFA-status by the triene/tetraene (C20:3n-9/C20:4n-6) ratio 4. The small intestine was 
excised, flushed with ice-cold PBS and divided into a proximal, mid and distal segment of 
similar size. Smaller parts from the middle of each small intestinal segment were harvested 
for histology and gene expression. The remaining part of the small intestine was opened 
lengthwise and the mucosa was removed by scrapping the luminal surface with a glass 
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coverslip. Mucosa was homogenized in buffer (see below for details) and used for the 
determination of enzyme activity, proteins and LA concentrations in mucosal phospholipids. 
Glucose/lactose absorption. Glucose absorption and lactose digestion were determined by a 
combined U-13C-glucose/1-13C-lactose absorption test. After an overnight fast, mice received 
0.5 mg U-13C-glucose, 5 mg 1-13C-lactose and 5 mg naturally enriched lactose in 300 µL 
PBS via gastric gavage. Before and at time points 7.5, 15, 30, 45, 60, 90, 120 and 180 min. 
after administration, blood samples were obtained by blood spot technique from the tail for 
determination of blood concentrations of (total) glucose, 13C6-glucose (glucose originating 
from U-13C-glucose)  and 13C-glucose (originating from 1-13C-lactose) 25. For reasons of 




Lipid absorption, triene/tetraene ratio, blood glucose and serum insulin concentrations. Lipid 
absorption and erythrocyte triene/tetraene ratio were determined as described previously 
4,27
. Blood glucose levels were measured with a Lifescan EuroFlash glucose meter (Lifescan 
Benelux, Beerse, Belgium). Insulin was measured in a solid phase two-site enzyme 
immunoassay in which two monoclonal antibodies are directed against separate antigenic 
determinants on the insulin molecule (Ultrasensitive Mouse Insulin kit; Mercodia, Uppsala, 
Sweden).  
Histology and villus length along the small intestinal axis. Morphology of proximal, mid and 
distal small intestine was assessed by hematoxylin and eosin staining of formalin-fixated 
material. Proliferating cells were detected by staining of nuclear Ki-67 antigen. 
Morphometrical analysis of small intestinal samples was performed as described by 
evaluation of 4, 6 and 7 villi per proximal, mid and distal intestinal segment, respectively, of 
4 to 6 animals per group. The digitized images were evaluated at 10 x magnification using 
the calibrated image analysis system (Leica Quantimet 570 C; Leica Qwin Pro V 2.8). The 
epithelial surface lining was demarcated and measured as a parametrical length, whereby 1 
pixel was equal to 0.544 µm.  
Glucose/lactose absorption. The analysis of 13C6-glucose and 13C-glucose concentrations 
from blood spots was performed according to Van Dijk et al. by gas chromatography-mass 
spectrometry (SSQ700, ThermoFischer B.V., Breda, The Netherlands) 25. 
Disaccharidase activity assay in mucosal homogenates. A portion of small intestinal mucosa 
(from the proximal, mid and distal part) was homogenized with PBS buffer containing 
protease inhibitors (Roche, Indianapolis, USA) in order to make 4% homogenates for use in 
enzyme activity assay. Enzyme activity level of lactase was measured in freshly scraped 
intestinal mucosa as described previously by Dahlqvist 28. Activity levels were normalized to 
protein levels, measured by the BCA method as described by the manufacturer (Pierce, 
Rockford, IL). 
Measurement of mRNA expression by real-time PCR (Taqman). mRNA expression of the 
differentiation marker and lactose digesting enzyme (lactase) was measured in proximal, 
mid and distal small intestine by real-time PCR as described previously 29. In addition, 
mRNA expression levels of intestine-specific transcription factors (Cdx-2, Gata-4 and Hnf-
1α) were measured by real-time PCR in the mid part of the small intestine. PCR results were 















LA determination in phospholipids of intestinal mucosa. Thirty mg of intestinal mucosa was 
homogenized in 200 µl of 0.9% NaCl and lipids were extracted according to Bligh and Dyer  
after the addition of the fatty acid internal standard (C17:0) and anti-oxidant (BHT) 30. Lipid 
extracts were fractionated into phospholipids and other lipids using TLC (20 x 20 cm, Silica 
gel 60 F254; Merck) with hexane/diethyl ether/acetic acid (80:20:1, v:v:v) as running solvent. 
Phospholipid spots were scraped and phospholipids were extracted by methanol/chloroform. 





Values represent means ± SD for the indicated number of mice per group. Using SPSS 
version 12.0.2 statistical software (Chicago, IL, USA), we calculated significance of 





Body weight and food ingestion were assessed every two weeks and there were no 
significant differences in basal or final body weight, nor in food intake (data not shown) 
between EFA-deficient and control mice. 
 
Pronounced EFA deficiency of EFA-deficient mice 
After eight weeks of treatment, in mice fed the EFA-deficient diet, the triene/tetraene ratio in 
red blood cell membranes was strongly increased compared with the control group (0.23 ± 
0.06 vs. 0.01 ± 0.00; respectively, p<0.01). Conform previous observations, the mice fed the 
EFA-deficient diet also showed other characteristics of EFA deficiency including increased 
bile flow (+78%, p<0.05), biliary secretion rates of bile salts (+212%, p<0.01) and 
phospholipids (+82%, p<0.05), and higher levels of triene/tetraene ratio in plasma (0.55 ± 
0.20 vs. 0.01 ± 0.00, p<0.01), compared with control mice (data not shown) 4. Fat balance 
during 72 hours revealed a decreased total fat absorption in EFA-deficient compared to 
control mice (81% vs. 99%, resp., p<0.01; fig 1). The absorption of saturated fatty acids, 
palmitic (C16:0) and stearic (C18:0) acids, was affected to a greater extent than that of the 
unsaturated fatty acids oleic (C18:1n-9) and linoleic acid (C18:2n-6). Together, these 
observations indicated that the mice fed the EFA-deficient diet had profound EFA deficiency 
after 8 weeks on the experimental diet 4. 
 
 
Gene GenBank Forward Primer Reversed Primer TaqMan® probe 
β-actin NM_007393 AGC CAT GTA CGT 
AGC CAT CCA 
TCT CCG GAG TCC 
ATC ACA ATG 
TGT CCC TGT ATG CCT 
CTG GTC GTA CCA C 
Lactase XM_129479 CGT CTG CTT CCT 
ATC AGG TTG AA 
GTG GGA AAA TGT 
GTC CCA GAT ACT 
TCC TTT GCC ATC TGC 
TCT CCA CGC 
Cdx-2 NM_007673 GTC CCT AGG AAG 
CCA AGT GAA A 
CTC CTG ATG GTG 
ATG TAT CGA CTA 
CCT TCT CCA GCT CCA 
GCC GCT G 
Gata-4 NM_008092.2 GAG ATG CGC CCC 
ATC AAG 
GAC ACA GTA CTG 
AAT GTC TGG GAC AT 
CTG TCA TCT CAC TAT 
GGG CAC AGC AGC TC 
Hnf-1α NM_009327 CTC CAG CAG CCT 
GGT GTT GT 
GAG GCC ATC TGG 
GTG GAG AT 
CAC AGC CAC CTG CTG 
CCA TCC AAC 
 
















EFA deficiency in mice not associated with alterations in intestinal morphology 
Hematoxylin/eosin (data not shown) and Ki67 staining of the three segments of the small 
intestine revealed no clear differences in morphology or proliferative capacity between EFA-
deficient and control mice (fig 2). The villus lengths were similar in EFA-deficient and control 
mice, as determined by morphometrical measurements in the three segments of the small 




















EFA deficiency is associated with delayed glucose clearance 
Basal blood glucose concentrations were similar in EFA-deficient and control mice. After 
intragastric administration of the glucose/lactose bolus, glucose concentrations rapidly 
increased in control mice, with a maximum concentration at 30 min. after administration (fig 
3). In EFA-deficient mice, the increase in blood glucose levels was similar to that in control 
mice up to 30 min., but then continued to increase, reaching a maximum concentration at 60 
min. The glucose concentrations between 60 and 180 min. were slightly, but significantly 
higher in EFA-deficient mice compared to controls (+10-15%, p<0.05). Accordingly, the area 
under the curve was higher for the EFA-deficient mice compared with controls (+15%, 
Figure 1. Fat absorption of total dietary fat, and 
of major dietary fatty acids (16:0, 18:0, 18:1n-9 
and 18:2n-6) in EFA-deficient and control mice. 
Feces were collected after a 72h period in 
which the food intake was monitored by 
weighing food containers. Absorption was 
calculated by subtracting fecal excretion of 
these fatty acids after 72h from their dietary 
intake in 72h and then multiplying the result by 
100. Data represent means ± SD of 7 mice per 
group. *P< 0.05 and **P< 0.01 for EFA-
deficient vs. control mice. 
Figure 2. A Ki67 staining of sections of the three 
parts of the small intestine (proximal, mid and distal) 
from EFA-deficient and control mice. B Morphometry 
of the villus length in the three segments of the small 
intestine (proximal, mid and distal) of EFA-deficient 
and control mice. Data represent means ± SD of 4-6 
mice per group. No significant differences were found 
between the two groups. 
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p<0.05, data not shown). Based on the apparently delayed glucose clearance, we 
determined insulin concentrations at the end of the experiment (at ~180 min.). In EFA-
deficient mice insulin concentrations were significantly higher than in control mice (0.55 

























Similar glucose absorption but delayed lactose digestion in EFA-deficient mice 
To assess the competence of monosaccharide absorption in EFA deficiency, we determined 
blood appearance of 13C6-glucose (fig 3). After the administration of the bolus, blood 13C6-
glucose concentration rapidly increased with a maximum at 45 min. for both groups. After 45 
min., 13C6-glucose rapidly disappeared until 120 min., after which the rate of disappearance 
decreased in both EFA-deficient and control mice. Thus, the blood 13C6-glucose appearance 
and disappearance was similar in EFA-deficient and control mice, supporting unaffected 
monosaccharide absorption in the former.  
In order to measure the competence of disaccharide digestion and absorption, we 
determined blood appearance of 13C-glucose, originating from the administered 1-13C-
lactose (fig 3). 13C-glucose reached a maximum concentration in control mice at 45 min. 
after bolus administration. The 13C-glucose disappeared from the blood within the next 2 
hours, with the slowest disappearance during the last hour after the bolus administration. 
Blood appearance of 13C-glucose in EFA-deficient mice, however, increased to a slower 
extent and reached its maximal concentration at approximately 60 min. after the bolus 
administration. Thus, the 13C-lactose uptake was delayed in EFA-deficient compared to 
control mice. 
 
Figure 3. A Total blood glucose response in EFA-
deficient and control mice measured at different time 
points (7.5, 15, 30, 45, 60, 90, 120 and 180 min.) after 
the intragastric glucose/lactose bolus. B Blood 
appearance of 13C6-glucose originating from the 
administered U-13C-glucose in EFA-deficient and 
control mice after an intragastric administration of 
glucose/lactose bolus. C Plasma appearance of 13C-
glucose originating from the administered 1-13C-
lactose in EFA-deficient and control mice after an 
intragastric administration of glucose/lactose bolus. 
Data represent means ± SD of 7 mice per group. *P< 
0.05 for EFA-deficient vs. control mice. 
 
79 
Decreased mRNA expression and lactase activity in mid small intestine of EFA-
deficient mice 
Lactase is a critical disaccharidase during early postnatal life and a sensitive intestinal 
marker for functional changes occurring in the small intestine of the adult animal. Its activity 
relatively decreases during weaning to low adult levels, thus the total lactase activity 
remains the same during the adutlhood 32. Measurement of the enzyme activity of lactase 
along the proximal-to-distal axis of the small intestine revealed a lower activity in the mucosa 
of the mid part of the small intestine of EFA-deficient compared to control mice (fig 4). The 
decreased lactase activity corresponded with lower mRNA levels of lactase, as shown by 
quantitative PCR (fig 4). We determined if reduced lactase mRNA expression levels were 
regulated at the transcriptional level. However, the mRNA expression of transcription factors 
involved in regulation of the lactase mRNA expression, namely Cdx-2, Gata-4 and Hnf-1α 




















Decreased lactase activity and mRNA expressions are associated with low LA 
concentrations in the mid small intestine 
EFAs are involved in regulation of membrane fluidity and alterations in membrane lipid 
matrix. Therefore, it has been proposed that EFAs indirectly influence normal conformation 
and functioning of the proteins embedded in the inner and/or outer leaflet of the membrane 
14
. For this reason we tested if lactase activity in the mid segment of the small intestine 
correlated with LA levels. Phospholipid LA concentration was determined the mucosa of the 
three segments of the small intestine (fig 5). LA concentrations were highest in the mid part 
of the small intestine in control mice. Interestingly, LA concentration was significantly lower 
in the mid part of the small intestinal mucosa of EFA-deficient compared to control mice (26 
mol% vs. 16 mol%, respectively, p<0.01). LA concentrations in proximal and distal part were 
similar in both groups. In the mid small intestine LA concentrations positively correlated with 
lactase activity (r=0.88, p<0.001) and mRNA expression of lactase (r=0.79, p<0.01) (fig 5). 
Decreased mRNA levels in the mid intestine indicate that the intestinal impairment can not 
exclusively be the result of alterations in membrane composition and fluidity. 
Figure 4. A Enzyme activity of lactase in the three segments of 
the small intestine of EFA-deficient  and control mice. Enzyme 
activity is expressed as glucose production after 1 hour of 
incubation of intestinal mucosa with the substrate of lactase. Data 
represent means ± SD of 6 mice per group. **P< 0.01 for EFA-
deficient vs. control mice. B mRNA expression levels of lactase 
gene, normalized to -actin, in the three segments of the small 
intestine of EFA-deficient and control mice. Data represent means 
± SD of 6 mice per group. **P< 0.01 for EFA-deficient vs. control 
mice. C Relative mRNA expression of the transcription factors 
Cdx-2, Gata-4 and Hnf-1α (involved in regulation lactase 
expression) in the mid part of the small intestine. Data represent 
means ± SD of 5-6 mice per group. No significant differences were 



























Our previous studies suggested that EFA deficiency in mice affects fat absorption at the 
level of the small intestinal mucosa 4. We now explored the effects of EFA deficiency in mice 
on mucosal histology and on a physiological function of the small intestine, carbohydrate 
digestion and absorption. Our data demonstrate that EFA deficiency is not only associated 
with fat malabsorption, but also with impaired lactose digestion in the murine model of EFA 
deficiency. The impaired lactose digestion coincided with an ~50% reduced lactase activity 
and mRNA expression in mid small intestine of EFA-deficient mice. Intestinal lactase activity 
and mRNA expression strongly correlated with mucosal linoleic acid concentrations, which 
were depressed in EFA deficiency, particularly in mid-intestine.  
As expected from previous studies, our murine model of EFA deficiency was clearly 
deficient, as indicated by elevated triene/tetraene ratios in erythrocytes and plasma, fat 
malabsorption, and other biochemical signs of EFA deficiency, like increased bile flow and 
biliary output 4. EFA deficiency in mice did not affect morphology or proliferative capacity of 
the small intestine. As far as we know, our study is the first to describe the effects of EFA 
deficiency on the intestinal morphology in mice. Christon et al. have shown that low dietary 
linoleic acid levels were associated with alterations in villi and crypt sizes in rats 33. We did 
not observe differences in villus length between EFA-deficient and control mice using 
morphometrical evaluation of the villus length in the proximal-to-distal axis of the small 
intestine. These results indicate that EFA deficiency associated malabsorption of fats and 
disaccharides is not associated with morphological alterations in small intestine of mice.  
To assess small intestinal function in EFA-deficient mice, we studied carbohydrate 
absorption, using stable isotope methodology 25. The advantage of stable isotope 
methodology is that it can easily be extrapolated to patient studies 21,22. EFA-deficient mice 
Figure 5. A LA (C18:2n-6) concentration in small intestinal 
mucosa along the proximal-to-distal axis of EFA-deficient and 
control mice. Concentrations are indicated in mol% of total fatty 
acids. Data represent means ± SD of 6 mice per group. **p< 0.01 
for EFA-deficient vs. control mice. B Relationship between the 
mucosal LA concentration (mol%) and enzyme activity of lactase 
(nmol/µg protein/h) in the mid part of the small intestine (y=ax+b;  
a=0.06234±0.01033; b=-0.5825±0.2315). There is a positive 
correlation (r=0.88, p<0.0001) between the LA concentration and 
lactase activity in mucosa, a phenomenon specific for the mid 
part of the small intestine. C Relationship between the mucosal 
LA concentration (mol%) and relative mRNA expression of 
lactase in the mid part of the small intestine (y=ax+b;  
a=0.06212±0.01510; b=-0.4109±0.3384). There is a positive 
correlation (r=0.79, p<0.0001) between the LA concentration and 
lactase activity in mucosa, a phenomenon specific for the mid 
part of the small intestine. 
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had higher total blood glucose levels from 60 min. after the administration of the 
glucose/lactose bolus. High total glucose levels in blood could theoretically be explained by 
lower blood glucose clearance (slower postprandial uptake of glucose by the peripheral 
tissues), rather than by disturbed intestinal absorption. This hypothesis is supported by 
higher insulin concentrations at the end of the experiment in EFA-deficient compared with 
control mice. This observation is in accordance with previous studies suggesting a 
relationship between EFA deficiency and insulin resistance 34. However, we cannot exclude 
that the increased content of saturated fats in the EFA deficient diet contributes to this 
phenomenon, independently from EFA deficiency 35. 
Measurement of the absorption of 13C6-glucose, originating from the administered U-13C-
glucose, revealed similar appearance and disappearance of the labeled glucose in both 
groups. This observation indicates that EFA deficiency does not affect the absorption of the 
monosaccharide glucose in mice. The blood appearance of 13C-glucose originating from 
lactose, however, was significantly delayed in EFA-deficient mice. The discrepancy in the 
effect of EFA deficiency on glucose and lactose absorption could be explained by the 
diverse intestinal fates of these carbohydrates. Unlike glucose, which is directly transported 
by the glucose transporters across the brush border membrane of the enterocyte, lactose 
first needs to be hydrolyzed by the enzyme lactase 7,8. In order to investigate whether our 
functional results corresponded with altered lactase activity or expression, we measured 
these parameters in EFA-deficient and control mice. Lactase is the critical enzyme for 
hydrolysis of lactose and a good marker of functional changes in the small intestine 10. The 
delayed lactose digestion corresponded with an approximate 50% reduction in both lactase 
activity and mRNA expression compared to control mice. The mRNA levels of relevant 
transcription factors for lactase mRNA expression were unaffected in EFA-deficient mice, 
suggesting that the expression of lactase is regulated in a post-transcriptional manner during 
EFA deficiency. 
Under physiological conditions phospholipids of the small intestinal mucosa contain 
considerable amounts of LA (C18:2n-6) and of its long-chain polyunsaturated fatty acid 
metabolite arachidonic acid (AA, C20:4n-6) 36. During EFA deficiency the levels of this major 
dietary EFA are decreased in intestinal mucosa 12,37. We observed LA deficiency in mucosal 
phospholipids, particularly the mid part of the small intestinal mucosa, which strongly 
correlated with reduced lactase activity and mRNA expression. We speculate that the 
decreased levels of LA in this intestinal segment correspond to the predominant location of 
nutrient absorption 38. It is tempting to speculate that low levels of LA in phospholipids of 
cellular membranes lead to structural and physiological changes in the lipid membrane, 
eventually causing functional changes in membrane anchoring lactase enzyme. Since not 
only lactase activity but also its mRNA expression was decreased in EFA deficiency, it is 
likely that altered membrane fluidity is not the single factor involved. 
Our present results indicate that EFA deficiency has functional consequences for small 
intestinal function in mice, and it provides indirect support for the hypothesis that reduced 
mucosal function is involved in fat malabsorption in EFA deficiency. EFA deficiency in 
(pediatric) cholestatic patients seems primarily caused by fat malabsorption due to bile 
deficiency. Recently, we reported that cholestasis per se does not affect carbohydrate 
digestion or absorption, using a rat model of short-term cholestasis 39. Our present study 
indicates, however, that EFA deficiency aggravates the malabsorption of fat, and decreases 
the small intestinal capacity to digest carbohydrates. Decreased levels of LA in the mid part 
of the small intestine seem to play a pathophysiological role in the diminished mucosal 
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function in EFA deficiency. Our findings imply that the nutrition of cholestatic patients 
encountering EFA deficiency should accommodate the decreased capacity to absorb fat, the 
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Essential fatty acid deficiency in mice: 
milder fat malabsorption and a more 



























Cholestatic liver disease is frequently accompanied by fat malabsorption and essential fatty 
acid (EFA) deficiency. EFA deficiency in mice disturbs fat malabsorption via unidentified 
mechanisms, presumably at the level of the intestinal mucosa. The farnesoid X receptor 
(FXR) is involved in the regulation of bile salt homeostasis in the enterohepatic circulation. 
We addressed the role of FXR in fat absorption and bile salt homeostasis in EFA deficient 
mice.  
Fxr-/- and Fxr+/+ (control) mice were fed an EFA deficient diet for 8 weeks, after which fat 
absorption was determined by 72 h fat balance. Bile production and intestinal mRNA 
expression of proteins relevant for bile salt homeostasis and lipid homeostasis were 
analyzed. 
EFA deficient diet induced a similar degree of EFA deficiency in Fxr-/- and Fxr+/+ mice 
(triene/tetraene ratio: 0.14 (median, range 0.09-0.32) vs. 0.13 (0.07-0.24), resp. Fat 
absorption, however, was significantly better preserved in Fxr-/- mice (78±4% of amount 
ingested) compared with controls (70±4%, P<0.05). Correspondingly, Fxr-/- mice gained 
more body weight during the experimental period compared with controls (+14±7 vs. +7±5% 
of initial body weight, respectively; P<0.05). Bile flow and biliary secretion rates of bile salts, 
cholesterol and phospholipids were similar in Fxr-/- and control mice. The composition of the 
biliary bile salt pool was altered in Fxr-/- mice, however, characterized by increased 
hydrophobicity (cholic acid-muricholic acid ratio: 1.5 (0.93-4.21) vs. 1.0 (0.34-1.12), P<0.05). 
Fxr-/- mice had a higher fecal bile salt loss (+60%, P<0.01), coinciding with a lower intestinal 
mRNA expression of bile salt transporter Asbt in the terminal ileum.  
We conclude that inactivation of FXR ameliorates the fat malabsorption and improves 






Cholestasis is defined as a decreased flow of bile and its consituents into the small intestine. 
Biliary bile salts aid in the absorption of lipids and lipid-soluble vitamins from the intestine. 
Consequently, cholestatic liver disease is frequently accompanied by fat malabsorption and 
essential fatty acid (EFA) deficiency, eventually leading to malnutrition. Malnutrition seriously 
worsens the prognosis and treatment outcome in cholestatic children 1-3.  
The fatty acids linoleic (LA; C18:2n-6) and linolenic (ALA; C18:3n-3) acid cannot be 
synthesized de novo. These so-called essential fatty acids therefore need to be acquired 
from external sources, usually the diet. After absorption, linoleic LA and ALA can be 
converted into long chain polyunsaturated fatty acids (LCPUFAs) such as arachidonic (AA; 
C20:4n-6), eicopentaenoic (EPA; C20:5n-3) and docosahexaenoic (DHA; C22:6n-3) acid. 
Deficiency of EFAs and LCPUFAs has been associated with obesity, hypertension, diabetes 
mellitus, schizophrenia, Alzheimer’s disease and cancer 4,5.  
Not only cholestasis can induce fat malabsorption, EFA deficiency in itself also causes fat 
malabsorption in rats and mice 5. The mechanism by which EFA deficiency, in the absence 
of cholestasis, decreases fat absorption is incompletely understood. EFA deficiency-induced 
fat malabsorption in rats has been ascribed to decreased bile formation, impaired 
triglyceride re-esterification and impaired chylomicron formation 6,7. EFA deficiency in mice, 
however, is accompanied by increased bile formation 8.  
The farnesoid X receptor (FXR) has been implicated in the regulation of bile salt and lipid 
metabolism 9. Fxr-deficient mice display increased bile flow and bile salt pool size, and a 
more hydrophobic bile salt composition due to an increased contribution of cholic acid (CA) 
8,10
. Interestingly, we previously demonstrated that EFA-deficiency in (wild-type) mice has 
similar phenotypic characteristics 8. Based on this similarity, we addressed whether FXR 
inactivation would affect the phenotype of EFA deficiency in mice. We hypothesized that 
EFA deficiency in Fxr-null mice would ameliorate fat malabsorption, compared with control 
mice, by (further) increasing bile flow, bile salt pool size and relative CA contribution. 
 
 
MATERIAL AND METHODS 
 
Animals and housing 
We used Fxr knockout mice that were originally described by Kok et al. 10. Male 
homozygous (Fxr-/-) and wild-type (Fxr+/+) mice (C57BL/6J-129/OlaHsd; 25-35 g) were bred 
at the animal facility of the University of Groningen. Mice were housed in a light- and 
temperature-controlled facility. Food and water were available ad libitum. The experimental 
protocol was approved by the Ethics Committee for Animal Experiments, Faculty of Medical 
Sciences, University of Groningen, Netherlands. 
 
Experimental diet 
We used high-fat EFA-deficient (16 wt% and 34 energy% fat) to induce EFA deficiency in 
mice. The diet was custom synthesized by Arie Bloks BV (Woerden, the Netherlands, diet 
code: #4141.08). The EFA-deficient diet contained 70 mol% palmitic acid (C16:0), 19 mol% 
stearic acid (C18:0), 9 mol% oleic acid (C18:1n-9) and 2 mol% linoleic acid (C18:2n-6). 
Fatty acid contents of the diets were analyzed by extracting, hydrolyzing and methylating 
total dietary fatty acids as described by Muskiet et al. and subsequent separation and 
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Mice were fed standard laboratory chow containing 6 weight% fat from weaning, and 
switched to an EFA deficient high-fat (16 weight%) diet at 8 wk of age. At the end of an 8 
wk-period on EFA deficient diet, feces were collected over 72 hours to measure fat balance. 
Bile production was determined by bile collection for 30 min via cannulation of the 
gallbladder. After bile collection, mice were sacrificed by obtaining a large blood sample via 
cardiac puncture. Erythrocyte EFA status was assessed by the triene/tetraene ratio, 
obtained from gaschromatography of fatty acid methyl esters 12. The small intestine was 
excised, flushed with ice-cold PBS and was divided into 3 pieces of equal length. Material 
was harvested for gene expression from the middle of each piece and the distal end of the 
third piece, representing the proximal, medial, distal and terminal ileal segment of in the 
intestine.   
 
Analytical methods 
The erythrocyte triene/tetraene ratio was determined as described by Werner et al. 12. Fat 
absorption was determined by quantification of fatty acid ingestion and fecal excretion over a 
72 h period, using gas chromatography 13. Bile salt composition of bile and fecal excretion of 
bile salts were determined 14. Plasma and biliary cholesterol and phospholipids, and plasma 
triglyceride concentrations were determined by routine laboratory techniques. 
 
RNA isolation and measurement of mRNA levels by real-time PCR (Taqman) 
mRNA expression levels in proximal, medial, distal and terminal ileal part of the small 
intestine were measured by real-time PCR, as described previously 15. PCR results were 





















Gene GenBank Forward Primer Reversed Primer TaqMan® probe 
β-actin NM_007393 AGC CAT GTA CGT 
AGC CAT CCA 
TCT CCG GAG TCC 
ATC ACA ATG 
TGT CCC TGT ATG CCT 
CTG GTC GTA CCA C 
Fat BC010262 GAT CGG AAC TGT 
GGG CTC AT 
GGT TCC TTC TTC 
AAG GAC AAC TTC 
AGA ATG CCT CCA AAC 
ACA GCC AGG AC 
Fatp-4 NM_011989 CCA GAC AAG GGT TTT 
ACA GAT AAG CT 
ACC TGC TGT GCA 
CCA CAA TG 
CGG GCA CCA CGG 
GGC TAC CC 
Ifabp NM_007980 GAG TTG AGG CCA 
AGC GAT TCT 
GAG CCT GGC ATT 
AGC ATG ATG 
CTC TTC AGC GTT GCT 
CCA GGC TCT GAG 
Dgat-1 NM_010046.2 GGT GCC CTG ACA 
GAG CAG AT 
CAG TAA GGC CAC 
AGC TGC TG 
CTG CTG CTA CAT GTG 
GTT AAC CTG GCC A 
Dgat-2 NM_026384.2 GGG TCC AGA AGA 
AGT TCC AGA AG 
CCC AGG TGT CAG 
AGG AGA AGA G 
CCC CTG CAT CTT  
CCA TGG CCG 
Mttp NM_008642 CAA GCT CAC GTA CTC 
CAC TGA AG 
TCA TCA TCA CCA 
TCA GGA TTC CT 
ACC GCA AGA CAG 
CGT GGG CTA CA 
Fxr-α U09417 CTT TCT GAA AGC TTA 
TTT GGT ATG CTA A 
AGT ACG ATT CCA 
AAT CCA GAT TCT G 
AAC ACG CGG CAG 
GCC CTC TG 
Fxr-β AK002513 
 
GTG AAG CCA GCT 
AAA GGT ATG CTA A 
AGT ACG ATT CCA 
AAT CCA GAT TCT G 
AAC ACG CGG CAG 
GCC CTC TG 
Fgf-15 NM_008003 GCC ATC AAG GAC 
GTC AGC A 
CTT CCT CCG AGT 
AGC GAA TCA G 
CGC TCA TGC AGA 
GGT ACC GCA CG 
Asbt NM_011388 ACC ACT TGC TCC ACA 
CTG CTT 
CCC GAG TCA ACC 
CAC ATC TT 
CCC TTG GAA TGA TGC 
CTC TTT GCC TC 
Ibabp NM_008375 CCC CAA CTA TCA CCA 
GAC TTC G 
ACA TCC CCG ATG 
GTG GAG AT 
TCC ACC AAC TTG TCA 
CCC ACG ACC T 
 






Results are provided in means ± SD or median and range for the indicated number of mice 
per group. Using SPSS version 12.0.2 statistical software (Chicago, IL, USA), we analyzed 
the results with the two-tailed Student’s t-test for normally distributed data or with the Mann-
Whitney U-test for data that were not normally distributed. Variance among data was 





EFA deficiency in Fxr-/- mice: higher weight gain and fat absorption 
EFA deficiency was induced in Fxr-/- and Fxr+/+ mice to a similar extent as indicated by the 
triene/tetraene ratio measured in RBC (median (range): 0.14 (0.09-0.32) vs. 0.13 (0.07-
0.24), resp., NS). After 8 weeks on an EFA deficient diet, Fxr-/- mice had gained more weight 
compared to Fxr+/+ mice (+14±7 vs. +7±5% of initial body weight, P<0.05). Fat ingestion was 
similar in Fxr-/- and Fxr+/+ mice, while fecal fat excretion was lower in Fxr-/- mice (197±56 vs. 
268±53 µmol/day, P<0.05; Fig 1). Absorption coefficients of total fatty acids, palmitic acid 
(C16:0), stearic acid (C18:0), oleic acid (C18:1n-9) and linoleic acid (C18:2n-6) were higher 
in Fxr-/- mice compared to Fxr+/+ mice (all P<0.05; Fig 1).We quantified the mRNA 
expression of proteins that have been implicated in fatty acid transport, including fatty acid 
translocase (Fat), fatty acid transport protein 4 (Fatp-4), and cytosolic intestinal fatty acid 
binding protein 1 (Ifabp-1). mRNA expression of Fat, Ifabp-1 and Fatp-4 was not changed in 
Fxr-/- mice. Fat and Fatp-4 expression was significantly higher in proximal and medial part 
compared to the distal part of the small intestine in both groups (P<0.01), similar to previous 
reports 16-18. Ifabp-1 expression was higher in the medial part compared to the proximal and 

























































































































































































Figure 1. (A) Fat ingestion, fecal excretion and net absorption measured over a 72h period in EFA deficient Fxr+/+ (white bars) and Fxr-/- 
mice (black bars). (B) Absorption percentages of total fatty acids and of the major fatty acids: palmitic acid (C16:0), stearic acid (C18:0), 
oleic acid (C18:1n-9) and linoleic acid (C18:2n-6). (C) mRNA expression of Fat, Fatp-4 and Ifabp, normalized to β-actin levels, in the 
proximal (P), medial (M) and distal (D) part of the small intestine of EFA deficient Fxr+/+ (white bars) and Fxr-/- mice (black bars), measured 
by quantitative PCR. (D) mRNA expression of Dgat-1, Dgat-2 and Mttp, normalized to β-actin levels, in the proximal (P), medial (M) and 
distal (D) part of the small intestine of EFA deficient Fxr+/+ (white bars) and Fxr-/- mice (black bars), measured by quantitative PCR. Fxr-/- 
mice; n=7 and Fxr+/+ mice; n=5. Results are expressed as means ± SD. *P<0.05. 
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The enzymes involved in re-esterification of triglycerides in the enterocyte include acyl-
CoA:diacylglycerol acyltransferase (DGAT) 1 and 2, catalyzing the esterification of 
diacylglycerol to triglycerides. Microsomal triglyceride transfer protein (Mttp) is essential for 
the proper assembly of cholesterol, triglycerides, phospholipids and apolipoprotein B into 
chylomicrons 19,20. Expression of Dgat-1, Dgat-2 and Mttp showed higher expression in the 
proximal and medial part compared to the distal part (P<0.01; Fig 1), similar to previous 
reports 21,22. Inactivation of FXR did not alter this expression pattern. 
 
EFA deficiency in Fxr-/- mice increases plasma cholesterol and phospholipids 
concentration  
Plasma triglycerides were slightly, but not significantly higher in EFA deficient Fxr-/- mice, 
compared with controls (0.6±0.2 vs. 0.4±0.0 mmol/L, NS). Plasma concentrations of 
cholesterol (+31%, P<0.01) and phospholipids (+38%, P<0.05) were increased in EFA 













Bile salt homeostasis and enterohepatic circulation 
Figure 3 shows that bile production parameters were similar in EFA deficient Fxr-/- and 
control mice. Bile flow was also similar in Fxr-/- and control mice (5.5±1.1 vs. 6.5±1.5 
µL/min/100 g body weight, respectively, as was the biliary bile salt output (258±104 vs. 
239±117 nmol/min/100 g body weight, respectively). Fxr-/- mice fed a regular (not EFA-
deficient) diet and wild type EFA deficient mice both have an increased contribution of CA to 
total bile salt composition 8,10. Figure 4 shows the result of the combination, EFA deficient 
Fxr-/- mice; the contribution of CA to total bile salts was higher in EFA deficient Fxr-/- mice, at 
the expense of β-muricholic acid (β-MA) and α-muricholic acid (α-MA), resulting in a 
increased cholic acid-muricholic acids ratio, compared with controls [median 1.5, (range 











Figure 3. Biliary secretion rates of (A) bile salts, (B) cholesterol, and (C) phospholipids in EFA deficient Fxr+/+ (white 




















































































































































































Figure 2. Plasma concentrations of (A) triglycerides, (B) cholesterol, and (C) phospholipids in EFA deficient 


































































































































































































Fecal bile salt excretion is increased in EFA deficient Fxr-/- mice 
EFA-deficiency increased fecal bile salt excretion in Fxr-/- mice (3.6±0.6 vs. 2.3±0.4 
µmol/day, P<0.01), coinciding with decreased Asbt mRNA expression (-30%; P<0.05). Fxr 
deficiency decreased the expression of the FXR target genes Fgf-15 and Ibabp in EFA 















We addressed to what extent the gastrointestinal phenotype, i.e. fat malabsorption and bile 
salt homeostasis, of EFA deficiency was influenced by FXR inactivation in mice. Our data 
show that inactivation of FXR renders mice more resistant to EFA deficiency induced fat 
malabsorption and increases their weight gain, possibly by the production of bile with a more 
hydrophobic bile salt composition.  
For our study, we used the Fxr-/- mice originally described by Kok et al. 10. The complete 
abolishment of Fxr-α and Fxr-β expression (Fig 5) in the Fxr-/- mice confirmed that the mice 
did not express the Fxr gene. Kok et al. demonstrated that chow-fed Fxr-/- mice had an 
increased bile salt pool size and an increased fecal bile salt loss 10. This observation was 
explained by the abolishment of the negative feedback regulation that FXR exerts on hepatic 
bile salt synthesis under physiological conditions. Sinal et al., however, reported a 
decreased bile salt pool and fecal bile salt loss in another Fxr-/- mouse model 23. It is 
tempting to speculate that the difference between the two mouse models is due to the fact 
that the Fxr-/- mice used in Sinal’s study still have a DNA-binding domain which could affect 
the expression FXR target genes.  
Similar to FXR inactivation, EFA deficiency in mice increases bile salt pool size, bile flow 






































































































Figure 4. Biliary bile salt composition in EFA 
deficient Fxr+/+ (white bars, n=5) and Fxr-/- 
mice (black bars, n=7). Expressed are cholic 
acid (CA), β-muricholic acid (β-MA) and α-
muricholic acid (α-MA) as a percentage of 
the total bile salt concentration. Inset: cholic 
acid-muricholic acids ratio. Results are 





















































) Figure 5. mRNA expression of Fxr 
and relevant Fxr target genes in the 
terminal ileum in EFA deficient Fxr+/+ 
(white bars, n=5) and Fxr-/- mice (black 
bars, n=7). (A) mRNA levels were 
determined of Fxr-α, Fxr-β, Fgf-15, 
Asbt and Ibabp, all normalized to β-
actin, using quantitative PCR. Results 
are expressed as means ± SD. 
*P<0.05 and **P<0.01. 
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deficiency would further increase bile flow, biliary bile salt output and pool size in Fxr-/- mice, 
compared with EFA deficient control mice. However, bile flow, biliary bile salt output and the 
bile salt pool size were similar in EFA deficient Fxr-/- and control mice. This observation 
suggests that either FXR inactivation or EFA deficiency maximally induces biliary bile salt 
output and pool size.  
The fat absorption coefficient was higher in EFA deficient Fxr-/- mice compared to control 
mice, associated with a higher body weight gain in the former. Previous studies in EFA 
deficient wild type mice indicated that the fat malabsorption involves the mucosal phase of 
fat absorption, i.e, fatty acid translocation, triglyceride esterification and/or chylomicron 
formation 8. We did not find indications for different mRNA expression levels of Fat, Ifabp-1, 
and Fatp-4, or of Dgat-1, Dgat-2 and Mttp in EFA deficient Fxr-/- and control mice. These 
results do not support the theoretical possibility that fatty acid transport across intestinal 
membranes, triglyceride re-esterification or chylomicron assembly account for the relatively 
preserved fat absorption in EFA deficient Fxr-/- mice. Our data do show, however, that 
inactivation of FXR was associated with an increase in cholic acid-muricholic acids ratio 
during EFA deficiency in mice. The increase in the cholic acid-muricholic acids ratio renders 
the bile salt pool more hydrophobic. The cholic acid-muricholic acids ratio (hydrophobicity of 
the bile salt pool) in bile has been positively associated with the capacity to absorb 
cholesterol in rats 24,25. In analogy to these data on cholesterol absorption, we speculate that 
the higher cholic acid-muricholic acids ratio in EFA deficient Fxr-/- mice enhances the 
absorption of fatty acids and monoglycerides, possibly by facilitating their transfer across the 
unstirred water layer and thus their translocation across the apical membrane of the 
enterocytes. A higher cholic acid-muricholic acids ratio is found in EFA deficiency in mice 
(+63%), as well as in Fxr-/- mice (+77%), compared to the control situations. The increase in 
the cholic acid-muricholic acids ratio was not higher in EFA deficient Fxr-/- mice (+53%) 
compared to the increase in EFA deficient mice (+63%) or Fxr-/- mice (+77%), suggesting 
that FXR inactivation or EFA deficiency maximally increase the hydrophobicity of the bile 
salt pool 8,10. In EFA deficient mice fat absorption was lower than in non EFA deficient mice, 
despite the high cholic acid-muricholic acids ratio in the former 8. These observation 
suggests 1. that fat absorption would have been even more affected if the bile salt pool 
composition was not changed upon EFA deficiency; 2. that other factors than bile salt pool 
composition seem to contribute to EFA deficient fat malabsorption. 
The mechanism underlying EFA deficiency-induced or FXR deficiency-induced increased 
hydrophobicity of the bile salt pool is still unclear. As discussed previously by Kok et al., it is 
counterintuitive that Cyp7a1 expression is increased and Cyp8b1 expression remains similar 
in Fxr-/- mice. Cyp8b1 catalyzes the 12-hydroxylation of intermediates of the classic 
pathway of bile salt biosynthesis, leading to cholic acid biosynthesis and therefore appears 
to be important in determining the ratio between the ratio of cholic acid to chenodeoxycholic 
acid metabolites, the muricholic acids 26,27. 
In conclusion, EFA deficiency in Fxr-/- mice causes milder fat malabsorption and a higher 
weight gain compared to Fxr+/+ mice, probably related to the production of bile with more 
hydrophobic bile salts. These results support the theoretical concept that antagonists of FXR 
and/or increasing the hydrophobicity of the bile salt pool could ameliorate the phenotype of 
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Cholestatic liver disease covers a wide range of conditions characterized by defective bile 
formation associated with reduced bile salt transport from the liver into the intestinal lumen. 
Physiological consequences include retention of bile salts and other bile consituents in the 
hepatocytes, limited availability of bile salts in the intestinal lumen and elevated plasma bile 
salt levels. These consequences eventually lead to liver injury, lipid malabsorption, pruritus, 
jaundice and potentially peripheral tissue injury. Cholestatic patients, especially children, 
frequently develop failure to thrive which consists of failure to grow and nutritional 
deficiencies, including those of fat-soluble vitamins and essential fatty acids (EFA). A 
malnutritional state strongly affects prognosis of cholestatic patients. Identification of 
nutritional deficiencies in cholestasis and understanding of the pathophysiology underlying 
these deficiencies will help to improve the prognosis of cholestatic children by allowing 
optimalization of their nutritional status. We therefore aimed to elucidate the effects of 
cholestasis and EFA deficiency on intestinal function, with emphasis on digestion and 
absorption of fats and carbohydrates.  
 
Fat digestion and absorption in cholestatic conditions 
Fat absorption is significantly impaired during cholestasis and EFA deficiency. In cholestatic 
disorders, EFA deficiency is induced by fat malabsorption. However, EFA deficiency itself is 
also able to induce fat malabsorption. In this way, cholestatic children can enter a ‘vicious 
circle’ of fat malabsorption inducing EFA deficiency and vice versa. Hence, unraveling the 
mechanisms behind cholestasis-induced fat malabsorption and EFA deficiency-induced fat 
malabsorption are of great importance.  
Fat malabsorption in cholestasis is obviously to a great part due to limited availability of bile 
salts in the intestinal lumen, resulting in impaired fat solubilization. In chapter 3 we set out to 
address intestinal function in cholestasis. Our data indicate that fat absorption is impaired in 
cholestatic as well as in bile-deficient rats. Fat malabsorption in cholestatic and bile-deficient 
animals is at least for a large part caused by insufficient micellar solubilization due to limited 
availability of bile salts and phospholipids in the intestinal lumen. Interestingly, bile-deficient 
rats that do not show systemic accumulation of bile salts as seen in cholestasis, but also 
lack luminal bile salts, had milder fat malabsorption than cholestatic rats. Bile-deficient rats 
appear to compensate by ingesting more fat. Cholestatic and bile-deficient rats share the 
intestinal phenotype, but differ in the accumulation of bile salts in hepatocytes, 
cholangiocytes and circulation. We speculate that in absence of accumulation of bile salts, 
compensation mechanisms exist to counteract fat malabsorption.  
The mechanism behind EFA deficiency induced fat malabsorption is less clear. EFA 
deficiency in rats has been ascribed to decreased bile flow and biliary secretion of bile salts 
and  phospholipids, leading to impaired fat solubilization 1,2. In addition, intracellular events 
such as triglyceride re-esterification and chylomicron formation were found to be impaired 
1,3
. Fat digestion and fatty acid uptake by the enterocytes, however, were not affected 1,3. In 
mice, data in literature about EFA deficiency-induced fat malabsorption only relates to bile 
formation. In contrast to rats, EFA deficiency in mice is not due to impaired bile formation. 
Rather, EFA deficiency in mice increases bile flow and biliary secretion of bile salts and 
phospholipids 4. Cholestasis is associated with accumulation of bile salts in hepatocytes and 
cholangiocytes. Bile salts are natural ligands for the nuclear receptor FXR, which is  involved 
in bile salt homeostasis and lipid homeostasis. Since bile salt homeostasis and lipid 




involved in EFA deficiency-induced fat malabsorption. The FXR deficient and EFA deficient 
conditions separately have been associated with increased bile flow and bile salt pool size 
4,5
. EFA deficient Fxr-/- mice had similar bile flow and similar bile salt pool sizes compared to 
EFA deficient control mice, suggesting that the bile flow and biliary bile salt output is 
maximally induced during EFA deficiency or FXR inactivation. Concluding, the amelioration 
of fat malabsorption in EFA deficient Fxr-/- mice compared to EFA deficient control mice is 
not due to altered bile flow. 
In chapter 6, we suggested that altered composition of the bile salt pool might underly the 
improvement of fat malabsorption in EFA deficient Fxr-/- mice. The cholic acid to muricholic 
acids ratio was increased in EFA deficient Fxr-/- mice compared to EFA deficient mice, 
rendering the bile salt pool more hydrophobic. In rodents, the majority of the bile salt are 
conjugated with taurine. The order of taurine-conjugated bile salts ranging from relatively 
hydrophilic to relatively hydrophobic is: α-muricholic acid - β-muricholic acid – 
ursodeoxycholic acid – cholic acid – chenodeoxycholic acid. Increased hydrophobicity of the 
bile salt pool has been associated with increased absorption of cholesterol 6-9, probably due 
to enhanced solubilization of cholesterol and/or facilitated dissociation at the unstirred water 
layer. Increased solubilization and/or dissociation could also account for increased uptake of 
fatty acids, leading to amelioration of fat malabsorption as seen in EFA deficient Fxr-/- mice 
compared to EFA deficient control mice. This phenomenon was also observed in the 
separate deficiencies, EFA deficiency and FXR deficiency 4,5. We can speculate about the 
mechanism underlying the increased hydrophobicity of the bile salt pool in absence of FXR 
and EFAs. The key enzyme regulating the hydrophobicity of the bile salt pool is sterol 12α-
hydroxylase CYP8B1. CYP8B1 is required for the conversion of cholesterol to the primary 
bile salt cholic acid. The rate-controlling enzyme involved in bile salt biosynthesis CYP7A1 is 
required for synthesis of both cholic acid and chenodeoxycholic acid. In rodents, the majority 
of chenodeoxycholic acid is converted to α-muricholic acid, which is subsequently converted 
to β-muricholic acid. Thus the CYP8B1 activity level relative to the CYP7A1 activity level 
determines the hydrophobicity of the bile salt pool. Kok et al. demonstrated that FXR 
inactivation in mice was associated with increased mRNA expression of Cyp7a1, while 
mRNA expression of Cyp8b1 was similar in Fxr-/- mice compared and control mice. The ratio 
of Cyp7a1 to Cyp8b1 expression, however, was increased, suggesting a shift of the balance 
towards chenodeoxycholic acid and muricholic acids synthesis rather than cholic acid 5. We 
speculate that Cyp8b1 may not be involved in regulation of bile salt pool hydrophobicity.  
In cholestatic animals, in contrast, the cholic acid to muricholic acid ratio is decreased, 
leading to increased hydrophilicity of the bile salt pool (unpublished observations). 
Concomitantly, CYP8B1 expression has been shown to be repressed in cholestatic rats 10. 
Thus, the hydrophobicity of the bile salt pool is decreased in cholestatic animals to 
counteract hydrophobic bile salt-induced cytotoxicity and the hydrophobicity of the bile salt 
pool is increased in EFA deficient animals to counteract fat malabsorption.  
Interestingly, FXR inactivation and inactivation of its target gene SHP have been associated 
with protection against bile salt-induced liver injury 11,12. Thus, removal of FXR or its ligands, 
bile salts, results in an improvement in fat absorption and protection against bile salt-induced 
liver injury. Since bile salts and FXR are involved in many other physiological functions, such 
as energy homeostasis and glucose homeostasis 13, antagonism of FXR would likely lead to 
many side effects. However, if we can unravel which mechanisms underly the amelioration 
of fat malabsorption and hepatoprotection in EFA deficient Fxr-/- mice compared to EFA 
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deficient control mice and bile-deficient rats compared to cholestatic rats, we might have a 
target to intervene clinically.  
 
Carbohydrate digestion and absorption in cholestatic conditions  
Defects in bile production, as observed in cholestasis, limit the availability of bile salts in the 
intestinal lumen for the facililation of lipid-soluble nutrient absorption. Another aspect of 
cholestasis is a strongly increased plasma bile salt level, due to regurgitation of bile salts 
into the circulation from the hepatocytes 14-16. We wondered whether this high plasma bile 
salt level could affect intestinal epithelial cells through processes such as proliferation, 
differentiation or apoptosis, eventually leading to altered intestinal function. There have been 
numerous reports demonstrating that bile salts can induce proliferation, differentiation or 
apoptosis in vitro, depending on their hydrophobicity, conjugative state, concentration, cell 
signaling pathways and cell type involved 17-32.  
As cholestatic liver disease is frequently accompanied by nutritional defects 16, we aimed to 
explore intestinal digestion and absorption of carbohydrates in cholestatic conditions. In vivo 
data about intestinal function during cholestasis, specifically carbohydrate digestion or 
absorption is scarce. Jejunal absorption of glucose was found unaffected in cholestatic rats 
33
. Also bile-deficiency alone, i.e. without cholestasis did not impair sucrase enzyme activity 
in rats 34, suggesting that intestinal nutrient absorption is maintained in animal models of 
intestinal bile deficiency. We addressed whether  carbohydrate digestion was affected in 
cholestatic rats (chapter 3). Interestingly, carbohydrate digestion was maintained in 
cholestatic rats, but impaired in EFA-deficient mice (chapter 5). This discrepancy can be 
explained by the fact that the cholestatic rats were subjected to the carbohydrate digestion 
and absorption test 1 week after bile duct ligation, which is too short to develop EFA 
deficiency. Concluding from chapter 3, 4 and 5 it is highly likely that lactose digestion is 
impaired in cholestatic disorders that are accompanied by EFA deficiency.  
Enterocytes are protected during cholestasis, both in in vitro (chapter 4) and in vivo (chapter 
3). In chapter 4 we propose that nutrient absorption is not affected in cholestatic conditions, 
because nutrient absorption and bile salt re-absorption are localized in different intestinal 
segments. The jejunum is the major site of nutrient absorption, while bile salt re-absorption 
is restricted to the terminal ileum 35. We demonstrated that reduced sucrase activity was 
associated with increased expression of intestinal bile salt transporters (ASBT). Concluding, 
intestinal function, i.e. sucrase activity, is impaired when high amounts of bile salt are 
transported into the enterocytes. In accordance with this theory, Lee et al. showed that 
mRNA and activity levels of sucrase were strongly reduced in the terminal ileum compared 
to the duodenum, jejunum and proximal ileum 36. That the separation of nutrient absorption 
and bile salt re-absorption in the intestine is highly important and tightly regulated was also 
demonstrated by Bosse et al. The authors identified the transcription factor Gata-4 as the 
major determinant of jejunal-ileal identities in mice. Synthesis of a transcriptionally inactive 
Gata-4 mutant in the mouse jejunum resulted in an attenuation of expression of genes 
involved in nutrient absorption and an induction of genes involved in bile salt re-absorption 
35
.  
Snipes et al. noted pathological changes in the intestines of EFA deficient rats, i.e. restricted 
surface area due to villi shortening and a lack of cellular differentiation 37. This effect has 
been ascribed to the decreased EFA content in membrane phospholipids 1,3. Our study with 
EFA deficient mice also pinpointed the defect in lactose digestion to the jejunum, though not 




linoleic acid (LA) concentration was observed between jejunal membrane phospholipids of 
EFA deficient and control mice. Cell membrane fluidity is determined by its lipid composition. 
Incorporation of saturated fatty acids and cholesterol in the membrane will render the 
membrane more rigid, while incorporation of unsaturated fatty acids will make it more fluid. 
The number of receptors and their affinity to their respective ligands is considered to depend 
on the fluidity of the cell membrane 38. A reduction in plasma membrane fluidity has also 
been associated with decreased luminal membrane permeability to macromolecules 39. 
Moreover, decreased incorporation of EFA-derived fatty acids in membrane phospholipids 
has been associated with altered activity of hydrolytic enzymes in the jejunum 40.  This is in 
accordance with the observation that lactose digestion was impaired in EFA deficient mice. 
In contrast to lactose digestion, glucose absorption was maintained in EFA deficient mice. 
The altered composition of membrane fatty acids may only affect activity of hydrolytic 
enzymes such as lactase that are attached to the membrane 41, while the membrane-
spanning glucose transporters are unaffected. However, it should be realized that not only 
the activity of lactase was decreased in EFA deficient jejunum, but also its mRNA 
expression. This observation indicates that the effects of EFA deficiency cannot completely 
be explained by alterations of the cell membrane fluidity. 
 
Concluding remarks and perspectives 
In conclusion, cholestasis as such does not lead to impaired intestinal carbohydrate 
digestion. When accompanied by EFA deficiency, however, cholestasis in rats is also 
associated with impaired lactose digestion. Thus, our initial conclusion (chapter 3) that 
carbohydrate addition to the diet of cholestatic patients should be valuable for optimalization 
of their nutritional status has to be fine-tuned. Addition of monosaccharides to the diet of 
cholestatic patients is not be beneficial, since they have a high glycemic index. However, by 
adding small amounts of disaccharides more frequently per day, we may be able to 
maximally utilize the limited carbohydrate digestion capacity.  
In order to assess carbohydrate digestion and absorption in an animal model we adapted an 
existing test based on stable isotope dilution technique 42,43. The blood spot technique, 
developed by our group, made it possible to test these parameters in mice 44. Combination 
of both techniques makes it possible to test digestion and absorption of various nutritional 
compounds using small volumes of blood, and can thus be utilized for small animals and 
neonates. The development and adaptation of this technique to specific nutrients, organisms 
and disorders, will accelerate the identification of specific nutritional deficiencies in 
cholestatic children  
Regarding the role of FXR in therapies for EFA deficiency, FXR has been implicated in so 
many regulatory functions that antagonizing FXR solely for the purpose of enhancing fat 
absorption is not applicable. Perhaps, if we identify the mechanism behind the FXR 
inactivation-induced amelioration of fat malabsorption, we can aim to develop gene-selective 
or organ-selective ligands to specifically target the gene or organ responsible.  
 
In this thesis we gained more insight in the pathophysiology of cholestasis-induced failure to 
thrive. On this account, we can aim to further optimize the nutritional status of children with 
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Cholestatic liver disease covers a wide range of conditions characterized by defective bile 
formation associated with reduced bile salt transport from the liver into the intestinal lumen. 
Physiological consequences include retention of bile salts and other bile consituents in the 
hepatocytes, limited availability of bile salts in the intestinal lumen and elevated plasma bile 
salt levels. These consequences eventually lead to liver injury, lipid malabsorption, pruritus, 
jaundice and potentially peripheral tissue injury. Cholestatic patients, especially children, 
frequently develop failure to thrive which consists of failure to grow and nutritional 
deficiencies, including those of fat-soluble vitamins and essential fatty acids (EFA). A 
malnutritional state strongly affects prognosis of cholestatic patients. Identification of 
nutritional deficiencies in cholestasis and understanding of the pathophysiology underlying 
these deficiencies will help to improve the prognosis of cholestatic children by allowing 
optimalization of their nutritional status. We therefore aimed to elucidate the effects of 
cholestasis and EFA deficiency on intestinal function, with emphasis on digestion and 
absorption of fats and carbohydrates.  
 
Chapter 2 relates to the nutritional deficiencies that accompany cholestatic liver disease in 
children as well as treatment options based on nutrient supplementation. Important factors in 
the pathophysiology of malnutrition in pediatric cholestasis are poor dietary intake, increased 
energy expenditure and impaired absorption of fats and fat-soluble nutrients. To counteract 
malnutrition in cholestasis, dietary energy intake in cholestatic children is usually increased 
to 120-150% of the recommended daily energy intake. In addition, up to 60% of the fat 
components, particularly long-chain triglycerides are substituted by medium-chain 
triglycerides whose absorption occurs relatively independent from the presence of bile 
components in the intestinal lumen. Pediatric cholestatic patients comprise a heterogeneous 
group: consequently clinical manifestations of the disease may vary widely. This makes a 
tailor-made dietary approach for these children crucial. 
 
As stated above, cholestasis is often accompanied by a strongly elevated plasma bile salt 
level. Many reports have demonstrated that bile salts can induce cellular proliferation or 
apoptosis, depending on the bile salt species, concentration and cell type involved. We have 
evaluated whether elevated plasma bile salt concentrations could affect intestinal function, 
for instance by affecting proliferation, differentiation or apoptosis. In chapter 3, we 
investigated the effect of cholestasis on intestinal function, i.e., on digestion and absorption 
of sucrose and glucose in rats, with stable isotope methodology. We compared cholestatic 
rats to control rats and bile-deficient rats, to be able to differentiate between consequences 
of elevated plasma bile salts and absence of bile from the intestine. Intestinal sucrose 
digestion and glucose absorption occurred to a similar extent in cholestatic, control and bile-
deficient, indicating that this aspect of intestinal function, i.e., carbohydrate digestion and 
absorption, is preserved in cholestatic conditions. 
 
In chapter 4, we studied the effect of conjugated bile salts in cholestatic concentrations on 
intestinal epithelial cells in vitro. The human colon carcinoma cell line Caco-2, which 
develops small intestinal characteristics upon differentiation, was exposed to cholestatic 
conditions at different developmental stages. Exposure of proliferating or short-term 
differentiative cells to conjugated bile salts in cholestatic concentrations did not affect 
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intestinal cell proliferation, differentiation or apoptosis, indicating that intestinal cells in the 
respective developmental stages are resistant to cholestatic conditions. Exposure of long-
term differentiative cells to cholestatic conditions, however, resulted in decreased sucrase 
activity, coinciding with increased expression of the bile salt transporter ASBT. Nutrient 
absorption, including sucrase activity, is most efficient in the jejunum, while active bile salt 
absorption is restricted to the terminal ileum. We speculated that enterocytes are protected 
from bile salt-induced effect through absence of the intestinal bile salt transporter ASBT. 
 
Cholestasis-induced fat malabsorption often leads to EFA deficiency. EFA deficiency in 
itself, however, can also induce fat malabsorption. The pathophysiological basis of EFA 
deficiency-induced fat malabsorption is incompletely understood, but is probably located at 
the mucosal level. We have evaluated whether EFA deficiency would also affect 
carbohydrate digestion or absorption. In chapter 5, we tested this theory by subjecting EFA 
deficient mice to a lactose digestion/glucose absorption test using stable isotope 
methodology. Lactose digestion, but not glucose absorption, was impaired in EFA deficient 
mice. Impaired lactose digestion coincided with decreased activity and mRNA levels of 
lactase in the jejunum. In addition, we found a positive correlation between jejunal lactase 
activity and membrane phospholipid linoleic acid content, suggesting that altered fatty acid 
composition of cellular membranes affects lactose digestion during EFA deficiency. 
 
The farnesoid X receptor (FXR) has been implicated in the regulation of bile salt and lipid 
metabolism. Fxr-deficient mice have increased bile flow and bile salt pool size, and a more 
hydrophobic bile salt composition due to an increased contribution of cholic acid (CA). 
Interestingly, we previously demonstrated that EFA-deficiency in (wild-type) mice has similar 
phenotypic characteristics. Based on this similarity, we wondered whether FXR could be 
involved in EFA deficiency-induced fat malabsorption. In chapter 6, we assessed fat 
absorption and bile salt homeostasis parameters in EFA deficient Fxr-/- mice compared to 
EFA deficient control mice. Inactivation of FXR resulted in milder fat malabsorption and 
increased weight gain, coinciding with increased hydrophobicity of the bile salt pool. Thus, 
FXR appears to be involved in EFA deficiency-induced fat malabsorption, possibly by 
modulating the hydrophobicity of the bile salt pool.  
 
According to the work described in this thesis, cholestasis when accompanied by EFA 
deficiency seems to have a clear negative influence on intestinal function. This information 
allows us to develop strategies to optimize the nutritional status of cholestatic patients and 






Cholestatische leverziekten worden gekarakteriseerd door verminderd transport van gal van 
de lever naar het darmlumen. Fysiologische gevolgen hiervan zijn de accumulatie van 
galzouten en andere galcomponenten in bloed, lever en andere organen, en verminderde 
beschikbaarheid van galzouten in het darmlumen. Cholestatische leverziekten zijn dan ook 
vaak geassocieerd met leverschade, vetmalabsorptie, jeuk en geelzucht. Kinderen met een 
cholestatische leverziekte ontwikkelen vaak het zogenaamde “failure to thrive”; gestoorde 
groei en deficiënties van belangrijke voedingsstoffen, inclusief vet-oplosbare vitamines en 
essentiële vetzuren (EFA). Een slechte voedingsstatus heeft een sterk effect op de 
prognose van cholestatische patiënten. Identificatie van de specifieke deficiënties die 
optreden tijdens cholestase en het ophelderen van de onderliggende pathofysiologie zal 
bijdragen aan het optimaliseren van de voedingsstatus van cholestatische kinderen. In dit 
proefschrift is onderzoek beschreven met betrekking tot de effecten van cholestase en EFA 
deficiëntie op de darmfunctie, met de nadruk op de digestie en absorptie van vetten en 
koolhydraten.  
 
In hoofdstuk 2 worden de nutritionele deficiënties besproken die optreden bij cholestatische 
leverziekten in kinderen, evenals behandelingstrategieeën gebaseerd op 
voedingssupplementen. De ondervoeding die optreedt tijdens cholestase wordt vaak 
veroorzaakt door anorexia, verhoogd energieverbruik en sterk verminderde absorptie van 
vetten en vet-oplosbare nutriënten. Om dit te ondervangen wordt de energiewaarde van het 
voedsel dat cholestatische kinderen moeten innemen, verhoogt tot 120-150% van de 
geadviseerde dagelijkse hoeveelheid. Tot 60% van de vetcomponenten, de lange keten 
vetzuren, worden vervangen door medium keten vetzuren, die onafhankelijk van de 
aanwezigheid van galcomponenten in het darmlumen worden opgenomen. Pediatrische 
cholestatische patiënten vormen een heterogene groep, waarvan de klinische manifestaties 
van de aandoening sterk variëren. Dit maakt een toegepaste aanpak voor deze kinderen 
cruciaal. 
 
Cholestase wordt vaak vergezeld door een sterk verhoogd galzoutconcentratie in het 
plasma. Galzouten kunnen cellulaire proliferatie, differentiatie en apoptosis induceren, 
afhankelijk van het specifieke galzout, concentratie en het betrokken celtype. We hebben 
onderzocht of de verhoogde galzoutconcentratie in het plasma de darmfunctie beïnvloedt, 
bijvoorbeeld door proliferatie, differentiatie of apoptosis te beïnvloeden. In hoofdstuk 3 
hebben we het effect van cholestase op de darmfunctie onderzocht, specifiek op de 
splitsingscapaciteit en absorptie van sucrose en glucose in ratten met behulp van stabiele 
isotopen methodologie. We hebben cholestatische ratten vergeleken met galdeficiënte 
ratten, om te kunnen discrimineren tussen de gevolgen van de verhoogde plasma 
galzoutconcentratie en de afwezigheid van galzouten in de darm. Sucrose digestie en 
glucose absorptie in de darm verliep in gelijke mate in cholestatische, controle en 
galdeficiënte ratten. Dit wijst erop dat koolhydraat splitsing en absorptie geconserveerd zijn 
tijdens cholestase. 
 
In hoofdstuk 4 hebben we het effect van geconjugeerde galzouten in cholestatische 
concentraties op epithele darmcellen in vitro onderzocht. De humane colon carcinoma cellijn 
Caco-2, welke dunne darm karakteristieken ontwikkelt wanneer de cellen differentiëren, 
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werd blootgesteld aan cholestatische condities in verschillende ontwikkelingsfases. 
Blootstelling van prolifererende cellen en korte-termijn gedifferentieerde cellen aan 
geconjugeerde galzouten in cholestatische concentraties had geen effect op Caco-2 
proliferatie, differentiatie of apoptose. Dit duidt op resistentie van de darmcellen tegen 
blootstelling aan galzouten in cholestatische concentraties. Blootstelling van lange-termijn 
gedifferentieerde cellen daarentegen, resulteerde in een reductie van de splitsingscapaciteit 
van het brush-border enzym sucrase gelijktijdig met verhoogde expressie van de 
galzouttransporter ASBT. Opname van nutriënten, inclusief de splitsingscapaciteit van 
sucrase, is het meest efficiënt in het jejunum, terwijl actieve absorptie van galzouten 
plaatsvindt in het terminale ileum. We speculeren dat enterocyten die betrokken zijn bij de 
absorptie van nutriënten worden beschermd tegen cholestatische condities door de 
afwezigheid van de galzouttransporter ASBT. 
 
Vetmalabsorptie, veroorzaakt door cholestase, leidt vaak tot EFA deficiëntie. EFA deficiëntie 
kan echter zelf ook vetmalabsorptie induceren. De pathofysiologische basis van de door 
EFA deficiëntie geïnduceerde vetmalabsorptie is nog niet opgehelderd, maar is 
waarschijnlijk gelokaliseerd op het mucosale niveau. We hebben onderzocht of EFA 
deficiëntie een effect heeft op koolhydraat splitsing of absorptie. In hoofdstuk 5 hebben we 
dit onderzocht door EFA deficiënte muizen te onderwerpen aan een gecombineerde lactose 
splitsing/glucose absorptie test, gebruik makend van stabiele isotopen methodologie. In 
tegenstelling tot glucose absorptie, was de lactose splitsing sterk verminderd in EFA 
deficiënte muizen tegelijk met verlaagde activiteit en mRNA niveaus van lactase in het 
jejunum. Tevens vonden we een positieve correlatie tussen lactase activiteit in het jenunum 
en het aandeel van linolzuur in membraan phospholipiden. Dit wijst erop dat een veranderde 
compositie van vetzuren in het cellulaire membrane de lactose splitsing tijdens EFA 
deficiëntie beïnvloedt.  
 
De farnesoid X receptor (FXR) is betrokken bij de regulatie van galzout- en vetmetabolisme. 
Fxr-deficiënte muizen zijn gekarakteriseerd door een verhoogde galflow en galzoutpool, 
evenals een verhoogd aandeel van cholaat in de galzoutpool en daardoor meer hydrofobe 
compositie. Voorheen hebben we aangetoond dat EFA deficiëntie in wild-type muizen 
vergelijkbare karakteristieken heeft. Gebaseerd op deze gelijkenis, vroegen wij ons af of 
FXR betrokken is bij vetmalabsorptie geïnduceerd door EFA deficiëntie. In hoofdstuk 6 
hebben we dan ook gekeken naar vetabsorptie en galzouthomeostase parameters in EFA 
deficiënte Fxr-/- muizen vergeleken met EFA deficiënte controle muizen. Inactivatie van FXR 
resulteerde in een mildere vetmalabsorptie en verhoogde gewichtstoename, tegelijk met 
verhoogde hydrofobiciteit van de galzoutpool. Concluderend, FXR lijkt betrokken bij vet 
malabsorptie geïnduceerd door EFA deficiëntie, waarschijnlijk door middel van modulatie 
van de hydrophobiciteit van de galzoutpool. 
 
Op grond van deze bevindingen lijkt cholestase in combinatie met EFA deficiëntie een 
duidelijk negatieve invloed uit te oefenen op het functioneren van de darm. Deze informatie 
stelt in staat om rationele voedingsaanpassingen te maken om de voedingsstatus en 






Het lijkt eeuwen geleden dat ik begon als AIO en toch is de tijd echt omgevlogen. Het is 
bijna onwerkelijk dat alles nu klaar is en dat ik echt ga promoveren. Heel veel geleerd en 
helaas ook heel veel hersencellen om zeep geholpen;-). Ik heb het natuurlijk allemaal niet 
alleen gedaan en wil bij deze graag iedereen bedanken. Omdat ik niemand wil vergeten, 
begin ik met de enorme lijst van alle (ex-)collega’s; Folkert, Dirk-Jan, Uwe, Frans S, Torsten, 
Feike, Terry, Thierry, Fjodor, Klary, Mark, Gemma, Henkjan, Edmond, Ekkehard, Frank B, 
Frank P, Janneke, Marianne, Renze, Juul, Henk, Rick, Vincent, Janny, Nicolette, Klaas, 
Theo B, Theo v D, Elles, Hilde R, Gea, Christian, Anja, Robert, Renate, Yan, Thomas, 
Tineke, Miriam, Aldo, Janine, Hester, Frans C, Karin G, Jaap, Anniek K, Anniek W, Jelske, 
Maaike, Esther, Niels, Sabina, Maxi, Annelies, Jan Freark, Marijke, Hilde H, Anke, Harmen. 
MDL-collega’s; Titia, Jannes, Martijn, Hans, Axel, Sandra, Rebekka, Krzysztof, Antonella, 
Laura, Marieke, Elise, Han, Klaas-Nico, Mariska, Manon, Janette, Tjasso, Lisette, Fiona en 
iedereen die ik vergeten ben. Jullie allemaal bedankt! Natuurlijk wil ik een paar personen 
speciaal bedanken, maar ik begin toch met de dieren. 
Ik wil graag de ratten en muizen bedanken die “meegewerkt” hebben aan de totstandkoming 
van dit proefschrift. Ik hoop dat jullie het nu fijn hebben op de “eeuwige kaasvelden”.  
Natuurlijk wil ik ook graag mijn begeleiders bedanken. Henkjan, ik heb ontzettend veel van 
jou geleerd, meestal met behulp van Albert Heijn kassa’s en rijen met klanten;-). Folkert, 
bedankt voor de goede tips en je hulp bij de operaties van de ratten. Edmond, je bent er van 
het begin tot het einde bij geweest, bedankt voor alles! Frans S, jij hebt een belangrijke 
bedrage geleverd aan dit proefschrift. Ook vond ik onze samenwerking voor het CA/DCA 
project heel prettig. Jammer dat we het niet af hebben kunnen krijgen voor in mijn boekje. 
Ook wil ik graag de leescommissie bedanken voor het beoordelen van mijn manuscript. Han 
Moshage, Robert Porte (bedankt voor de nuttige tips) en Pieter Sauer bedankt.  
De experimenten die in dit proefschrift beschreven staan heb ik zeker niet alleen gedaan. 
Rick, bedankt voor je hulp bij de dierproeven. De manier waarop jij met de dieren omgaat en 
de gezelligheid tijdens de proeven hebben mij vooral tijdens de eerste proeven er doorheen 
gesleept. Henk, je hebt geen idee hoe blij ik ben dat jij voor lange tijd deel hebt uitgemaakt 
van ons ‘groepje’. Volgens mij weet jij echt alles. En het is ongelofelijk dat je het uithoudt bij 
ons op de kamer;-). Verder wil ik ook graag Renze, Juul, Klaas, Theo B en Elles bedanken 
voor hun hulp bij mijn experimenten. 
Het is vooral te danken aan een supergezellige groep AIO’s/Post-docs dat ik zo’n leuke tijd 
heb gehad. Promotiefeestjes, bieravonden, wijnavonden, filmavondjes of gewoon even een 
biertje drinken in de stad. Altijd gezellig!! Ik ben het volledig met Jelske eens dat wij ‘zeer 
zeker de gezelligste’ AIO-kamer van Groningen bewonen. Veel tranen van het lachen (soms 
ook van het huilen...). Huidige en ex-bewoners; Jelske, Titia, Maaike, Esther, Niels, Martijn, 
Miriam, Anniek W, Hans, Marieke, Tineke en Renate bedankt. Het lijkt erop dat de bazen de 
neiging hebben voornamelijk vrouwen aan te nemen, een enkele uitzondering daar gelaten. 
In dit geval ben ik ze daar erg dankbaar voor. Esther, als medebewoonster van de 
gezelligste AIO-kamer van Groningen heb jij een groot aandeel in alle lol die we hebben. 
Mijn uitstapjes naar de wereld van de techno & dance in A’dam en Buddha’s Casa waren 
heel leuk, maar toch niet helemaal mijn ding. En ik ben toch echt te stijf voor poweryoga;-). 
Anke, jij bent mijn held. Ik hoop dat ik straks iemand anders kan vinden die bezorgd om mij 
is als ik dronken naar huis fiets;-). Ik zal proberen niet alleen ‘j’ meer te sms-en;-). Maxi, 
waarom is er altijd een digitale camera in de buurt als je een feestje geeft?! En waarom gaat 
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het dan op de één of andere manier altijd mis met de drank? De schnaps van je vader 
waren te lekker. Tja, en daarna nog wodka-appelsap… Arme Frans Bauer. Arm 
stokbroodlijkje in mijn oven… Anke en Maxi, onze filmavondjes in/op de ‘boat’ waren/zijn 
geweldig. More ‘boating’ to come in the future I hope;-) Sorry, dat ik zo vaak in slaap val;-). 
Ach, ‘some things are just weird’. Marijke, jij bent echt te lief voor deze wereld. Ik hoop dat je 
het fantastische leven krijgt dat je verdient. Hilde, misschien is het die plek, maar je bent 
echt een waardig opvolger van Aldo. Je lijkt rustig en beheerst, maar je kan ook ineens 
super uit je dak gaan. Sorry dat ik op je tenen heb staan dansen;-). Annelies, zo jong nog en 
al een echt huis. Dan doe ik toch iets verkeerd;-). Ik ben blij dat je ons toch niet kon missen 
na je stage. 
Jelske en Titia, de keuze voor jullie als mijn paranimfen was snel gemaakt. Bedankt dat jullie 
mij bij willen staan tijdens de laatste loodjes! Jelske, mijn buurvrouw. Gelukkig voor alle vier 
de jaren. Ik kan me onze kamer niet voorstellen zonder jou naast mij en dat hoef ik gelukkig 
uiteindelijk ook niet mee te maken. Onze drie bieravonden waren toch wel de leukste. 
Zonder onze bier-breaks tijdens de vele avondjes doorwerken, had ik het echt niet 
getrokken. Titia, jij bent zo’n lieve vriendin van mij geworden. Heerlijk, die avondjes met jou 
en Jannes op het balkon of binnen, wijntjes en sigaretjes erbij. Als ik ‘Somebody to love’ van 
George Michael & Queen hoor, moet ik aan jullie denken;-). Ik ga onze afspraken ontzettend 
missen straks, maar ik weet zeker dat we in de toekomst nog vaak lekker wijntjes gaan 
drinken met z’n drietjes. Ik voel me zo vereerd dat ik me, als één van de weinigen, mag 
bemoeien met jullie huwelijk;-). Jullie allebei, ontzettend bedankt!! 
Jammer dat je maar twee paranimfen mag kiezen, anders zou ik er namelijk vier hebben. 
(Sa)bina, ‘partner in crime’, samenwerken met jou was geweldig. Jouw bijdrage aan dit 
proefschrift is ontzettend groot geweest. Fantastisch dat je je eigen weg gaat en dat je alles 
zo goed kan relativeren. Gut is stapelgek als ze ons stuk niet willen! Maaike, jammer dat dit 
boekje geen geluid kan maken, anders zou ik deze zinnen laten neuriën. Ik heb zo 
ontzettend veel gelachen in onze kamer, en heel vaak om en met jou. Geweldig, hoe jij altijd 
geïnteresseerd bent in alles en iedereen, zowel wetenschappelijk als sociaal. Altijd goede 
tips op beide vlakken. Wat mij betreft ben je al een perfecte diamant;-)! Sabina en Maaike, 
voor mij zijn jullie mijn extra paranimfen, bedankt!! 
Eén van de leuke bijkomstigheden van het leven als AIO zijn de buitenlandse congressen 
die je mag bezoeken. Chicago (DDW 2005) was te gek, met name door het gezelschap van 
mede-chicago-chickies Anniek W en Anja. Mijn leven is niet meer hetzelfde na het horen (en 
vooral ook zien) van Big James & the Chicago Playboys. Gelukkig kon ik de paalsmurf 
uiteindelijk van achter de paal vandaan trekken om te dansen, door de wilde 
dansmanoeuvres van zekere bazen en een paar zwaarlijvige ‘sisters’ soms met gevaar voor 
eigen leven. Liever een ijskonijn, dan een lelijke …;-). Mijn enige ‘vakantie’ dit jaar was de 
DDW in Washington. Helaas voor mij een vergeefse poging om aansluiting en passie voor 
het wereldje te krijgen, maar daarom niet minder leuk. Ik heb heel veel gezien van een hele 
mooie stad. Zonder Hans, ex-bewoner van de gezelligste AIO-kamer van Groningen, was 
het lang niet zo leuk geweest! 
Syrinx; Trineke, Anna, Wiewie, Cynthia en Ruth. Het was voor jullie misschien niet altijd te 
begrijpen waar ik precies mee bezig was. Toch heb ik ontzettend veel gehad aan jullie 
luisterend oor. Marianne en Karin (de J), beiden ex-collega maar gelukkig nog steeds goede 
vriendinnen. Bedankt dat jullie de leuke en de minder leuke verhalen wilden aanhoren 
tijdens onze gezellige etentjes. Lieve Willemijn, ik heb jou ontzettend gemist de afgelopen 
tijd. Vooral onze maandagavondjes...bij jou kan ik alles kwijt en je begrijpt ook alles, want je 
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hebt het zelf meegemaakt. Als we elkaar weer zien na een hele lange tijd is alles weer als 
vanouds. Bedankt voor alles! 
(Tante) Marijke, aan jou heb ik zo ontzettend veel gehad en nog steeds. Een mailtje of een 
telefoongesprek, en ik zie het weer zitten. (Ome) Ton, heerlijke etentjes op de boot of 
ergens in de stad en hele lange gesprekken over het leven. Robin, je bent en blijft mijn 
kleine broertje, maar ongelofelijk hoe groot en wijs je bent geworden, bedankt voor je 
nuchterheid en relativeringsvermogen. Tot slot wil ik graag mijn ouders bedanken. Lieve 
papa en mama, bedankt voor jullie onvoorwaardelijke steun. Bij jullie is het nog steeds thuis. 
Als afsluiting gooi ik er toch nog maar wat quotes tegen aan. ‘What doesn’t kill you makes 
you stronger’ vind ik gewoon mooi. Jelske, ik wil je laatste stelling niet pikken, maar ik vind 
‘m zo mooi dat ik ‘m hier toch wil noemen. ‘Don’t cry because it’s over. Smile because it 
happened.’ Die twee zinnetjes hebben voor mij een dubbele betekenis. Ik ga jullie allemaal 
zo ontzettend missen!!!  
Een promotie zonder feestje is als ijs zonder slagroom, frieten zonder mayo en stamppot 
zonder rookworst! Geniet er van, dat ga ik ook doen! Zo, nu ga ik op avontuur, de wijde 

































Leonie Los werd op 26 februari 1980 geboren in Zwolle. Na het behalen van haar VWO 
diploma aan het Carolus Clusius College te Zwolle begon zij in 1998 met de studie 
(Medische) Biologie aan de Rijksuniversiteit Groningen. Het eerste wetenschappelijk 
onderzoek werd uitgevoerd binnen de vakgroep Hematologie van Prof. dr. E. Vellenga en 
betrof onderzoek naar STAT5 en MAPK/ERK signaaltransductie in TPO-gestimuleerde 
megakaryocyten en EPO-gestimuleerde erythrocyten. Het tweede onderzoek werd 
uitgevoerd binnen de vakgroep Immunologie in Verona (Italië) onder begeleiding van Prof. 
dr. M. Colombatti. Het onderzoek betrof de optimalizatie van de koppeling van de toxine 
saporin aan antilichamen specifiek voor kankercellen. Eind augustus 2003 studeerde Leonie 
af en begon met promotie-onderzoek bij de vakgroep Kindergeneeskunde van de medische 
faculteit van de Rijksuniversiteit Groningen onder begeleiding van Prof. dr. H.J. Verkade, 
Prof. dr. F. Kuipers en Dr. E.H.H.M. Rings. De resultaten van het onderzoek uitgevoerd 
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